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ABSTRACT 
 
Magnetic resonance imaging (MRI) is a vital tool in today’s modern healthcare system. 
MRI is preferred over positron emission tomography (PET) and X-ray computed tomography 
(CT) because it is non-invasive, non-radioactive, and provides 3-D imaging directly in vivo. 
 Contrast agents are used in order to enhance the resolution of the images from MRI. All 
currently used contrast agents are based on gadolinium and image water protons in the human 
body. However, gadolinium-based contrast agents are principally unable to quantitatively 
image specific biomarkers of diseased states, lacking a ratiometric mechanism.  
 Fluorine-based MRI does not suffer from these limitations, but its low sensitivity, with a 
limit of detection (LOD) in the micromolar range first requires a contrast agent designed 
specifically to address this issue of sensitivity, which can be accomplished using contrast 
agents with an incorporated lanthanide center.  
 Fluorine MRI eliminates background signals and has a large chemical shift range which 
enables fluorines in different environments to each be imaged independently. This in turn 
allows for the development of ratiometric, responsive contrast agents whereby the total probe 
concentration and the concentration of the analyte can be independently determined. 
 In this thesis, the theory, practicality, utility, and potential for fluorine-based MRI 
contrast agents is described. Sensitivity is addressed, synthesis is described, and 
demonstrations of the potential for fluorine MRI are examined in vitro and in vivo in order to 
design highly-sensitive, responsive, and biocompatible fluorine contrast agents. 
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1  Introduction 
1.1 Basic Principles of MRI 
 
Clinical diagnostics and biomedical research rely heavily on the ability to 
image the human body. Of particular interest to the medical community is magnetic 
resonance imaging (MRI), an imaging procedure that is non-invasive and does not 
expose the patient to high-power ionizing radiation in the case of X-ray or computed 
tomography (CT) scanning, radioactive isotopes in the case of positron emission 
tomography (PET), and offers better resolution than single-photon emission computed 
tomography (SPECT). MRI only minimally perturbs the subject, and offers full spatial 
and temporal imaging with higher resolution when compared to CT, PET, or SPECT. 
As a result, among imaging techniques that are clinically available, MRI stands as 
being especially promising and safe. The prognoses of many diseased states can be 
detected by MRI, and these results can allow medical analysis and subsequent 
treatment options to patients prior to advanced stages of diseases such as cancer, 
stroke, spina bifida, and multiple sclerosis, among others. In 2013, over 45 million 
MRI scans were performed in in the United States alone.1 
1.1.1 Magnetic Field, and Nuclear Precession, the Radio-Frequency Pulse 
 In theory, any nucleus having an intrinsic magnetic moment and angular 
momentum resulting in a non-zero spin. can be imaged by MR. The most common 
nuclei are 1H, 13C, 19F, and 31P for nuclear magnetic resonance (NMR), but within the 
scope of MRI, imaging of 1H is by far the most common and most widely used. 
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When MRI-active nuclei are placed in a powerful magnetic field, their nuclear 
spins align with the vector of the magnetic field, defined in 3-D space as the Z-axis. 
As the nuclear alignment along the Z-axis is established, the nuclei then precess about 
the Z-axis due to their intrinsic angular momentum but in summation retain alignment 
with the Z-axis. As shown in Figure 1-1, following magnetic alignment, a low-energy 
radio-frequency (RF) pulse on the order of microseconds distorts the precessing nuclei 
out of the Z-axis and in to the XY plane using an RF pulse, commonly 90˚. A 90˚ 
pulse deflects the precessing nuclei fully into the XY plane and depleting magnitude 
along the Z-axis, after the magnetic moments of the nuclei decay their magnitude in 
the XY plane and restore their magnitude along the Z-axis as the nuclei realign with 
the magnetic field. The times required for nuclei to relax are relaxation times.  
1.1.2 T1 and T2 Relaxation 
The longitudinal (spin-lattice) time, known as T1, is a time constant measuring 
the time required for nuclei to restore their magnitude along the Z-axis following a 90˚ 
pulse. The transverse (spin-spin) time, T2, is a second time constant measuring the 
time required for nuclei to deplete their magnitude in the XY plane following a 90˚ 
pulse. T1 is measured by and inversion-recovery sequence while T2 is measured by the 
Cargill-Purcell-Meiboom-Gill (CPMG) pulse sequence. The relaxation times are 
described as T1 and T2 are first order. The differences between the two are illustrated 
in Figure 1-1, where T1 is represented as the restoring magnitude of the red arrow 
along the Z-axis, and T2 is represented as the depleting magnitude of the red arrow in 
the XY-plane. Differences in chemical environments affect the relaxation times, which 
can be analyzed and processed in order to form an image.  
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Figure 1-1: Schematic of MRI spin echo RF pulse sequence and relaxation recording. (Figure used with 
permission from Pierre, V. C.). 
 
Work by Damadian et al. established that a sharp difference in T1 relaxation is 
observed between normal and malignant tissues, with the greatest T1 changes observed 
in breast, skin, intestine, stomach, and adipose tissues (Table 1.1).2,3 Similar results 
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were observed by Hollis et al.4 and Hazlewood et al.,5 and it was presumed the shorter 
relaxation times of healthy tissues were a function of more rapid exchange of the 
coordinated water molecules in healthy tissues. Other explanations have been 
suggested over time but this initial conclusion is still the most accepted mechanism for 
longer T1 times in cancer cells. 
1.1.3 The MRI Experiment 
Current clinical MRI procedures detect endogenous water protons in human 
patients. Three-dimensional images of patients are obtained by imaging slices that are 
then stacked in layers and are rendered with a computer to assemble a three-
dimensional image. 
The MRI pulse sequence defines a set of RF pulses, magnetic gradients, and 
delay times such as time to echo (TE, the time between the RF pulse until the 
maximum signal returned from the gradient echos) and time to repetition (TR, the time 
between each scan event). The gradient-echo pulse sequence is most commonly used 
in clinical MRI, and can be T1-, T2-, and/or T2*-weighted, depending on what is being 
imaged and the type of image desired. It can also depend on whether MRI contrast 
agents are used. 
1.1.4 MRI Contrast Agents 
Contrast agents may also be used in the MRI procedure. Contrast agents are  
small magnetic compounds or are based on nanoparticles. that decrease the relaxation 
times (T1 and T2) of water protons and all other nearby nuclei, increasing contrast 
between regions where the contrast agent accumulates versus the background tissue 
signal. There are several mechanisms by which this can happen. First, in most cases 
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the contrast agent passively diffuses throughout the body, to different tissues and at 
different rates due to different associations between the interactions of the contrast 
agent with the organ it comes in contact with. These differences increase the contrast 
difference observed between various biological features. The magnetic effect of most 
contrast agents are provided by gadolinium(III)-based contrast agents (GBCA’s) or 
magnetic iron-oxide nanoparticles (MION’s), which enhance proton relaxation 
through diffusion or proton exchange with the bulk water solvent.  
1.2 Two Major Classes of Clinical MRI Contrast Agents 
1.2.1 Contrast Agents Based on Gadolinium 
All FDA-approved and currently available contrast agents are based on 
gadolinium(III). Gadolinium(III) is a paramagnetic lanthanide metal that enhances the 
relaxation times of water protons in the body. In a typical Gd(III) contrast agent, the 
otherwise toxic Gd(III) ion is ligated with an organic molecule that occupies, in most 
cases, eight out of nine available coordination sites, with the last open coordination 
site filled by a water molecule. Several examples of such systems are illustrated in 
Figure 1-2.  
The most pronounced relaxation enhancement involves the exchange of water 
molecules coordinated to the gadolinium center and their transfer to the bulk water 
solvent, decreasing relaxation times. This is known as “inner-sphere” relaxivity and 
accounts for over 60% of the relaxation enhancement.6 The remaining relaxation 
enhancement is due to the “outer-sphere” contribution, which is the result of 
interactions between paramagnetic complexes and nearby water molecules. 
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Gadolinium(III) is the lanthanide of choice since Gd(III)’s electronic relaxation time is 
close to that of the 1H oscillation frequency.7 
 
Figure 1-2: Structures of 1) Magnevist (Gd-DTPA), 2) Dotarem (Gd-DOTA), and 3) Vasovist (MS-
325), each with one water molecule coordinated to the Gd(III) center. 
In 1988, the first gadolinium-based contrast agent, Magnevist Figure 1-2, was 
approved for clinical use as an MRI contrast agent, and eight others have followed 
since then. These agents are not visualized directly nor do they have responsive 
elements. Though MS-325 targets liver and Eovist targets liver, they are still 
considered unresponsive. Regardless, these contrast agents enhance MR image 
resolution of differences between different tissues can often be more accurately 
resolved using a contrast agent. Their use is sometimes critically important.  One 
example is depicted in Figure 1-3, where brain tissue that had undergone a stroke is 
only clearly observed after the use of a contrast agent, and this symptom of stroke 
might not otherwise be seen by MRI. 
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Figure 1-3: Lab Labels provided by :http://commons.wikimedia.org/wiki/ 
File:Bluthirnschranke_nach_Infarkt_nativ_und_KM.png, provided by: 
http://commons.wikimedia. 
 
1.2.1.1 Drawbacks of Gadolinium-Based Contrast Agents 
The use of Gd(III) contrast agents raises toxicity concerns in those with kidney 
disease, specifically nephrogenic system fibrosis (NSF), wherein the contrast agent is 
not cleared from the body fast enough to eliminate any risks associated with the 
release or transmetallation of Gd(III) from the chelate. NSF is a serious illness that 
often is not detected. 
And while Gd(III) has proven to be the most useful lanthanide metal to use for 
decreasing relaxation times in water protons in the bulk solvent, it’s not necessarily the 
best paramagnetic metal used in the design of other types of contrast agents. 
Relaxation times of water protons also suffer a loss in relaxation time before further 
enhancement at about 1.0 T.8 
Gray matter  White matter 
 
Ventricle (CSF) 
 
Contrast Agent Added 
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1.2.2 Contrast Agents Based on Magnetic Iron-Oxide Nanoparticles (MIONs) 
Another class of MRI contrast agents is based on magnetic, iron-oxide 
nanoparticles (MIONs). Several types of MIONs exist, consisting of magnetite (Fe3O4) 
or maghemite (ϒ-Fe2O3) iron oxide particles, with many different sizes and surface 
functionalizations. These superparamagnetic nanoparticles are particularly effective at 
reducing the T2 (spin-spin) relaxation times of water protons. Their use requires high 
concentrations comparable to GBCA’s to allow for sufficient MRI contrast; typical 
administrative dosages of either type are 5-10 grams of contrast agent.9-12 Most 
research on MIONs deals with tailoring the nanoparticles for use as blood-pool agents 
as well as surface functionalization to allow for improved cellular uptake and lower 
administrative concentrations.10,13 
Concomitant with surface functionalization of MION’s, other chemical 
reporters must be introduced in order to afford a viable, responsive contrast agent. The 
functionality and response of these agents is caused by the aggregation of the 
monomeric particles, causing decreases in both T1 and T2, and producing contrast in 
the MR image. While these agents have been widely documented in the literature, they 
remain experimental in that only one has been FDA-approved, and it is no longer 
manufactured for medical use.14  
1.2.2.1 Drawbacks of MION’s 
Concomitant with surface functionalization of MION’s, other chemical 
reporters must be introduced in order to afford a viable contrast agent for imaging a 
specific target. The functionality and response of these agents is caused by the 
aggregation of the monomeric particles, causing decreases in both T1 and T2, and 
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producing contrast in the MR image. While these agents have been widely 
documented in the literature, they remain experimental in that only one has been FDA-
approved, and it is no longer manufactured for medical use.14  
The aggregation states necessary for enhancing the MR image obtained are 
very desirable in order to differentiate between the observed contrast resolution. The 
aggregates desired are not readily formed in a system where the MION’s would 
normally just passively diffuse throughout the biological system. While their 
distribution can be predicted, they are severely limited as unresponsive MR contrast 
agents, and for an unresponsive system, are demonstrated to be more challenging than 
the previously described Gd(III) agents in MR imaging. Their responsive derivatives, 
discussed later in chapter 1.5.3, are what have maintained interest in MION’s as MRI 
contrast agents. 
1.3 Other MRI Contrast Agents 
1.3.1 Contrast Agents Based on Manganese 
Multiple contrast agents have also been reported based on manganese. Two 
manganese-based contrast agents have been commercially available but are no longer 
marketed:  
manganese(II) dipyridoxal diphosphate (Mn-DPDP, Teslascan), shown in  
, is FDA-approved as an injection for liver imaging,15 as well as 
orallyadministered manganese(II) chloride (LumenHance),16 for general imaging 
purposes as well as imaging certain calcium efflux events.17 While gadolinium agents 
have continually attracted more attention than manganese agents, the same reported 
toxicity issues such a nephrogenic systemic fibrosis (NSF) was reported in 2006 for 
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manganese agents.18,19 This has decreased the 
interest of manganese, and further development 
of contrast agents based on manganese has been 
decreased. 
Figure 1-4: Structure of Mn-DPDP. 
Both free manganese(II) ion and chelated manganese(II or III) have severe 
safety concerns.20-23 Free manganese(II) ion administered as buffered MgCl2 for oral 
administration is nearly as toxic as gadolinium(III) with a toxicity of 0.5 mm/kg in 
rats.24 Additionally, manganese(II) ions interfere and/or compete with endogenous 
calcium(II) ions in numerous biological processes, which are not fully understood. 
Chelated manganese(II) in most cases releases manganese(II) ions through 
displacement of the metal in the ligand by calcium(II) ions,20 and the increased 
membrane permeability of manganese chelates results in undesirable and 
unpredictable biodistribution. Combined with excessively long clearance times, the 
safety of manganese-based contrast agents remains of issue. 
Porphyrin derivatives have been commonly used as ligands for manganese-
enhanced contrast.25,26 Most recently Cheng et. al. have reported a manganese 
porphyrin dimer that binds to HSA with successful imaging in vivo at 3 T, however 
little change was observed at higher field strengths.27 Qazi et. al. reported successful 
loading of a manganese porphyrin into a bacteriophage for targeted tumor delivery,28 
but found that the high resultant concentration of manganese resulted unexpectedly in 
only marginally-reduced relaxation rates over the same total concentration of contrast 
agent in a homogenous solution.  
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Both of these examples suggest that the contrast enhancement from manganese 
is fundamentally limited by concentration. While manganese agents have been used in 
non-targeted imaging, they are no longer commercially available, and the new 
developments with manganese are still in experimental stages. Safety issues such as 
instability in the presence of endogenous  
Ca(II) ions and its deposition in fatty tissue represent severe limitations to their 
future development for clinical use as responsive contrast agents as well. 
1.4 Fluorine MRI Contrast Agents 
1.4.1 Desirable MR Properties of 19F  
Imaging 19F by MRI has drawn considerable interest due in part to fluorine’s 
MR properties. The 19F nucleus is 100% naturally abundant, has high MR sensitivity 
(0.834 relative to 1H),29 and an extremely large chemical shift range (>350 ppm), 
making signal overlap from different 19F nuclei extremely unlikely. Furthermore, the 
19F nucleus is virtually non-existent in biological systems, effectively eliminating 
background signals and producing greater contrast in the MR image.  Small amounts 
of solid fluorides are found at various concentrations in teeth and bone, but are below 
MRI detection limits due to their low concentrations and extremely short T2 relaxation 
times.30 As a result, multiple fluorine labels can be detected individually, whether 
different labels are used in one contrast agent, or during simultaneous use of multiple 
19F contrast agents.  
Fluorine also has a high gyromagnetic ratio of approximately 40 MHz per 
tesla, only 6% lower than 1H. This is a critical advantage for 19F MRI since clinical 
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magnets already in use today, could be adjusted to image 19F. This requires only 
adjustments in tuning and experiment design and does not require a different probe. 
1.4.2 Considerations of 19F Imaging 
The predominant issue in all classes of 19F contrast agents is fluorine’s low 
sensitivity in MRI. While the lack of background signals is advantageous in one 
regard, it is also a challenge to introduce 19F contrast agents in sufficiently high 
concentrations for in vivo imaging. The concentrations required for 19F MRI are in the 
millimolar range (ca. 10-50 mM), whereas 1H MRI agents image endogenous water 
molecules up to 55 M.31 
Fluorine also has considerably long relaxation times, with T1 values of 0.5-3 
seconds. This requires recycle delay times (d1’s) in MR pulse sequences to be 3-5 
times T1, resulting in scan repetition times of 3-6 s.32 Such long repetition times, 
combined with the time limits for clinical imaging procedures (60 minutes or less), 
ultimately reduces sensitivity, and often prevents many proposed 19F contrast agents 
from being clinically viable for MRI.33,34  
1.4.3 Current 19F Contrast Agents 
1.4.3.1 Organic, Diamagnetic Fluorinated Molecules 
The MRI contrast agents discussed thus far all detect the 1H nuclei of 
endogenous water molecules, but MRI is not restricted to 1H. MRI-active nuclei 
include 13C, 15N, 31P, and of particular interest, 19F.  The concept of fluorine-based 
MRI was reported in 1977 by Holland et al.,35 only four years after Lauterbur’s 
demonstration of 1H MRI in 1973.36 Initially, the presence of 19F nuclei in many drugs 
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prompted exploration in to 19F MRI imaging. The anti-cancer medication 5-
fluorouracil (5FU) was quickly identified as a molecule to image, with Wolf et al., 
performing the first experiment with that drug ten years later in 1987.37 Further 
improvements for imaging 5FU have been made include superior spatial resolution38 
and further enhanced chemical shift changes of 5FU in different biological 
environments.39  
Other fluorinated drugs are being continuously examined as potential 19F 
imaging agents. The anti-depressant fluoxetine, the anesthetic haloperidol, and the 
benzodiazepine fluphenazine have drawn particular attention, having particularly short 
19F T1 values compared to other fluorinated agents. The immediate advantage of 
imaging fluorinated drugs is that they have already proven to be safe and are approved 
in most countries, eliminating any synthetic work and essentially eliminating 
pharmacokinetic studies. 
However, imaging fluorinated pharmaceuticals has not resulted in their 
conversion to also serve as MRI contrast agents, but have shown to be useful imaging 
agents in some cases. The most promising agents however still are met with imaging 
difficulty due to fluorine’s low sensitivity, and they lack any design considerations that 
are otherwise used strictly to improve sensitivity and contrast. These design 
considerations are discussed further in section 1.4.2. 
1.4.3.2 Perfluorocarbons 
Another class of contrast agents have been developed, which are highly-
fluorinated or perfluorinated small organic molecules (perfluorocarbons or PFC’s), 
developed specifically for MR imaging. The structures of these molecules are simple 
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hydrocarbons that have been converted to their respective fluorocarbons. Several 
examples include perfluorobenzene, perfluoro-octylbromide (PFOB), and perfluoro-
15-crown-5, which are depicted in Figure 1-5. Larger PFC’s exist, but as the size of 
PFC’s increase, obtaining MR contrast can decrease as well due to their decreased 
tumbling rates and thusly their decreased T1, and in particular, their T2 values. 
 
 
 
 
1 2 3 
Figure 1-5: Examples of perfluorocarbons used as MRI contrast agents: 1) Perfluorobenzene, 
2) Perfluoro-Octylbromide (PFOB), and 3) Perfluoro-15-crown-5. 
With several exceptions, and while having an extremely low solubility in water 
or buffer, these compounds are biocompatible when used as an emulsion for 
intravenous injection.40 Practical considerations however, in particular from multiple 
fluorine resonances due to inequivalent 19F nuclei as in the case of agents such as 
PFOB, create complications in an MR experiment as their multiple resonances cause 
the appearance of fragments in MRI, which can clearly be seen in Figure 1-6, looking 
at the MRI phantom image for PFOB.  
The MRI phantom image produced from multiple fluorine resonances is 
resolved to two images at different positions with only slight overlap, whereas 
perfluoro 15-crown-5 shows only one resonance and one image in the phantom image: 
Nonetheless, they both demonstrate low signal-to-noise (SNR) ratios.41  
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Perfluorobenzene has shown particular promise due to its single 19F resonance, 
faster relaxation times than its non-aromatic counterparts, and lack of biological 
toxicity. However, its low molecular weight relative to other perfluorinated 
compounds results in high volatility, which alone prevents its safe use for human 
study.42 Additionally, the high lipophilicity and membrane permeability of 
perfluorocarbons designed as MRI contrast agents present safety concerns in their 
toxicity due to extremely long clearance times, for example, up to 250 days for 
perfluoro-15-crown-5.43  
Higuchi et al. reported in 2005 that amyloid-beta (Aβ) plaques, the hallmark of 
Alzheimer’s disease pathology, could be detected by MRI using a molecule called 
FSB (or (E,E)-1-fluoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styryl-benzene).33 The 
structure of FSB was based on the organic dye Congo Red and can penetrate the 
blood-brain barrier.  
The authors cite their previous work where an analogous compound BSB 
(having a bromine in place of the fluorine in FSB) was found to label amyloid-beta 
plaques. They reasoned that FSB should label plaques as BSB does and allow for 
plaque detection by 19F MRI. The greatest contrast was observed using a T2-weighted 
gradient-echo experiment, and the authors concluded that cross-linking and protein 
interactions in the plaques are responsible for the decreased T2 values observed. 
However, having a single fluorine atom per molecule of FSB, the sensitivity was also 
very low. 
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Figure 1-6: NMR Spectra and gradient-echo phantom images of perfluorooctylbromide 
(PFOB) and perfluoro-15-crown-5. Images reproduced from Srinivas et. al. and used with permission. 
Table design reproduced from Wolters et. al 
Work by Flaherty 44et al. consisted of adding more 19F nuclei to the structure of 
FSB, in on example by saturating the benzene core, and in another example where 
trifluoromethyl groups were placed on the peripheral phenyl rings.44 (Figure 1-7) The 
sensitivity was increased, and these compounds were found to be preferentially more 
specific for Aβ plaques than FSB, but a mechanism behind these observations wasn’t 
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concluded. Furthermore, these three agents could not be used in high amounts to 
increase sensitivity, showing nephrotoxicity at 40 mg/kg. 
 
 
Figure 1-7: FSB, both Flaherty molecules (unnamed): Chemical structures of FSB, 
and their further derivatives as produced by Flaherty et al. 
Perfluoro-15-crown-5 was examined in 2008 by Flogel et al. for imaging 
inflammation and ischemia, symptoms that are related to trauma and cardiac disorders, 
among others.45 The compound was emulsified and injected intravenously to mice 
models and imaged by MRI. The compound was found to primarily locate areas with 
ischemia. This was done by taking a standard 1H MRI scan to show where the trauma 
occurred, then comparing it to the 19F MRI scan. It was found that the crown ether 
preferentially deposited in border regions between healthy tissue and inflamed or 
ischemic tissue. Repeat trials were done over several days and the distribution of 19F 
MR signals seemed not to change. However, as noted before, the extremely long 
elimination time of perfluoro-15-crown-5 renders it unsafe for clinical use. 
Hexafluorosulfane (SF6), combined with other inert gases as an inhalant, has 
been shown to localize in the lungs and other airways and used partially to measure 
pO2 or to visualize abnormalities.46 This compound benefits from having a desirable 
safety profile with clearance times in hours rather than in days, and what’s most 
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noteworthy about this compound is that it has an extremely short T1 value of 5.9 ms. 
The short T1 time is unique to this compound, and has been suggested that this is due 
to the sulfer-fluorine bond, which is one of the strongest single bonds ever measured. 
As the literature has presented, however, is that the different instrumentation is 
required to successfully image this compound, which is likely due to the unreported 
value of the concomitant shortening of T2 along with the reduction in T1.47 
1.4.4 Limits to Degree of 19F Labeling 
One approach to increase the sensitivity of fluorine contrast agents is to 
incorporate as many chemically-equivalent 19F nuclei as possible within the contrast 
agent. Perfluorinated compounds (PFC’s; discussed in section 1.3.3) have very high 
degrees of fluorine labeling, but they also suffer from extremely low solubility in 
water or buffer due to the hydrophobic nature of fluorine. Low solubility in water also 
increases clearance times that raise their safety concerns.  
The pharmacokinetics, especially clearance times, of a contrast agent should be 
part of its design. An ideal contrast agent would have both high 19F labeling while 
retaining high water solubility.  
1.4.5 How To Address These Issues 
The design of a viable 19F MRI contrast agent for biological use would be most 
efficient using chemically equivalent fluorine labeling. The extent of fluorine labeling 
should be as high as possible while maintaining high water solubility, and high water 
solubility should also result in clearance times of at most, 24 h.  
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1.4.6 Metal-Based 19F MRI Contrast Agents 
1.4.6.1 Use of Paramagnetic Metals 
The incorporation of a paramagnetic metal center within the contrast agent, 
spaced within ca. 6.0-7.5 Å from the detected nuclei and the metal center can 
significantly decrease relaxation times, often by over two orders of magnitude.32,48 
This effect is known as paramagnetic relaxation enhancement (PRE), and allows for 
more scans to be taken per unit time, providing greater contrast in the MR image. 
Lanthanide(III) ions are commonly used, especially Gd(III) for imaging 1H.  
Without the use of a paramagnetic metal center, local concentrations of 
fluorinated compounds require up to and in excess of 100 mM in biological systems to 
obtain useful MR images.34,49 Such high concentrations of fluorinated agents are 
difficult to achieve in vivo and also pose safety concerns even if they are chemically 
inert. 
1.4.6.2 Design Considerations of Metal-Based 19F Contrast Agents 
The metal ions themselves are inherently toxic and require the use of ligands 
that form kinetically and thermodynamically stable complexes with the 9-coordinate 
Ln(III) ions. Concomitant with 1988’s introduction of [Gd-DTPA]2- (Magnevist) there 
has been extensive study of different ligand systems to bind Ln(III) ions. Most are 
modifications of DTPA or of DOTA frameworks. In 1H MRI, Gd(III) has proven to be 
superior to the other Ln(III)’s. However, the PRE of 19F nuclei provided by Gd(III) 
often shortens their T2 times to the extent where there is virtually no signal resolved in 
19F MRI/MRS.  
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Other Ln(III) metals must then be used to afford viable 19F contrast agents. The 
clinical success and demonstrated safety profiles of Gd(III)-based contrast agents can 
be applied to other Ln(III) ions, as all are nine-coordinate and approximately the same 
size (although the ionic radius does become smaller through the series).   
Nitrogenous macrocyclic frameworks, such as 1,4,7-triazonane (TACN), 
1,4,7,10-tetraazacyclododecane (cyclen) or 1,4,8,11-tetraazacyclotetradecane (cyclam) 
are popular starting points in contrast agent design. The secondary amines are easily 
substituted with organic groups (informally known as pendant “arms”), completing the 
coordination environment for the metal, and imparting other functionalities such as 19F 
labels.  
Enhanced signal intensities in 19F MRI/MRS can be obtained with high 19F 
labeling provided that 1) each 19F label is chemically equivalent for optimal 
sensitivity, and 2) the resultant complex remains highly soluble in water. 
1.4.6.3 Sensitivity, Water Solubility, and Biocompatibility 
The predominant issue in all classes of 19F contrast agents is fluorine’s low 
sensitivity in MRI. This is due to their extremely long T1 times. The recycle delay 
period (d1) of 19F nuclei can range from 2.2-5 seconds between scans in order to allow 
full relaxation decay before the next scan begins. Gradient-echo imaging benefits from 
scan repetition prior to full relaxation,50 and other techniques including turbo gradient-
echo (TGE),51 gradient-echo and spin-echo (GRASE),52 and sweep imaging with 
Fourier transform (SWIFT)53,54 can all be used and can help increase the SNR of 
contrast agents, but offer only modest improvements in sensitivity.   
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The greater impact on 19F sensitivity is obtained by decreasing relaxation times 
of 19F nuclei which is best accomplished by incorporating a paramagnetic metal center 
within the contrast agent. Different metals can reduce relaxation times to various 
extents, and also can reduce T1 and T2 by different ratios.  Since the repetition time 
between MRI scans is limited by T1, metals that provide the shortest T1 values are 
desired. However, concomitant with a reduced T1 value is also a reduced T2 value, 
which can result in line broadening and decreased SNR’s. Therefore metals providing 
T2/T1 ratios closest to 1 are actually the most effective for increasing sensitivity.  
Additional parameters such as tumbling rate (τR) in solution, the distance 
between the paramagnetic center and the 19F nuclei (d), and field strength of the MRI 
instrument also affect the sensitivity. These parameters will be discussed in further 
detail in Chapter 2. 
Another critical limitation in 19F MRI is fluorine’s hydrophobicity. A viable 
MRI contrast agent must be soluble in water and at appreciable concentrations, but a 
molecule’s water solubility decreases as more and more 19F nuclei are installed on the 
molecule. But as discussed in 1.4.4 and 1.5.2, fluorine’s low sensitivity issue benefits 
from high fluorine labeling, presenting the need of balancing ligand design to 
maximize the fluorine loading while retaining sufficient water solubility.  
Sensitivity is also dependent on local concentrations in vivo. The 
administration therefore of as high doses as possible of a 19F contrast agent produces 
the greatest contrast. However, use of high concentrations of a metal-based 19F 
contrast agent, even when the metal is chelated with the strongest of ligands (e.g. 
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DTPA and DOTA derivatives), raises the same risks for patients with kidney 
impairment or NSF as do Gd(III) agents. 
One way to address this problem of course would be reducing the amount of 
contrast agent used, but since improving sensitivity is critical for 19F contrast agents, 
lower doses are not an ideal solution. Instead, another solution is concerned with 
ensuring that the in vivo clearance of the contrast agent occurs quickly enough so that 
appreciable amounts of transmetallation do not occur. Thus, while 19F-based contrast 
agents might require high dosage, the potential safety risks can be reduced if the 
contrast agent is rapidly cleared from the biological system. 
1.5 Responsive or “Smart” Contrast Agents 
 
Contrast agents can also be designed to produce a change in the MR image in 
response to their interaction(s) with biomarkers. These contrast agents are known as 
responsive or “smart” probes, which are unrelated to targeted probes such as MS-325 
(Vasovist) or Eovist, which have a predictable biodistribution but do not have a 
response mechanism.   
1.5.1 The Importance of a Ratiometric Response 
All of the above examples also suffer from an inability to quantitatively 
measure any desired target. Stated another way, they are not ratiometric. In 2009 
Gianolio et al. reported a 19F-based probe that responds to pH with changes observable 
both in the 1H and 19F MR images.55 The signal that directly indicates pH levels of the 
local environment responds to manipulation of a sulfonamide group, changing the 
relaxation times of 1H nuclei, where other contrast agents usually lack a ratiometric 
response due mostly to overlap of the resonances that are observed between unreacted 
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and reacted states. A single MR image cannot be used to determine the exact 
concentration of the contrast agent, this probe can be independently imaged by 1H 
MRI as well as 19F MRI as it contains 19F reporter nuclei that do not undergo this 
change in relaxation rates upon response to the analyte while the 1H nuclei that are 
imaged do. Thus, combing the results from the 1H image and the 19F image allows for 
a ratiometric response. However, while tuning a standard 1H MRI device to 19F is a 
reasonable endeavor for longer-term studies, it is not reasonable to continuously re-
tune an MR device back and forth between 1H and 19F in order to assemble a 
diagnostic scan, so for clinical use, unless two separate magnets are available, this 
probe’s ratiometric response cannot be used easily since both a 1H and 19F experiment 
must be conducted within a short period of time, which is much shorter than the time 
required for 1H and 19F tuning of a single MR instrument.  
A solution then for designing a ratiometric probe for MRI purposes would 
require that two or more independent signals from the same nuclei, be imaged in one 
combined procedure. Current Gd(III) agents image water protons, as is the case with 
other traditional MRI contrast agents. One of the most important advantages then of 
19F MRI involves its ability to differentiate between two signals, both provided by a 
single 19F MRI contrast agent. 
Responsive MRI contrast agents contain functional groups that, in presence of 
a particular biomarker, alter the MR and/or chemical properties of the probe. This 
produces a change in the observed contrast between the probe in absence of the 
biomarker and the probe in presence of the biomarker, which can be resolved by 
MRI/MRS. The chemical groups used to target specific biomarkers commonly are not 
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selective for a single biomarker alone, leading to false positives in the MR image. 
Ideal contrast agents are therefore those that are selective for a single analyte. 
When a contrast agent is in the presence of its targeted biomarker, there must 
be a change in the MR properties of the probe that is significant enough to be resolved 
by MRI/MRS. Multiple response mechanisms can be detected by MRI/MRS, 
depending on the nature of the responsive contrast agent. 
1.5.2 Responsive Gd(III)-Based Contrast Agents 
Responsive Gd(III)-based contrast agents are limited to a single mechanism—
change in the hydration number (q) of the Gd(III) center.7,56 As q is increased, more 
water molecules can interact with the inner sphere of the metal center, enhancing 
relaxivity, and brighten the MR image. 
Several issues are encountered with this response mechanism. By increasing 
the q value, the Gd(III) center can also interact with endogenous anions such carbonate 
and phosphate.57,58 These interactions negate the enhanced relaxivity to various 
degrees, producing a nebulous response. Increasing q also increases the lability of the 
Gd(III) ion, resulting in greater safety concerns. Finally, it is impossible to determine 
whether any contrast enhancement observed by MRI is a result of either higher 
concentrations of the biomarker, higher concentrations of the contrast agent, or a 
combination of both, since accurate quantification of these contrast agents has 
remained elusive. 
1.5.3 Responsive MION-Based Contrast Agents 
Responsive contrast agents based on MION’s function through the formation 
of aggregates in response to a biomarker. These aggregated states alter the observed 
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relaxation times—most often with an increase in T1 and decrease in T2—which can be 
resolved by MRI/MRS.14 Unlike Gd(III)-based agents, these systems are not affected 
by endogenous ions, but still suffer from several issues limiting their practical use. 
Their response by MRI is observed as darkening which is more difficult to detect, the 
observed change in relaxation times is less than two-fold limiting their practicality, 
and they exhibit a non-linear response to different concentrations of analyte.59  
It has been reported that the aggregate size of MION’s must be limited to 
approximately 200 nm, and as aggregation occurs, the T2 times increase as the 
aggregate grows in size. What this means is that the contrast effect of the agent 
changes gradually as the aggregates become larger and larger, producing a grayscale 
image much like what a Gd(III) agent would create. Likewise, differences in chemical 
environments also affect the relaxation times, which can be analyzed and processed in 
order to form an image.  
More importantly, these agents have demonstrated that their response to an 
analyte can occur from two different states of aggregation, following the bell-shaped 
curve in Figure 1-859 which is the report of a MION-based contrast agent used for the 
detection of Cu(I).   
As seen in Figure 1-8 the green trace enhances r2 to a point with increasing 
concentrations of Cu(I), but then r2 decreases following that point. Also, the blue trace 
with the highest amount of Cu(I) follows no pattern relating to the other three traces or 
the control. This results in that the recorded relaxation times might not correlate to one 
single value of analyte concentration, in this case Cu(I), leading to an ambiguous 
response. 
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Figure 1-8: The responsive MION agent, selective for Cu(I), shows in green a non-
linear response, while the 100 µM trace in blue doesn’t follow any pattern related to 
the other four traces. Reproduced from Smolensky et al. (Dalton Trans., 2012, 41, 
8039). 
Furthermore, their response is dependent on aggregation, and does not change 
linearly.59 Some MION systems are ratiometric while others are not—which is a 
property necessary to quantify (as opposed to strictly visualize differences in) analyte 
concentrations in target tissue by MRI.59 While MION-based contrast agents have 
proven to be safer than other contrast agents, these factors represent strict limitations 
within the scope of MION-based contrast agents for clinical use. 
1.5.4 Responsive 19F-Based Contrast Agents 
The response mechanisms available for imaging fluorine-based contrast agents 
are unrelated to those of Gd(III)- and MION-based responsive contrast agents, a result 
provided by using fluorine as the detected nuclei rather than endogenous water 
protons. Three independent mechanisms can be used to detect the response of 19F-
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based probes: changes in the chemical shift of the 19F signal, changes in the relaxation 
rates of 19F nuclei, and changes in the signal intensity observed by MRI/MRS. 
1.5.4.1 Change in Chemical Shift 
Known as the lanthanide-induced shift (LIS), but also can be applied to other 
paramagnetic metals such as Fe(II) (which is explored in this work) is dictated by the 
McConnel-Robertson equation, which predicts that the magnitude of the LIS carries an 
d3 dependence, where d is the distance from the nuclei being imaged and the 
paramagnetic center. The response mechanism of a fluorine probe should then result in 
a conformational change of the molecule that changes the distance between the 
paramagnetic center and the 19F nuclei. 
The change in chemical shift (∆δ) when applied to MRI (as long as the 
chemical shift change is of an appreciable value, ca. 8-10 ppm or greater) provides that 
one MR image at a particular chemical shift could detect the probe in absence of a 
biomarker while a second image at a different chemical shift could detect the probe in 
presence of the biomarker. Either image alone can be used directly to detect either the 
appearance or disappearance of the original or the shifted resonance, creating an 
“on/off” type of probe.  
1.5.4.2 Change in Relaxation Times 
A second response mechanism for 19F-based probes that can be imaged by 
MRI is a change in the relaxation times of the 19F-nuclei on the contrast agent. This 
response mechanism also is generated by a conformational change in the contrast 
agent in response to an analyte. According to Bloch-Redfield-Wangsness (BRW) 
theory, the enhancements in relaxation rates, in a similar fashion to the McConnel-
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Robertson equation (d3 dependency), carry an d6 dependency, where d again is the 
distance between the 19F nuclei and the paramagnetic center. A change in d produces a 
change in the relaxation times.  
1.5.4.3 Change in Signal Intensity 
 A third response mechanism is reliant only on the intensity of the observed 
signal, which is provided as the T2 relaxation time is changed. Changes in T2 result in 
either increased or decreased line broadening. This immediately presents a possible 
complication in that the observed signal intensity of any 19F contrast agent is also 
determined by its local concentration, which remains an issue for Gd(III)-based agents 
which have a single 1H chemical shift. Fluorine-based contrast agents however can be 
designed with different fluorine labels with different chemical shifts, and can be 
independently imaged by MRI/MRS. 
If a 19F-based contrast agent’s response mechanism results in a change of 
signal intensity, the local concentration must be determined as well. Installing an 
additional fluorine label that does not respond to the presence of the biomarker, and 
having a different chemical shift from the reporter 19F nuclei, can allow separate 
imaging separately to determine local concentrations of the contrast agent. 
Incorporating such a fluorine label would likely be challenging, and may also reduce 
water solubility. 
Another approach to determine local concentrations would be to image a 
prominent 1H resonance on the probe. This approach might be difficult as well, since 
conformational changes in the contrast agent would likely affect most if not all 1H 
nuclei in a similar fashion as 19F nuclei are affected. 
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The possible complications with resolving these issues in a contrast agent, 
whose response mechanism results in a change in the signal intensity, are the most 
difficult to address when compared to the other two response mechanisms described. 
1.5.5 Current Responsive Metal-Based 19F MRI Contrast Agents 
Despite fluorine’s low sensitivity, there are many reports of fluorinated 
chemical probes that have been resolved by MRI/MRS, using all three response 
mechanisms (a change in chemical shift, a change in relaxation times, and/or a change 
in signal intensity).  
An example Figure 1-9 of a chemical shift-changing 19F probe was reported by 
Deutsch et al. in 1989.60 A number of fluorinated anilines were synthesized and 
chemical shift changes as a function of pH were recorded. Different substitution 
patterns of 19F nuclei on the aromatic ring changed the pKa values of the anilines, and 
their transition from protonated and deprotonated states resulted in chemical shift 
changes of 5-12 ppm, and the fluoroanilines reported showed responses from pH = 2 
to pH = 8. These results were confirmed by MR imaging of rats in vivo by Vervoort et 
al.61 
Changes in either the T1 and/or the T2 relaxation times of the 19F nuclei can 
also be used for imaging. In 2008, Mizukami et al. reported real-time in vitro imaging 
with a Gd(III) complex was used to monitor enzymatic activity using the cleavage of a 
portion of the fluorinated molecule by caspace-3.62 
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Figure 1-9: Mizukami Peptide Gd OCF3 Complex: In this image of Mizukami’s gadolinium probe, the 
metal is complexed with a DO3A ligand, connected to a short peptide, and terminating with a para-
trifluoromethyl group. The fluorine reporter group is highlighted in blue while the amide bond that is 
cleaved by the enzyme is highlighted in red. 
The molecule Figure 1-9 contains a ligated Gd(III) center, a peptide linker that 
also serves as the substrate for the enzyme, and a para-trifluoromethoxy reporter 
group. The activity of the enzyme cleaves the reporter group and the relaxation times 
are then increased. However, the change in the relaxation times were trivial, and while 
the proof-of-concept study was successful, this system would not be feasible for in 
vivo use due to nebulous responses and merging of the resonances prior to and after 
the enzymatic cleavage of the CF3 reporting group. Additionally, the sensitivity is very 
low, meaning a system such as this would not provide the required contrast for a 
clinical MRI procedure in vivo demonstrating the same response characteristics. 
An example of a probe imaged by change in signal intensity was reported by 
Takaoka et al. in 2011.63 A series of 19F-labeled compounds were attached to several 
protein substrates. These molecules would self-assembled in to aggregates, where little 
to no signal was observed from the aggregates alone (despite high 19F labeling) due to 
decreased T2 values of the 19F nuclei. When exposed to the target proteins, the 
aggregates disassemble back to their monomeric states and T2 times are restored, and 
the 19F signal can be seen by MRS. The greatest signal enhancement was observed 
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using biotin and methotrexate as substrates. They concluded that this system is an 
“on/off” system, in that in absence of protein no signal is observed, while the addition 
of the protein resulted in a strong signal observed by MRS.  
1.6 Proposed 19F Metal-Based Complexes and Project Aims 
 
The primary goal of the work carried out and described in this thesis is to 
synthesize and analyze responsive 19F metal-based contrast agents that improve upon 
currently reported probes in their performance by MRI/MRS, and to provide important 
information of their in vivo biocompatibility, biodistribution, clearance times, and 
their pharmacokinetics. This study requires the synthesis and analysis of prototypical 
19F contrast agents, their behavior in response to different paramagnetic metals used, 
19F MRI imaging, compatibility in blood, optimization of ligand field environment, in 
vivo studies to determine biocompatibility, and finally to synthesize a ratiometric and 
responsive 19F contrast agent that provides sufficient sensitivity to be resolved in MRI 
imaging procedures of 30 minutes or less.  
The results of each of these specific aims will be discussed in detail in the 
following chapters. 
2 Design of Metal-Based 19F MRI Contrast Agents—Optimizing 
Magnetic Resonance Properties 
2.1 Introduction 
 
As discussed in Chapter 1, a clinically viable 19F contrast agent requires hi-gh 
sensitivity and biocompatibility. Sensitivity can be increased by increasing the number 
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of chemically equivalent fluorine nuclei in a contrast agent and by reducing their 
relaxation times. The biocompatibility of such probes can benefit from high water 
solubility, low toxicity, and rapid clearance of the contrast agent. These properties can 
be evaluated and adjusted in the design of a contrast agent for optimal performance in 
MRI. The most appropriate design for a safe and clinically viable 19F contrast agent 
would consist of a strongly chelated, paramagnetic metal center with a high degree of 
equivalent 19F nuclei and high water solubility. Chapter 1 briefly described how 
certain structural properties can be manipulated in a probe’s design both to optimize 
sensitivity and to establish desirable pharmacokinetics.  
The focal point of this chapter will be optimizing sensitivity. Many of the MR 
properties of paramagnetic 19F contrast agents (T1, T2, 19FLIS) can be derived 
theoretically and measured experimentally. This chapter will discuss development and 
analysis of MR theory applied to the prototypical ligand DOTAm-F12 and its 
corresponding metal complexes. The work reported in this chapter was carried out first 
in order to optimize the sensitivity of 19F-based MRI contrast agents. 
2.2 19F Signal Intensity 
 
The signal intensity for spin-echo MRI is dependent on the number of nuclei in 
the volume being imaged and their longitudinal and transverse relaxation times (T1 and 
T2) according to the following equation:64,65 
! ≈ #$%& exp *+,+-. /1 − 2 exp34*+546,- .+7 8 + exp *4+,+7 .:  (2-1) 
where I is the intensity of the image, N(F) is the 19F nuclei density detectable 
by NMR, and TR and TE are the repetition time and echo times of the pulse sequence, 
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respectively.  Image intensity can be augmented by incorporating additional 
chemically equivalent 19F nuclei and by increasing 19F relaxation rates.  Linear 
polymers,66-69 dendrimers,70-74 hyperbranched or star polymers,64,75-77 and 
nanoparticle-based78-80 probes have been reported that maximize local 19F spin density 
and facilitate reduced fluorine relaxation times via the slow molecular tumbling of the 
structures.  However, when relaxation is modulated by decreasing the rotational 
correlation time (τR), the concomitant decrease in T2 negatively affects signal intensity.  
Optimizing signal intensity, thus, requires decreasing T1 as much as possible while 
minimizing the effect on T2 so as to achieve a T2/T1 value near one.  Paramagnetic 
metals are well known to decrease relaxation times of nearby nucleus by up to two 
orders of magnitude, with the relative decrease in T2 versus T1 being influenced by the 
nature of the metal and its complex.31,81,82 We postulated that this approach, with 
careful consideration of the complexes’ structure, can afford highly water soluble 
fluorine contrast agents; which can, in principle, further be exploited in the design of 
responsive imaging agents.  
 
2.3 Limitations of Reported 19F Responsive Probes 
 
Recent progress in the field of molecular paramagnetic 19F imaging agents has 
hinted at the possibility of exploiting this approach for biological imaging.  A DyIII 
triphosphonate complex with a trifluroaryl substituted amide arm ([Dy-DOPA-arCF3]) 
is soluble in water and increases SNR 13-fold compared to diamagnetic analogs.83 
Unfortunately, efforts to increase the number of 19F nuclei via tetra-substitution of the 
chelate with the trifluoroaryl moiety provided complexes with insufficient water 
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solubility for biological MRI.82 Despite the C4 symmetry of tetra-trifluoroethyl 
substituted Ln-DOTMP complexes ([Ln-F-DOTPME]-), the fluorine signal intensity 
was reduced due the existence of multi stereoisomers in solution.84 Stereoisomers 
arising from different configurations of the macrocyclic ring or arrangement of the 
pendant arms have also been observed with other fluorinated DOTA- or DOPA-based 
metal complexes designed for 19F MRI.85,86 For MRI applications, complexes that exist 
as multiple isomers in solution diminish the overall signal intensity at the imaging 
frequency and negatively affect the observed SNR. It is  apparent from these studies 
that the symmetry of the complex as well as the rate of interconversion between 
isomers are important considerations in the design of paramagnetic fluorine probes. 
2.4 DOTAm-F12 Metal Complexes 
 
Here, the synthesis and physical characterization of a water-soluble, 
paramagnetic 19F MRI contrast agent featuring a highly fluorinated chelate is 
presented.  The structures of the ligand and its metal complexes are shown in Figure 2-
1. Additionally, the potential of these imaging agents for use in 19F MRI is evaluated in water and rat blood. The ligand, DOTAm-F12 (2-1), consists of a 2,2,2-trifluoroethyl acetamide substituted macrocycle that features twelve chemically equivalent fluorine nuclei The corresponding M-DOTAm-F12 complexes containing La(III), Eu(III), Gd(III), Tb(III), Dy(III), Ho(III), Er(III), Tm(III), Yb(III), and Fe(II) are highly water-soluble and produce one fluorine resonance peak. 
 35
 
Figure 2-1: Chemical structures of DOTAm-F12 (2-1) and [M-DOTAm-F12]2+/3+ complexes. M = La 
(III) (2-2), Eu (III) (2-3), Gd (III) (2-4), Tb (III) (2-5), Dy (III) (2-6), Ho (III) (2-7), Er (III) (2-8), Tm 
(II)I (2-9), Yb (III) (2-10), and Fe (II) (2-11). 
 
Although prior studies on paramagnetic fluorine probes have focused entirely on 
lanthanide ions,31,81,82 it was postulated that the high-spin, paramagnetic Fe(II) and its 
high magnetic moment, could also yield sensitive fluorine probes with a short T1 time 
and high T2/T1 ratio.  
The ligand DOTAm-F12 was synthesized in two steps and readily forms lanthanide 
complexes from their respective halide salts as shown in Scheme 2-1 In a first step, 
2,2,2-trifluoroethylamine is coupled to bromoacetyl bromide in mixture of CH2Cl2 and 
aqueous K2CO3 to form the pendant arm 2.  This arm is then coupled to the cyclen 
backbone under standard conditions yielding the ligand DOTAm-F12 in high yield. The 
synthesis of this ligand can be readily scaled up to 10 g.  The lanthanide complexes Ln-
DOTAm-F12 are generated from equimolar amounts of the ligand and the respective 
lanthanide halide salt in aqueous solution at neutral pH after 3 days at 75°C. 
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2.4.1 Synthesis of DOTAm-F12 Metal Complexes 
  
Scheme 2-1 Synthesis of DOTAm-F12: aReagents and conditions: (a) K2CO3, H2O/CH2Cl2, 1 h, 80.7%; 
(b) cyclen, K2CO3, CH3CN, reflux, 8 h, 85.9%; (c) LnX3, NaOH, CH3CN/CH3OH/H2O, 75°C, 77-104 h, 
98.0%-99.9%; (d) Fe(OSO2CF3)2, CH3CN/CH3OH, 70°C, 30 h, quant. 
    The Fe(II) complex was formed under argon from irron(II)trifluoromethanesulfonate 
according to a procedure reported by Morrow.87  Notably, all the complexes 
demonstrate high water solubility (>100 mM) despite their high fluorine content (> 
25% by mass). 
2.4.2  Using Fe(II) as the Paramagnetic Metal 
Iron-based fluorine contrast agents have not yet been evaluated as MRI 
contrast agents. However, the properties of Fe(II) complex previously studied as 
paramagnetic chemical exchange saturation transfer (PARACEST) MRI agents87-89 
and reported NMR studies of fluorinated iron complexes90-93  encouraged us to also 
evaluate Fe(II)-DOTAm-F12.  In addition, iron complexes are anticipated to be less 
toxic to patients suffering from chronic and acute renal insufficiencies due to intrinsic 
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iron homeostatic mechanisms and iron-bind proteins, such as transferrin, that can 
regulate the concentration of iron in the blood.  Work by Morrow has illustrated that 
FeII macrocyclic complexes are air stable for days and inert to Fe dissociation,87,89 
supporting the use of such complexes for in vivo MRI applications.  
 
2.4.3 Characterization of [M-DOTAm-F12]2+/3+ Complexes and 
Resultant MR Properties 
The structures of the M-DOTAm-F12 complexes were evaluated by 1H and 19F 
NMR; the Tm complex was further investigated by X-ray crystallography and by DFT 
calculations.  
The 1H NMR spectra of each but two complexes demonstrated paramagnetic 
behavior with highly shifted resonances and reduced relaxation rates relative to the 
ligand alone. The 1H spectrum of the diamagnetic La(III) complex lacked any shifted 
resonances, and the spectrum of the Gd(III) complex displayed no detectable 
resonances from the compound. Gd(III) complexes are known to behave this way due 
to their extremely short T2 values leading to line broadening. Finally, the 1H spectrum 
of the Fe(II) complex reveals significantly shifted resonances that verify the presence 
of a paramagnetic, high-spin Fe (Figure 2-2). This is in agreement with the literature, 
which reports stabilization of the +2 oxidation state of iron by amide pendant groups.94  
By 19F NMR, each complex displays a single resonance as shown in Figure 2-
3. The sharper, secondary feature in the Gd(III) spectrum (δF = -72.9 ppm) is from the 
presence of uncomplexed ligand, and the signal at δF = -79.4 ppm in the Fe(II) 
spectrum is from the triflate counterion. Lanthanide complexes formed from DOTA-
tetraamide ligands are known to adopt a C4-symmetric geometry when each amide 
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pendant arm is the same. The Fe (II) complex also displays a single 19F resonance at δF 
= -70.9 ppm, indicating a C4 symmetric complex.  Morrow also observed C4 symmetry 
and one diastereomeric form of Fe(II)-DOTA-tetraamide complexes by 1H NMR, 
which suggests coordination of all four of the carbonyls.87,88 Compared to the 
lanthanide complexes (with the exception of Eu, Gd, and La), Fe(II)-DOTAm-F12 
yields a smaller 19F paramagnetic-induced pseudocontact shift (+2.0 ppm).  
Unfortunately, detailed crystallographic structural analysis of Fe(II)-DOTAm 
complexes is not yet represented in the literature.88  
They demonstrate paramagnetic character with each complex except the 
diamagnetic La(III) control (Figure 2-2).  Importantly, 19F NMR of each complex in 
D2O revealed one single fluorine resonance (Figure 2-2). 
  
Figure 2-2:  19F NMR of M-DOTAm-F12 complexes (282 MHz, D2O).  Note that in the 
spectra of FeII-DOTAm-F12 the peak at δF = -79.4 ppm corresponds to the 
trifluoromethanesulfonate counter ion.  
 
The presence of a single peak illustrates that any rotation of the trifluoromethyl 
arm occurs faster than the NMR time scale. This represents a major advantage over the 
isomeric mixtures of other 19F contrast agents, such as [Ln-F-DOTPME]- 31,84 and 
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DOTA-based complexes with aryl trifluoromethyl groups, 81,82,86 which were 
characterized by up to twelve 19F peaks at different relative intensities.  
Indeed, fluorine probes with unequivalent 19F nuclei that have small frequency 
differences between the 19F resonances can overlap in an MR scan, resulting in poorly 
resolved images.  
2.4.4 Lanthanide-Induced Shift and Bleaney Theory 
The NMR spectra give further information with regard to the solution 
structures of the complexes. In the case of lanthanide ions, the shift in a nuclei’s 
resonance caused by the paramagnetic metal is defined as the lanthanide-induced shift. 
The lanthanide-induced shift of the fluorine nuclei, 19FLIS, can be defined as ∆δF = δF 
paramagnetric - δF diamagnetic.  Since the 19F – M distances (d) in our complexes are greater 
than 5 Å, the contact shift, δc, is assumed to be negligible and the observed LIS results 
from the pseudocontact component, δpc.  Under these conditions, the 19FLIS is 
described by the McConnell-Robertson equation (Equation 2):31 FLIS	@A = 	CD 	 E-FG$HI&- JK LMN- O4	@PQR STG    (2-2) 
where, d is the 19F – Ln(III) distance, θ is the angle between the principal magnetic 
dipolar axis of the Ln(III) ion and 19F nuclei, B20 is the second order crystal field 
coefficient that is dependent on Ln(III) coordination environment, and CD is the 
Bleaney constant for the specific lanthanide.  Both the direction and magnitude of the 
shift are dependent on the identity of the lanthanide ion, allowing lanthanides to be 
ranked by their relative pseudocontact shift (PCS) strength according to their  Bleaney 
constants .31 
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For every lanthanide complex of DOTAm-F12, the direction of the shift 
matches the sign of the Bleaney constant:  Tb(III), Dy(III), and Ho(III) have a negative 
CD and the 19F resonance is shifted downfield, while the coefficients for Eu(III), 
Er(III), Tm(III), and Yb(III) are positive and their resonances are shifted upfield 
(Table 2-1).  This provides insights to the location of the fluorine atoms around the 
metal center, and thus the solution structures of the lanthanide complexes.  19F nuclei 
positioned equatorially, within a cone aligned with the principle magnetic axis, would 
shift downfield if the Bleaney coefficient is negative and upfield if it is positive.  
 
Table 2-1: 19F Chemical shift (δ), lanthanide induced shift (LIS, ∆δF), T1 and T2 relaxation 
times and MRI SNR of M-DOTAm-F12 complexes in water. 
 µeff/µBa Bleaney 
Constan
t c 
δ 
(ppm
) 
∆δF T1d 
(ms) 
T2d 
(ms) 
T2/T1
d
 
SNRf,
g
 
DOTAm-F12e - - -72.9 0 880 680 0.77 n.d. 
La-DOTAm-F12 - - -72.9 n/a 570 400 0.70 5.2 
Eu-DOTAm-F12 3.40-
3.51 
4.0 -73.5 -0.6 360 41 0.11 7.8 
Gd-DOTAm-F12 7.94 0 -72.9 0 12 <0.1 n/d ~1 
Tb-DOTAm-F12 9.7 -87 -54.0 +18.9 6.3 1.3 0.21 31 
Dy-DOTAm-F12 10.6 -100 -52.2 +20.7 5.9 2.2 0.37 6.0 
Ho-DOTAm-F12 10.6 -39 -62.0 +10.9 7.6 5.4 0.71 31 
Er-DOTAm-F12 9.6 32 -77.5 -4.6 14 8.8 0.63 13 
Tm-DOTAm-F12 7.6 53 -85.6 -12.7 26 16 0.61 18 
Yb-DOTAm-F12 4.5 22 -77.3 -4.4 130 55 0.42 20 
FeII-DOTAm-
F12 
~ 5.2b - -70.9 +2.0 5.7 5.6 0.98 40 
 
Conditions: aRef.31  bµeff for FeII-DOTAm complex of 1,4,7,10-Tetrakis(carbamoylmethyl)-
1,4,7,10-tetraazacyclododecane from Ref.88   cRef.31,95  dB0: 7.0 T, T = 20°C, D2O. eNMR in deuterated 
methanol.   fM-DOTAm-F12 = 5 mM, B0: 9.4 T, T = 33°C, TR = 5 ms.  gSNR were obtained at the 
optimum chemical shift for each complex using images shown in Figure 2-10: La, -78 ppm; Eu, -78 
ppm; Gd, -73 ppm; Tb, -73 ppm; Dy, -62; Ho, -62; Er, -78 ppm; Tm, -86 ppm; Yb, -86 ppm; 
Fe, -78 ppm. 
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Conversely, axially positioned nuclei, that are perpendicular to the principle 
magnetic axis, would be shifted in the opposite direction.  Indeed, opposing directions 
of 19FLIS are observed by Kim et al. for axial and equatorial positioned 19F nuclei.84 
The fact that the 19FLIS observed matches the sign of the Bleaney constant indicates 
(1) that all of the lanthanide complexes share a common structure in solution, and (2) 
that in each case the 19F nuclei are located equatorially to the principle magnetic axis.  
It can thus be inferred that the fluorines do not aggregate as a hydrophobic cap on top 
of the macrocycle, but rather remain independently solvated on the equator of the 
complex 
2.4.5 Determination of Coordinated Water Molecules (q) 
 This conclusion is further backed by 17O NMR of the Dy(III) complex.  
According to the method of Peters,96 evaluation of the chemical shift of the 1H 
resonance of water in aqueous solution of Dy-DOTAm-F12 verified the presence of 
one inner sphere water molecule, q, on the Dy(III) complex, as shown in Figure 2-3 
This agrees with previous reports of one bound water molecule in DOTA-tetramide 
complexes containing pendant amine, N-methyl, N-dimethyl, and N-aryl substituted 
arms.82,97,98 Occupation of the ninth coordination site of Dy-DOTAm-F12 with a water 
molecule is also consistent with the outward positioned pendant arms that place the 
fluorines equatorially and provide solvent access to the lanthanide metal.  
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.  
Figure 2-3: Chemical shift of 17O of H2O as a function of dysprosium complex 
concentration for [Dy-DTPA]2- (filled square) and [Dy-DOTAm-F12]3+ (open circle).  The 
hydration number, q, for [Dy-DOTAm-F12]3+ was determined from the ratio of the slopes 
assuming q = 1 
 
2.4.6 X-Ray Crystallography 
The structure of Tm-DOTAm-F12 was also investigated by X-ray 
crystallography.  In the crystalline state, Tm-DOTAm-F12 adopts a slightly distorted 
square-antiprismatic (SAP) geometry99,100 consistent with an observed interplanar 
angle between the oxygen and nitrogen planes of 41.6˚, shown Figure 2-4, in Figure 2-
5.  
Based on the average N-C-C-N and N-C-C-O torsion angles of 54.1˚ and -
23.4˚, respectively, the absolute configuration of the macrocycle is (δδδδ) in the 
crystal, while the pendant arms exhibit left-handed (Λ) helicity, which can be seen in 
Figure 2-6.  The related [Dy-DTMA]3+ with pendant N-methyl amide arms is also 
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SAP, but exists in the diastereomeric form with a left-handed (λλλλ) ring conformation 
and right-handed (∆) helicity in the pendant arms.97 
 
 
 The C2 symmetric structure of Tm-DOTAm-F12 contains two pairs of six 
chemically equivalent fluorine nuclei that are positioned between 5.28 – 6.76 Å from 
the Tm(III) center, with an average 19F – Tm(III)  distance of 6.26 Å, shown Table 2-2. 
The angle θ is defined by the 19F – Tm(III)  vector and the principle magnetic axis of 
the metal that extends through the center of the plane formed by the four nitrogen atoms 
of the cyclen backbone. This is shown in Error! Reference source not found., with 
the angle θ generated by use of the dark green dummy atom. The average θ value for 
Figure 2-4: X-ray crystal 
structure of Tm-DOTAm-F12, side 
view (ORTEP, 50% probability 
level). Hydrogen and chlorine atoms 
omitted for clarity  
Figure 2-5: X-ray crystal structure of 
Tm-DOTAm-F12, top view showing left-
handed (Λ) helicity of pendant arms 
(ORTEP, 50% probability level). 
Hydrogen and chlorine atoms omitted for 
clarity 
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Tm-DOTAm-F12 is 77° (ranging from 67° to 83°) and is consistent with equatorial 
trifluoromethyl groups.  Full X-ray refinement calculations are provided in the 
following 
 
,  
Figure 2-6: DFT-optimized structure of Tm-DOTAm-F12.  The angle θ is defined by the Ln (III) – 19F 
vector and the principle magnetic dipolar axis, which extends through the lanthanide ion into the center 
of the plane formed by the nitrogen atoms (represented by the dark green dummy atom).  
Table 2-2: Ln-F distances, d, and the angle, θ, between the lanthanide-fluorine vector and the principle 
magnetic dipolar axis of the Tm(III) center of Tm-DOTAm-F12 from X-ray structure and DFT 
calculation. 
 d 
(Å) 
θb 
(°) 
 X-ray 
structurea 
DFT 
calculations 
X-ray 
structurea 
DFT 
calculations 
F1 6.75 6.74 82 85 
F2 6.69 6.71 67 70 
F3 5.28 5.18 83 85 
F4 6.76 6.72 82 86 
F5 6.74 6.74 67 71 
F6 5.33 5.16 83 86 
F7  6.76  87 
F8  6.76  73 
F9  5.21  87 
F10  6.72  86 
F11  6.74  71 
F12  5.18  86 
average 6.26 6.22 77 81 
a
 The X-ray crystal structure of Tm-DOTAm-F12 is centrosymmetric and contains two pairs of six 
chemically equivalent fluorines.  b The angle, θ, was calculated from the 19F – Tm3+  vector and the 
principle magnetic axis of the Tm3+ metal that extends through the center of the plane formed by the four 
nitrogen atoms (N1-N2-N1#-N2#) of the chelate (detail of θ is shown Error! Reference source not 
found.) 
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Table 2-3:Crystal data and structure refinement for [Tm-DOTAm-F12]3+. 
Identification code  13251sqz 
Empirical formula  C24 H38 Cl4 F12 N8 O5 Tm 
Formula weight  1057.35 
Temperature  123(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  Cmca 
Unit cell dimensions  a = 25.5559(18) Å α = 90° 
 b = 18.5893(13) Å β = 90° 
 c = 18.6003(14) Å γ = 90° 
Volume 8836.4(11) Å3 
Z 8 
Density (calculated) 1.590 Mg/m3 
Absorption coefficient 6.819 mm-1 
F(000) 4184 
Crystal color, morphology white, block 
Crystal size 0.1 x 0.1 x 0.1 mm3 
Theta range for data collection 3.46 to 68.30° 
Index ranges -30 ≤ h ≤ 30, -22 ≤ k ≤ 22, -22 ≤ l ≤ 17 
Reflections collected 46172 
Independent reflections 4109 [R(int) = 0.0378] 
Observed reflections 3496 
Completeness to theta = 68.30°  98.8%  
Absorption correction Multi-scan  
Max. and min. transmission 0.7531 and 0.5364 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4109 / 0 / 254 
Goodness-of-fit on F2 1.083 
Final R indices [I>2sigma(I)]  R1 = 0.0635, wR2 = 0.1853 
R indices (all data) R1 = 0.0711, wR2 = 0.1928  
Largest diff. peak and hole 3.791 and -1.558 e.Å-3 
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Table 2-4: Atomic coordinates (×104) and equivalent isotropic displacement parameters (Å2 × 103) for 
[Tm-DOTAm-F12]3+. Ueq is defined as one third of the trace of the orthogonalized Uij tensor. 
 x y z Ueq  
Tm1 3435(1) 5000 0 17(1) 
Cl1 5000 3872(2) 1008(2) 58(1) 
Cl2 3268(1) 3070(1) 3074(1) 46(1) 
Cl3 5000 6018(2) 1136(2) 65(1) 
O1 3720(2) 6175(2) 74(2) 25(1) 
O2 3718(2) 4921(2) 1172(2) 26(1) 
O3 4353(2) 5000 0 25(1) 
N1 2826(2) 4200(2) 790(3) 24(1) 
N2 2827(2) 5786(2) 796(3) 25(1) 
N3 3785(2) 4304(3) 2227(3) 37(1) 
N4 3795(2) 7239(3) 692(3) 38(1) 
F1 3825(2) 5002(2) 3587(3) 54(1) 
F2 4459(2) 5676(3) 3239(3) 73(2) 
F3 3703(2) 5735(3) 2719(3) 66(1) 
F4 3826(2) 8595(3) 21(2) 53(1) 
F5 4459(2) 8275(3) -662(3) 77(2) 
F6 3701(2) 7748(3) -728(3) 62(1) 
C1 2576(3) 3613(4) 360(3) 38(2) 
C2 2406(3) 3859(4) -365(3) 39(2) 
C3 2406(3) 4638(3) 1127(4) 39(2) 
C4 2576(3) 5359(3) 1375(4) 38(2) 
C5 3164(3) 6344(3) 1113(3) 36(1) 
C6 3584(2) 6583(3) 580(3) 31(1) 
C7 4232(3) 7489(4) 265(4) 40(2) 
C8 4057(3) 8023(4) -267(5) 51(2) 
C9 3161(3) 3883(3) 1345(3) 36(1) 
C10 3576(2) 4411(3) 1584(3) 33(1) 
C11 4226(3) 4734(4) 2478(4) 42(2) 
C12 4056(3) 5277(5) 3000(4) 49(2) 
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Table 2-5: Anisotropic displacement parameters (Å2 × 103) for [Tm-DOTAm-F12]3+. The anisotropic 
displacement factor exponent takes the form:  -2π2 [h2 a* 2U11 + ... + 2 h k a* b* U12] 
 
_U11 U22  U33 U23 U13 U12 
Tm1 18(1)  17(1) 17(1)  -2(1) 0  0 
Cl1 38(1)  69(2) 67(2)  16(2) 0  0 
Cl2 63(1)  38(1) 38(1)  14(1) -2(1)  0(1) 
Cl3 46(2)  76(2) 74(2)  -14(2) 0  0 
O125(2)  18(2) 33(2)  -4(2) 5(2)  -3(2) 
O225(2)  36(2) 16(2)  2(2) 0(2)  -3(2) 
O313(3)  29(3) 33(3)  1(2) 0  0 
N124(2)  24(2) 24(2)  -5(2) 2(2)  -6(2) 
N225(2)  24(2) 26(2)  -5(2) 1(2)  -1(2) 
N339(3)  38(3) 34(3)  3(2) -3(2)  0(2) 
N436(3)  41(3) 36(3)  -1(3) -2(2)  -7(2) 
F150(3)  84(4) 29(2)  -5(2) 9(2)  -7(2) 
F258(3)  89(4) 73(3)  -24(3) -2(2)  -16(3) 
F361(3)  55(3) 83(4)  -10(3) -17(3)  11(2) 
F448(3)  28(2) 82(4)  3(2) -3(2)  7(2) 
F561(3)  80(3) 89(4)  36(3) 17(3)  -6(3) 
F658(3)  77(3) 51(3)  6(2) -13(2)  -10(2) 
C144(4)  37(3) 33(4)  -2(3) 2(3)  -19(3) 
C242(4)  41(3) 34(4)  -5(3) 2(3)  -14(3) 
C336(4)  33(3) 47(4)  1(3) 21(3)  -2(3) 
C444(4)  31(3) 39(4)  -3(3) 16(3)  -1(3) 
C538(3)  37(3) 34(3)  -16(3) 4(3)  -3(3) 
C639(3)  20(3) 36(3)  1(2) -5(3)  2(2) 
C733(3)  29(3) 58(4)  0(3) 4(3)  -5(3) 
C836(4)  45(4) 74(5)  5(4) 5(4)  -6(3) 
C941(3)  35(3) 31(3)  16(3) 3(3)  -4(3) 
C10 36(3)  40(3) 21(3)  0(3) 4(3)  4(3) 
C11 35(3)  62(4) 30(3)  1(4) -7(3)  -1(4) 
C12 37(4)  66(5) 44(4)  -6(4) -12(3)  -10(4) 
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Table 2-6: Hydrogen coordinates (× 104) and isotropic displacement parameters (Å2 × 103) for [Tm-
DOTAm-F12]3+. 
___ x  y  z  U(eq) 
H10A 4463 5320 281 30 
H10B 4430 4575 131 30 
H3N 3690(30) 4270(40) 2810(40) 45 
H4N 3680(30) 7740(50) 720(40) 46 
H1A 2828 3212 304 46 
H1B 2268 3427 625 46 
H2A 2112 4202 -307 47 
H2B 2273 3439 -637 47 
H3A 2119 4698 774 46 
H3B 2264 4370 1543 46 
H4A 2826 5302 1777 46 
H4B 2268 5625 1558 46 
H5A 3333 6153 1552 44 
H5B 2948 6763 1252 44 
H7A 4395 7076 14 48 
H7B 4499 7707 583 48 
H9A 3331 3444 1152 43 
H9B 2944 3741 1762 43 
H11A 4393 4976 2063 51 
H11B 4489 4415 2704 51 
 
The crystal structure of Tm-DOTAm-F12 together with the solution NMR data 
enabled testing the predicted structure of the macrocyclic lanthanide complexes by 
gas-phase DFT calculations. Gas-phase calculations were performed using 
Gaussian09101 with a B3LYP functional and the 6-31G(d) basis set and RECP of Dolg 
et al. for the light elements, and a related valence basis set, [5s4p3d]-GTO, for the 
Tm(III) that separately accommodates both the core and valence electrons.102-104 The 
optimized geometry of [Tm-DOTAm-F12]3+ obtained by DFT calculations is 
congruent with the crystal structure (Figure 2-7) 100.  
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The average 19F – Tm(III) 
distance (6.22 Ǻ) and angle θ (81°) 
are in agreement with the 
orientation of the 19F nuclei 
observed in the crystal structure 
(Figure 2-5, Figure 2-4, and Table 
2-2). Furthermore, the SAP 
geometry is confirmed with an 
interplanar angle of 36.8° between 
the N4 and O4 planes.  Relative 
energies of Tm-DOTAm-F12 with 
and without a coordinated water molecule indicate that the hydrated form is favored by 
-11.5 kcal/mol (Table 2-7). Overall, NMR spectroscopy, X-ray crystallography, and 
DFT calculations are in agreement; they confirm the SAP conformation of the 
complexes, the equatorial position of the trifluoromethyl groups, and the presence of 
one bound water molecule. 
The SAP geometry of Tm-DOTAm-F12 provides room for a coordinating 
water molecule.100 Nine-coordinate structures, with one bound water molecule, have 
been reported for similar tetraamide complexes such as [Dy-DTMA]3+,97 
[Eu-DOTAM]-,105 and chiral Ln-DOTAm complexes with arms possessing stereogenic 
centers.106 In the crystal structure, this water molecule at the ninth coordination site 
forms hydrogen bonds with the bridging Cl- anions (Figure 2-7).   
  
Figure 2-7: The SAP geometry of Tm-DOTAm-F12 
provides room for a coordinating water molecule. 
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Table 2-7: Calculated (DFT) total energy change for [Tm-DOTAm-F12]3+ and [Tm DOTAm F12]3+ • 
H2O forms of the complex. 
 [Tm-DOTAm-F12]3+ + H2O  ! [Tm-DOTAm-F12]3+ • H2O  (Equation 1) 
Compounds Sum of 
electronic and 
zero-point 
Energies (a.u.) 
Sum of 
electronic 
and thermal 
Enthalpies 
(a.u.) 
Sum of 
electronic 
and thermal 
Free Energies 
(a.u.) 
[Tm-DOTAm-F12]3+ • 
H2O 
-2987.720819 -2987.669499 -2987.807808 
[Tm-DOTAm-F12]3+ -2911.309796 -2911.261081 -2911.396634 
sH2O   -76.395168 -76.391390 -76.412841 
Reaction  
(Equation 1) 
Change in 
Energy 
(∆E, kcal/mol)a 
Change in 
Enthalpy 
(∆H, kcal/mol)a 
Change in  
Free Energy 
(∆G, 
kcal/mol)a,b 
 -9.95         -10.68 1.05 
      a
 1 a.u. = 627.509 kcal/mol. 
    
b
 Gibbs free energy change (∆G) was calculated at 298 K/ 1atm. 
Hydrogen bonds between coordinated water molecules and counter ions (PF6 
or trifluoromethanesulfonate) have been previously observed in macrocyclic 
tetraamide crystal structures,97,105,106 but are not expected to be present in solution.  
Interestingly, the solid-state packing structure of [Tm-DOTAm-F12]3+ reveals two 
intramolecular hydrophobic F-F interactions by the adjacent trifluoromethyl groups 
(Figure 2-8).  The short F-F distance of 2.76 Ǻ is less than the sum of the van der 
Waals-radii (2.94 Ǻ); contacts of this type are rare and, in most cases, a consequence 
of dense packing.107 These interactions (H-Cl and F-F) link the molecules together in a 
dimeric, “top-to-top” fashion (Table 2-7).  Full crystal structure data, atomic 
coordinates, and displacement parameters are provided in Table 2-4, Table 2-5, and 
Table 2-6. 
 51
2.5 Paramagnetic Relaxation Enhancement in Water 
 
The sensitivity of M-DOTAm-F12 complexes is higher than that of all 
previously reported fluorine probes, including the only other 19F – Ln complex that has 
been evaluated as an MRI contrast agent.83 Part of this higher sensitivity is due to the 
presence of twelve 19F nuclei which are chemically equivalent by NMR and MRS. 
While the X-ray crystal structure demonstrated two nonequivalent pairs of six 19F 
nuclei, the single 19F resonance observed by NMR/MRS suggests their exchange in 
solution occurs at a rate faster than the NMR timescale. The higher number of 
chemically equivalent fluorines per probe is necessary to increase the sensitivity of the 
probe. The presence of nonequivalent fluorines complicates MR image acquisition, 
and can lead to artifacts and decreased SNR.108 
A greater component to the increased sensitivity of M-DOTAm-F12 complexes 
comes from the paramagnetic nature of the metals.  Paramagnetic relaxation 
enhancement (PRE) can decrease T1 by two orders of magnitude (from 1 s to <10 ms) 
offering up to 10-fold higher SNR with a reduction in acquisition time.109 The 
enhanced relaxation mechanisms at high magnetic fields are described by the Bloch-
Redfield-Wangsness (BRW) theory in terms of the electron-nucleus dipole-dipole and 
Curie relaxation processes.82,109-112 As a result, the longitudinal (R1) and transverse 
(R2) relaxation rates are defined by the following relationships (Equations 2-3 to 2-
7):82  
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U@ = T@V *WXYZ.T 		[\-W]^^-Q_ 	` ab5cd@e	fd-b5cd- + Kb5cd@e	f\-b5cd- g +	TV *WXYZ.T f\-W]^^h$Ki+&-Q_ 		 Kb5@e	f\-b5-               (2-3) 
 
UT = 115 *kG4m.T 		noTkpqqTrF 	34steu + 3steu1 +	wuTsteuT + 13steu1 +	woTsteuT 8 +	@V *WXYZ.T f\-W]^^h$Ki+&-Q_ 		*4st + Kb5@e	f\-b5-.        (2-4) 
 kpqqT = 	xyT	kzT 	{${ + 1&                      (2-5) wu = 	 *|}W~ℏ .SG                   (2-6) 
τR+e = (τR-1 + @u4@)                   (2-7) 
Where d is the 19F – M(II)/(III)  distance, µ0 is the vacuum permeability, γF is the 
gyromagnetic ratio of 19F nuclei, T is the absolute temperature, and k is the Boltzmann 
constant. The effective magnetic moment, µeff, is proportional to the effective electron 
g-factor (gJ), the Bohr magneton (µB), and the electron angular momentum, J(J+1) 
(Equation 2-5).  The Zeeman frequency of fluorine, ωf, and the electron frequency, ωe, 
are both functions of the magnetic field strength, B0 (Equation 2-6).  The τR+e term is 
dependent on the rotational correlation time (τR) and the electron spin longitudinal 
relaxation time (T1e) (Equation 2-7). Together these equations define the relationship 
of R1 and R2 to the effective magnetic moment (µeff) of the metal, the 19F – MII/III 
distance (d), rotational correlation time (τR), field strength (B0), and temperature (T).  
Plotting these parameters and their effect on R1 and R2 is shown in Figure 2-8, Figure 
2-9. These figures show that while R1 has a target area for magnetic field strength as 
well as for τR,  R2 continues to increase with either value. Since R2 ultimately controls 
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the SNR obtained, a medium of optimal R1 and R2 values that result in effective 
imaging characteristics do potentially have limitations if high τR values are 
concomitantly with higher field strengths. Keeping τR values at 1000 ps or less 
suggests that there is virtually no limit to higher field strengths. Such high τR values 
correspond to supramolecular chemical structures. The τR values reported for probes 
similar to M-DOTAm-F12 are generally no higher than 200 ps. 
 
 
 
 
 
 
 
 
 
Optimizing the sensitivity of 19F MRI contrast agents requires understanding of 
each of these relationships.  In this work, the effect of the metal on the longitudinal (R1) 
and transverse (R2) relaxation rates of the 19F nuclei of M-DOTAm-F12 complexes is 
investigated.  Their T1 and T2 relaxation times (R1 = 1/T1 and R2 = 1/T2) are reported in 
Table 2-1. Since each complex shares the same ligand, the values of d and τR are 
Figure 2-9: Transverse relaxation rate of 19F 
nuclei of Tm-DOTAm-F12 as a function of 
the applied magnetic field, B0, and the 
rotational correlation time, τR. The analysis is 
based on Equation (4) and is done at 37 °C 
using the mean Tm-19F distance determined 
from X-ray crystallography (6.26 Å), 
assuming a magnetic moment, µeff, of 7.6 BM 
and an electronic relaxation time, τe, of 0.20 
ps, values typical of TmIII complexes. 
Figure 2-8: Longitudinal relaxation rate of 19F nuclei 
of Tm-DOTAm-F12 as a function of the applied 
magnetic field, B0, and the rotational correlation time, 
τR. The analysis is based on Equation (3) and is done 
at 37 °C using the mean Tm-19F distance determined 
from X-ray crystallography (6.26 Å), assuming a 
magnetic moment, µeff, of 7.6 BM and an electronic 
relaxation time, τe, of  0.20 ps, values typical of TmIII 
complexes. 
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mostly constant across the family of complexes. The differences in relaxation times are 
thus primarily a consequence of the effective magnetic moment (µeff) of the metal. Each 
lanthanide metal has a characteristic µeff/µB value that is relatively invariant with ligand 
structure (Figure 2-1).  
The BRW theory correctly predicts how each lanthanide ion affects the 
relaxation rates of 19F nuclei.  The shorter T1 relaxations times near 6 ms are observed 
for those lanthanide ions that have the higher effective magnetic moments (µeff of ~ 
10), namely Tb(III), Dy(III), and Ho(III).109 The 19F nuclei of the Fe(II) complex of 
DOTAm-F12 display the shortest longitudinal relaxation time (5.7 ms), suggesting 
that the iron complex also has a high µeff. In comparison, the fluorine nuclei of the 
diamagnetic La(III) complex and the free ligand display characteristically long 
longitudinal relaxation times (570 ms and 880 ms, respectively).  Incorporation of any 
of these four paramagnetic metal ions with high magnetic moments reduces the 19F T1 
time by over two orders of magnitude. Interestingly, Er(III) also displays a high 
effective magnetic moment (9.6), comparable to that of Tb(III), Dy(III), and Ho(III) 
and higher than that of GdIII (7.9). Yet the T1 of the fluorine nuclei of the Er(III) and 
Gd(III) complexes are comparable. At the other end of the spectrum, Eu(III) and 
Yb(III) which have lower effective magnetic moments, decrease 19F T1 values to a 
much lesser extent. 
The effect of the paramagnetic metal on the transverse relaxation times of the 
fluorine nuclei is more pronounced but follows a similar trend, with the notable 
exception of Gd(III). Tb(III), Dy(III), and Ho(III), which have the higher µeff, shorten 
the T2 of the fluorines to a greater extent, up to 500 fold compared to the diamagnetic 
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analog. In contrast, Eu(III) and Yb(III) which have lower µeff, decrease the T2’s of the 
19F barely 10 fold. Gd(III), predictably, has a substantially greater effect on the 
transverse relaxation time of the fluorines than on their longitudinal ones, and a greater 
effect on T2 than any other lanthanide.  The T2 of the 19F nuclei of the Gd(III) complex 
is estimated to be <0.1 ms, but could not be accurately determined using the CPMG 
pulse sequence due to extensive broadening of the 19F resonance. The relaxation data 
for M-DOTAm-F12 align with reported T1 and T2 values for previously reported 19F – 
Ln(III) complexes.83  In the current study, the T1 and T2 relaxation times are roughly 
double when moving from Ho(III) to Er(III) and again from Er(III) to Tm(III); this 
trend more closely follows the decreasing µeff of the metals than that previously 
reported.83 The Fe(II) complex presents interesting, and promising, properties: this is 
the only case where the effect of the paramagnetic metal ion on the T2 of the fluorines 
is comparable to its effect on T1. T1:T2 relaxation times decrease to 5.7 : 5.6 ms. 
2.5.1 Signal Enhancement in an MR Image 
Increasing the sensitivity of fluorine probes by decreasing the relaxation times 
of the fluorine nuclei is a balancing act. On one hand, decreasing T1 allows for a 
greater number of scans to be acquired in a same amount of time, thereby increasing 
the SNR of an image. On the other hand, when T2 values are very short, it is very hard 
to acquire images that are only T1-weighted. Too short a T2 and any benefit from 
decreasing T1 is lost. At first estimate, the most sensitive probes will have the shortest 
T1, maintain a T2/T1 ratio as close to 1 as possible, and have a T2 no less than 2 ms. 
This is where Fe(II) and the different lanthanide ions differentiate themselves.  
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Figure 2-10: MRI phantom images of [M-DOTAm-F12]2+/3+ in water at 5.0 mM. B0 = 9.4 T, T = 33 °C.  
A) 1H 3D gradient-echo images, TR = 10 ms, TE = 1.78 ms, 20°, FOV: 20 mm × 40 mm × 20 mm, 
matrix: 128 × 256 × 128, resolution: 0.156 mm isotropic.  19F gradient-echo images, TR = 5 ms, TE = 
1.34 ms, 90°, FOV: 32 mm × 32 mm, matrix: 64 × 64, slice thickness = 10 mm, na = 64. Images are 
shown with the same intensity scale after 2D zero-padding.  Transmitter offset for 19F images: -120 
ppm KF; -86 ppm Yb, Tm; -78 ppm Fe, La, Er, Eu;  73 ppm Tb, Gd,; -62 ppm Ho, Dy.  SNR for 19F 
images: Yb, 20, Tm, 18; Fe, 40; La, 5.2; Er, 13; Eu, 7.8; Tb, 31; Gd, 1; Ho, 31; Dy, 6.0. 
Figure 2-10 shows gradient echo images collected at 9.4 T with 5 mM samples of 
[M-DOTAm-F12]2+/3+. For the fluorine images, the imaging frequency for each 
complex corresponds to the chemical shift of the 19F resonance (Figure 2-2). A 
repetition time, TR, of 5.0 ms was selected because the shortest TR values result in the 
highest SNR providing that T2 is sufficiently long.83 In order to be able to compare 
SNR, each image was obtained with the same acquisition time (20.5 s) and the same 
resolution (in plane: 0.5 x 0.5 mm2, and 10 mm slice thickness).  
As is clearly apparent from these images, the SNR of solutions of these 
complexes is not directly proportional to T1 of the fluorine nuclei, nor does the trend in 
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SNR follow the trend in effective magnetic moment of the metal ion. Instead, with the 
exception of Tb(III), SNR more closely follows the T2/T1 ratio.  One extreme case is 
Gd(III) whose effect on the T2 of 19F is so pronounced (< 0.1 ms) that the highly 
broadened 19F resonance of the complex results in negligible signal intensity both by 
NMR (Figure 2-2) and MRI (Figure 2-10). Dy(III) and Eu(III) have T2/T1 values 
higher than Gd(III) but that are still relatively poor, between 0.1 and 0.4. They yield 
SNR’s between 6 and 8 ms that are comparable to that of the diamagnetic La(III) 
complex.  Er(III), Tm(III), and Yb(III)
 
have better T2/T1 values between 0.4 and 0.6, 
which lead to SNRs two to four times higher than La(III) (SNR of 10-20).  Ho(III) is 
the best of the lanthanide ions, with a T2/T1 of 0.7 leading to a SNR of 30. Notably, 
none of the lanthanide ions are as efficient as Fe(II).  Indeed, Fe(II) has the highest 
T2/T1 ratio of 0.98 and also the highest SNR of 40, eight times greater than the 
diamagnetic LaIII complex.  
Comparison of the SNR of the MR image of solutions of the diamagnetic 
La(III) complex with that obtained with the Ho(III) complex demonstrate the strength 
of using paramagnetic metal ion. Both of these complexes have similar T2/T1 value of 
0.7. However, the T1 of the fluorines of the paramagnetic Ho(III) complex is 75 times 
shorter than that of the diamagnetic La(III) complex. This enables the acquisition of 75 
times more scans in a same amount of time with the Ho(III) complex than with the 
La(III) one. As a result, exchanging La(III) by Ho(III) results in a six fold increase in 
SNR. 
A T2/T1 value near one signifies that the effect of T1 is maximized compared to 
the negative effect of line broadening induced by short T2.  Comparison with other 
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published lanthanide-based 19F complexes indicates that although the trend between 
T2/T1 and SNR holds, with some exception (Tb(III) in this study), the lanthanide ion 
which yields the most sensitive probe is not necessarily the same for all ligands.  ErIII 
was reported to be a good metal for the previously reported DOTA and DOPA-based 
system. 81,83 In the case of DOTAm-F12, however, it yields a SNR three times lower 
than Ho(III) and Tb(III) in water.  The extent to which a same lanthanide ion 
influences the sensitivity of a fluorine probe depends substantially on the ligand. With 
the aryl trifluoromethyl substituted Ln-DOTA complexes studied by Chalmers et al., 
Ho(III) increases the sensitivity 2.4 times over the diamagnetic Y(III).82 In this study, 
Ho(III) increases the sensitivity of the fluorine nuclei six times over its diamagnetic 
counterpart.  Ligand and complex geometry, and especially Ln-19F distances, must be 
taken into consideration when designing paramagnetic fluorine MR probes.  In 
addition, Fe(II), which has not been previously studied in the design of fluorine MRI 
probes, yields higher sensitivity than any of the lanthanides.  The resulting SNR with 
the FeII complex was eight times that of the diamagnetic analog.  
 
Gradient echo 19F images of FeII and TmIII DOTAm-F12 at three different 
concentrations in water are given in Figure 2-11. For each metal the image collection 
Figure 2-11: 19F gradient-echo images in water. A) [Fe-
DOTAm-F12]2+ samples at three concentrations (0.5 mM, 1 
mM, 5 mM, left to right), -73 ppm, TR = 10 ms, TE = 1.34 ms, 
90°, FOV: 32 mm × 32 mm, matrix: 64 × 64, slice thickness = 
10 mm, na = 512.  SNR for Fe: 0.5 mM, 5.2; 1 mM, 9.9; 5 mM, 
49.  B) [Tm-DOTAm-F12]3+  samples at three concentrations 
(0.5 mM, 1 mM, 5 mM, left to right), -86 ppm, TR = 20 ms, TE = 
1.34 ms, 90°, FOV: 32 mm × 32 mm, matrix: 64 × 64, slice 
thickness = 10 mm, na = 256.  Images are shown with the same 
intensity scale after two dimensional zero-padding. B0 = 9.4 T, T 
= 33°C.  SNR for Tm: 0.5 mM, 3.3; 1 mM, 6.6; 5 mM, 31. 
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parameters (TR, TE, and number of acquisitions) were altered so to achieve the best 
SNR while maintaining a constant acquisition time of 5.5 min. This enables us to 
compare the two best complexes more accurately. With these parameters, a 19F MR 
image of a 5 mM solution of FeII-DOTAm-F12 has a SNR of 49.  With the same 
acquisition time and the same resolution, a 5 mM solution of the Tm(III) analog is 
37% less sensitive (SNR = 31).  The theoretical limit of detection (where SNR > 3)113 
is extrapolated as 280 µM for the Fe(II) complex and 430  µM for the Tm(III) 
derivative. The best paramagnetic ions—that is—the ones that yield the highest SNR, 
is highly dependent on the media.  With the intent to produce a clinically viable 
contrast agent, the data obtained in water must be compared to data obtained in blood.   
It was anticipated that since the trifluoromethyl groups of the [M-DOTAm-F12]2+/3+ 
complexes are hydrophobic, they would likely interact with the proteins present in 
blood and in particular with serum albumin, the most ubiquitous protein found in the 
mammalian bloodstream. Serum albumin has previously been reported to bind 
hydrophobic molecules such as perfluorocarbons.114,115 Binding to large proteins such 
as albumins is anticipated to affect substantially the rotational correlation time, τR, of 
the complex.  As is apparent from Equations 2-3, 2-4 and 2-7, and the BRW 
theoretical predictions of R1 and R2 as a function of varying field strength and τR  time 
discussed earlier (plotted in Figure 2-8 and Figure 2-9), changes in rotational 
correlation times influence T1 and T2 differently, with longer τR (larger 
macromolecules) affecting T2 noticeably more than T1. The T2/T1 ratio of the fluorine 
nuclei for the different metal ions is thus expected to be different in blood than in 
water, and as such so would their sensitivity. 
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Table 2-8: 19F T1 and T2 relaxation times, T2/T1 ratio, and MRI SNR of M-DOTAm-F12 complexes in 
rat veinous blood at 37°C. 
 T1 a 
(ms) 
T2 a 
(ms) 
T2/T1 a SNRb,c 
La-DOTAm-F12 700 29 0.041 n.d. 
Ho-DOTAm-F12 10 2.7 0.26 ~1d 
Tm-DOTAm-F12 36 6.4 0.18 7.2 
Yb-DOTAm-F12 170 12 0.071 4.6 
FeII-DOTAm-F12 7.7 4.4 0.57 34 
 
Conditions: a B0: 7.0 T, rat veinous blood.b M-DOTAm-F12 = 5 mM, B0: 9.4 T.  cSNR were 
obtained at the optimum frequency for each complex using images shown in Figure 8B: Ho, -62 ppm; 
Tm, -86 ppm; Yb, -86 ppm; Fe, -78 ppm.d 19F MRI signal could not be observed.  
 
 Experimentally, fluorine T1 values in blood were found to be comparable to 
those measured in water (Figure 2-8). As predicted, unfortunately, the fluorine 
transverse relaxation times, T2, are substantially shorter in blood than in water.  For the 
Ho(III) complex, the fluorine T2 in blood was decreased two-fold to 2.7 ms, and was 
not able to imaged due to its T2/T1 ratio and thus significant signal loss.  The T2/T1 
ratio of the Tm(III) complex similarly decreases over three-fold to 0.18 as its T2 
decreases from 16 to 6.4 ms. Similar reduction of fluorine T2 in vivo compared to in 
vitro was observed recently with a 19F – Dy(III) chitosan polymer.116 In the current 
study, the Fe(II) complex behaves substantially better in rat blood than any of its 
lanthanide counterparts. The fluorine T1 relaxation time of the Fe(II)-DOTAm-F12 
surprisingly became longer by 2 ms, whereas the T2 relaxation time decreases by only 
1 ms. As a result, the T2/T1 ratio dropped from 0.98 in water to only 0.57 in blood.  It 
therefore appears, based on fluorine relaxation times alone, that the FeII-DOTAm-F12 
complex would be more appropriate for in vivo 19F MRI.  
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Figure 2-12: MRI phantom images of M-DOTAm-F12 in rat blood at 5.0 mM. B0 = 9.4 T, T = 33 °C.  
A) 1H 3D gradient-echo images, TR = 10 ms, TE = 1.78 ms, 20°, FOV: 20 mm × 40 mm × 20 mm, 
matrix: 128 × 256 × 128, resolution: 0.156 mm isotropic.  B)  19F gradient-echo images, TR = 5 ms, TE 
= 1.34 ms, 90°, FOV: 32 mm × 32 mm, matrix: 64 × 64, slice thickness = 10 mm, na = 64. Images are 
shown with the same intensity scale after 2D zero-padding. Transmitter offset for 19F images: -86 ppm 
Yb, Tm; -78 ppm Fe; -62 ppm Ho.  SNR for 19F images: Yb, 4.6, Tm, 7.2; Fe, 34; Ho, ~1. 
Gradient echo MR images obtained at 9.4 T illustrate the relative strength of 
the [M-DOTAm-F12]2+/3+ complexes in rat blood (Figure 2-12 and Table 2-8 for 
SNR).  As with the study in water, each image was collected with a TR of 5.0 ms and 
with a center frequency corresponding to the chemical shift of each complex, shown in 
Figure 2-12. Under these conditions, and as a consequence of the short T2, the SNR of 
the Tm(III) derivative drops by more than half in blood (7.2) versus water (18.1).  
Similarly, the SNR obtained with the Yb(III) in blood is 25% lower than that observed 
in water. The Ho(III) complex is affected the most by blood. Whereas in water it is 
one of the most sensitive complexes with an SNR of 31, in blood, the signal could not 
be detected, likely as a consequence of the too short T2 depicted in Figure 2-13.  
 
Figure 2-13: 19F gradient-echo images of Ho-DOTAm-F12 in water 
(right) and rat blood (left). B0 = 9.4 T, T = 33°C, TR = 5 ms, TE = 1.23 ms, 
90°, FOV: 32 mm × 32 mm, matrix: 64 × 64, slice thickness = 10 mm, na 
= 512, 2D zero-padding. 
 62
Likewise, De Luca et al. could not detect a chitosan polymer substituted with 
fluorinated Ho(III) complexes in mice with an imaging time of 1 h.116 It is possible 
that more recent imaging sequences, such as SWIFT,117 which could alleviate the 
effects of a short T2 if it is not too short, and could enable more sensitive 19F MRI with 
the lanthanide complexes. FeII-DOTAm-F12, unlike its lanthanide counterparts, 
remained an efficient contrast agent in blood with a sensitivity that is barely affected 
by blood components.  The SNR for the image obtained with the Fe(II) complex was 
34, 85% of that obtained in water. 
The limit of detection of the Fe(II) and Tm(III) complexes in blood was 
estimated from 19F gradient echo images of blood samples containing increasing 
concentrations of either complex can be seen in Figure 2-14.  
 
 
Figure 2-14: 19F gradient-echo images of A) Fe(II)-DOTAm-F12 
and B) Tm DOTAm-F12 in rat blood at three concentrations (5 
mM, 1 mM, 0.5 mM from left to right). B0 = 9.4 T, T = 33°C, TR = 
10 ms, TE = 1.34 ms, 90°, FOV: 32 mm × 32 mm, matrix: 64 × 64, 
slice thickness = 10 mm, na = 64.  2D zero-padding. Tm images 
are shown with two times higher intensity than Fe images. SNR 
for Fe: 5 mM, 40; 1 mM, 8.8; 0.5 mM, 4.3.  SNR for Tm: 5 mM, 
8.2; 1 mM, 5.3; 0.5 mM, 2.3.   
 
 
 
 
Note that in this figure the image intensity of the Tm(III) complex has been 
increased by a factor of two versus that of Fe(II).  Using the linear relationship 
between the SNR and the complex concentration, FeII-DOTAm-F12 is estimated to 
have a limit of detection of 300 µM in blood.  However, the SNR of the Tm complex 
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is not proportional to the concentration at concentration of 5 mM. Images in Figure 2-
12 suggest unequal distribution of Tm complex in the blood for 5 mM sample.  
Three-dimensional 19F MRI of phantoms of M-DOTAm-F12 complexes at 5 
mM were collected in blood with a resolution of 0.5 mm × 0.5 mm × 1 mm (Figure 2-
15).  Signal from three complexes was observed in number of slices in this 3D 
acquisition which took 33 min (Yb, Tm, and Fe). The signal of Fe complex has the 
highest signal intensity and was observed in largest number of slices. Together, the 
resolution and sensitivity obtained with Fe(II)-DOTAm-F12 are suitable for in vivo 
imaging of rat of mouse models in biomedical research applications.  
 
Figure 2-15: Three-dimensional 19F MRI phantom images of M-DOTAm-F12 at 5.0 mM in rat blood.  
Samples are positioned as Figure 2-14. B0 = 9.4 T, T = 33 °C, TR = 15 ms, TE = 0.99 ms, 90°, FOV: 32 
mm × 32 mm × 32 mm, matrix: 64 × 64 × 32, na = 64, acquisition time = 33 min. 
 
2.6 Conclusions and Future Directions 
 
A series of metal complexes of the C4 symmetric ligand, DOTAm-F12 has 
been synthesized and its potential as 19F MRI contrast agents has been evaluated. Nine 
paramagnetic lanthanide ions were studied, Eu(III), Gd(III), Tb(III), Dy(III), Ho(III), 
Er(III), Tm(III), and Yb(III), as well as the diamagnetic La(III) analog.  Fe(II), which 
is known to form stable complexes with macrocyclic polyaminocarboxamides, was 
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also evaluated. As opposed to currently used organic polyfluorocarbons such as 
perfluoro 15-crown-5 and other reported paramagnetic fluorine probes, the complexes 
of DOTAm-F12 are all highly soluble in water. These complexes are more sensitive 
than other fluorinated MR probes, in part due to the twelve fluorine nuclei which are 
chemically equivalent and thus appear as a single resonance by 19F NMR. Importantly, 
the sensitivity of these probes is further increased due to the paramagnetic nature of 
the metals which shorten T1, thereby enabling more scans to be acquired in the same 
amount of time. Shorter longitudinal relaxation times were observed for those metals 
with the highest effective magnetic moment, µeff. SNR observed in MR images, 
however, are not proportional to T1 but to a combination of T1 and the T2/T1 ratio. 
Higher SNR were observed for complexes that were characterized with fluorine T2/T1 
as close to unity as possible. In water, the Ho(III) and Fe(II) complexes were the most 
sensitive, followed by Tm(III)
 
and Yb(III). In blood, however, presumed binding of 
the probe with proteins result in a decrease in the transverse relaxation times of the 
fluorines for all the metal complexes except Fe(II). As a result, the Ho(III) complex 
could no longer be observed by MRI.  The Tm(III)-complex of DOTAm-F12 is the 
most sensitive lanthanide complex in blood. Fe(II)-DOTAm-F12, which as a T2/T1 
closer to unity, is the most sensitive fluorine contrast agent in blood with a limit-of-
detection of 0.30 mM.  
Further studies will evaluate the effect of magnetic field strength, B0, on the 
efficacy of the paramagnetic fluorine probes.  Evaluation of the Bloch-Redfield-
Wangsness (BRW) theory (equations 2-3 – 2-7) indicate that the longitudinal 
relaxation rates of the fluorine nuclei should be strongly dependent on B0, with higher 
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relaxation rates observed at higher magnetic fields (Figure 6). This dependence 
suggest that, unlike gadolinium-based contrast agents whose longitudinal relaxivity 
sharply decrease at medium-to-high magnetic field, paramagnetic fluorine probes 
would be more sensitive, and perhaps more appropriate, for high field MRI. 
Ligand design and the rotational correlation times are two other parameters that 
could also be exploited to further increase the sensitivity of this class of contrast 
agents.  Figures 6 and 7 show the predicted effect of τR and B0 on the longitudinal and 
transverse relaxivities, respectively, as calculated from the Bloch-Redfield-Wangsness 
equations using the Ln-19F observed in the Tm-DOTAm-F12 crystal structure and 
assuming a magnetic moment, µeff, of 7.6 BM and an electronic relaxation time, τe, of 
0.20 ps, values typical of Tm(III) complexes.  Slow rotational correlation times, 
corresponding to rigid and large macromolecules, are expected to decrease T2 
substantially while having a minimal effect on T1. As a result, the T2/T1 ratio of such 
macromolecules would be too small for the probes to be detectable by MRI. However, 
a small increase in the rotational correlation time (τR near 200 ps) would increase R1 
five-fold while having a moderate effect on R2. Such medium-sized complexes could 
be more sensitive MR probes.  Another possibility is to reduce the negative effect of 
short T2 on SNR by using alternative MR pulse sequences.  
Overall, the increased sensitivity of these highly water-soluble paramagnetic 
fluorine probes render them attractive alternatives to standard proton imaging by MRI. 
The ease by which MRI scanners can be re-tuned to the frequencies of fluorines 
further facilitates the promulgation of these probes. The ability to perform multi-color 
MR imaging with fluorine probes and the possibility to alter the transverse and 
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longitudinal relaxation rates of the fluorine nuclei as a function of the metal-19F 
distance and rotational correlation times open interesting opportunities for the design 
of ratiometric responsive MRI contrast agents. 
 The next chapter will focus on how manipulation of the field strength and 
the ligand field environment affects the MR properties of [M-DOTAm-F12]2+/3+. The 
studies that will be presented in Chapter 3 will look at different methods for increasing 
fluorine sensitivity rather than only looking at the effect of different metals. 
2.7 Experimental Materials and Methods 
General considerations. Starting materials were obtained from commercial 
suppliers and used without further purification.  Water was distilled and further 
purified by a Millipore cartridge system (resistivity 1.8 × 107 Ω).  All organic extracts 
were dried over anhydrous MgSO4 and solvents were removed under reduced pressure 
with a rotary evaporator. All synthetic compounds were characterized at the LeClaire-
Dow Chemical Instrumentation Facility at the Department of Chemistry at the 
University of Minnesota, Twin-Cities. 1H NMR spectra were recorded on a Varian 500 
at 500 MHz, 13C NMR spectra on a Bruker AV-500 at 125 MHz, and 19F NMR spectra 
were recorded on a Varian VXR-300 at 282 MHz. The residual solvent peak was used 
as an internal reference for 1H and 13C NMR; CFCl3 was used as an internal reference 
for 19F NMR of organic intermediates; and KF was used as an external standard for 
metal complexes. Data for 1H NMR are reported as follows: chemical shift (δ, ppm), 
multiplicity (s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; m, 
multiplet), integration, coupling constant (Hz). Data for 13C NMR and 19F NMR are 
reported in terms of chemical shift (δ, ppm). Longitudinal (T1) and transverse (T2) 
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relaxation times of 19F nuclei of metal complexes in D2O were measured using the 
inversion recovery sequence and the Carr-Purcell-Meiboom-Gill sequence, 
respectively.  A delay time of 30 ms and acquisition time of 64 ms were used for the 
collection of 1H and 19F NMR spectra of the paramagnetic M-DOTAm-F12 
complexes. Mass spectra (HR, high resolution; ESI, electrospray ionization) were 
recorded on a Bruker BioTOF II at the Waters Center of Innovation for Mass 
Spectrometry at the Department of Chemistry at the University of Minnesota, Twin-
Cities. X-ray data collection and structure solution were conducted at the X-Ray 
Crystallographic Laboratory of the Department of Chemistry at the University of 
Minnesota.  All calculations were performed using Pentium computers using the 
current SHELXTL suite of programs.   
2-Bromo-N-(2,2,2-trifluoroethyl)acetamide (2-12): 2,2,2trifluoroethyl amine 
(4.00 mL, 27.5 mmol) was dissolved in CH2Cl2 (50 mL) and magnetically stirred in an 
ice bath.  A solution of K2CO3 (16.5 g, 120 mmol) in distilled H2O (50 mL) and a 
solution of bromoacetyl bromide (2.40 mL, 27.7 mmol) in CH2Cl2 (50 mL) were 
simultaneously added dropwise over 30 min, after which the reaction was allowed to 
warm to ambient temperature and stirred for 1 h.  The organic phase was separated and 
washed with distilled H2O until the washes were at neutral pH (5 × 25  mL), washed 
with brine (1 × 20 mL), dried over MgSO4 and concentrated under reduced pressure to 
yield product (2-12) as white crystals (4.88 g, 80.7 %).  1H NMR (500 MHz, CDCl3, 
δ): 3.88-3.97 (m, 4 H), 7.19 (br s, 1 H). 13C NMR (75 MHz, CDCl3, δ): 28.9, 41.9 (q, J 
= 34.8 Hz), 124.4, (q, J = 277 Hz), 167.4. 19F NMR (282 MHz, CDCl3, δ): -72.9 (t, J = 
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8.7 Hz). HRMS-ESI (m/z): [M + H]+ calc for C4H5BrF3NO: 219.9579; found: 
219.9579.  The observed isotopic distribution matched the calculated one. 
 
2,2',2'',2'''-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetrakis(N-
(2,2,2- trifluoroethyl)acetamide) (DOTAm-F12, 2-1): Cyclen (500. mg, 2.91 mmol) 
was dissolved in dry CH3CN (150 mL) and magnetically stirred. K2CO3 (7.06 g, 51.2 
mmol) was then added, followed by the acetamide 2-12 (2.56 g, 11.6 mmol). The 
reaction was then heated to 60 °C for 8 h, cooled to ambient temperature, filtered, and 
concentrated under reduced pressure and further dried under high vacuum for 3 days 
yielding the free ligand as a white powder (1.82 g, 85.9%). 1H NMR (500 MHz, 
CD3OD, δ): 2.52 (q, J = 2.5 Hz, 4 H), 2.59 (q, J = 3.0 Hz, 4 H), 2.74 (t, J = 5.0 Hz, 4 
H), 3.01 (t, J = 5.0 Hz, 4 H), 3.16 (s, 4 H), 3.25 (s, 4 H), 3.78 (q, J = 9 Hz, 8 H). 
13C NMR (125 MHz, CD3OD, δ): 41.1 (q, J = 33.8 Hz), 58.7, 62.7, 126.1 (q, J = 276 
Hz), 173.9.  19F NMR (282 MHz, CD3OD, δ): -72.9 (t, J = 8.7 Hz).  HRMS-ESI (m/z): 
[M + Na]+ calc for C24H36F12N8O4: 751.2560; found: 751.2562. 
 
Ln-DOTAm-F12 complexes: Representative procedure for La-DOTAm-F12 
(2-2): Aqueous LaCl3 (101 mg, 0.412 mmol) was added to a stock solution of 
DOTAm-F12 (2-1) (300. mg, stock solution of 10 mg/mL ligand dissolved in 1:1 
CH3OH and CH3CN, 0.412 mmol) and magnetically stirred. The acidic mixture was 
basified with aqueous NaOH to pH  8 and heated at 75 °C for 90 h. Volatiles were 
removed under reduced pressure and further dried under high vacuum overnight 
yielding a white powder (2-2, 397 mg, 99.0%). 1H NMR (500 MHz, D2O, δ): see 
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Figure S1. 19F NMR (282 MHz, D2O, δ): -72.9 ppm. HRMS-ESI (m/z): [M-H]2+  calc 
for C24H36F12LaN8O4: 433.0827; found: 433.0809.  
 
Eu-DOTAm-F12 (2-3): DOTAm-F12 (150. mg, 0.206 mmol), EuCl3 (53.2 
mg, 0.206 mmol), 87 h, white powder (2-3, 200. mg, 98.5%). 1H NMR (500 MHz, 
D2O, δ): see Figure S2. 19F NMR (282 MHz, D2O, δ): -73.5 ppm. HRMS-ESI (m/z): 
[M-H]2+ calc for C24H36EuF12N8O4: 439.5862; found: 439.5867. The observed isotopic 
distribution matched the calculated one.  
 
 Gd-DOTAm-F12 (2-4): DOTAm-F12 (150. mg, 0.206 mmol), GdCl3 (54.3 
mg, 0.206 mmol), 100 h, white powder (2-3, 201 mg, 98.6%). 1H NMR (500 MHz, 
D2O, δ): see Figure S3. 19F NMR (282 MHz, D2O, δ): -72.9 ppm. HRMS-ESI (m/z): 
[M-H]2+ calc for C24H36F12GdN8O4: 442.0876; found: 442.0858.  The observed 
isotopic distribution matched the calculated one.  
 
Tb-DOTAm-F12 (2-5): DOTAm-F12 (150. mg, 0.206 mmol), TbCl3 (54.2 
mg, 0.206 mmol), 85 h, white powder (2-5, 203 mg, >99.0%). 1H NMR (500 MHz, 
D2O, δ): see Figure S4.  19F NMR (282 MHz, D2O, δ): -54.0 ppm. HRMS-ESI (m/z): 
[M-H]2+ calc for C24H36F12N8O4Tb: 442.5883; found: 442.5902.  
 
Dy-DOTAm-F12 (2-6): DOTAm-F12 (150. mg, 0.206 mmol), DyI3 (112 mg, 
0.206 mmol), 104 h, brown powder (2-6, 257 mg, 98.0%). 1H NMR (500 MHz, D2O, 
δ): see Figure S5. 19F NMR (282 MHz, D2O, δ): -52.2 ppm. HRMS-ESI (m/z): [M-
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H]2+ calc for C24H36DyF12N8O4: 445.0902; found: 445.0899.The observed isotopic 
distribution matched the calculated one.  
 
Ho-DOTAm-F12 (2-7): DOTAm-F12 (150. mg, 0.206 mmol), HoBr3 (83.3 
mg, 0.206 mmol), 99 h, pink powder (2-7, 231 mg, 98.4%). 1H NMR (500 MHz, D2O, 
δ): see Figure S6. 19F NMR (282 MHz, D2O, δ): -62.0 ppm. HRMS-ESI (m/z): [M-
H]2+ calc for C24H36F12HoN8O4: 445.5908; found: 445.5911.  
 
Er-DOTAm-F12 (2-8): DOTAm-F12 (150. mg, 0.206 mmol), ErBr3 (83.6 mg, 
0.206 mmol), 98 h, yellow powder (2-8, 231 mg, 99.1%). 1H NMR (500 MHz, D2O, 
δ): see Figure S7. 19F NMR (282 MHz, D2O, δ): -77.5 ppm. HRMS-ESI (m/z): [M-
H]2+ calc for C24H36ErF12N8O4: 446.0907; found: 446.0922.The observed isotopic 
distribution matched the calculated one.  
 
Tm-DOTAm-F12 (2-9): DOTAm-F12 (150. mg, 0.206 mmol), TmCl3 (56.7 
mg, 0.206 mmol), 98 h, white powder (2-9, 203 mg, 98.0%). 1H NMR (500 MHz, 
D2O, δ): see Figure S8. 19F NMR (282 MHz, D2O, δ): -85.6 ppm. HRMS-ESI (m/z): 
[M-H]2+ calc for C24H36F12N8O4Tm: 447.6927; found: 447.6923.  
 
Yb-DOTAm-F12 (2-10): DOTAm-F12 (150. mg, 0.206 mmol), YbCl3 (57.6 
mg, 0.206 mmol), 77 h, white powder (2-10, 206 mg, >99.0%). 1H NMR (500 MHz, 
D2O, δ): see Figure S9.  19F NMR (282 MHz, D2O, δ): -77.3 ppm. HRMS-ESI (m/z): 
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[M-H]2+ calc for C24H36F12N8O4Yb: 450.0950; found: 450.0959.The observed isotopic 
distribution matched the calculated one.  
 
FeII-DOTAm-F12 (2-11): DOTAm-F12 (50. mg, 69 µmol) was dissolved in 
CH3OH and CH3CN (1:1, 25 mL) and magnetically stirred.  
Iron(II)trifluoromethanesulfonate (24.3 mg, 68.7 µmol) was added and the reaction 
mixture was heated to 70 °C for 30 h under argon.  The resultant mixture was then 
concentrated under reduced pressure to yield the complex FeII-DOTAm-F12 (2-11) as 
an orange solid in quantitative yield. 1H NMR (500 MHz, D2O, δ): see Figure S10. 19F 
NMR (282 MHz, D2O, δ): -70.9 ppm. HRMS-ESI (m/z): [M]2+ calc for 
C24H36F12FeN8O4: 392.1009; found: 392.1000. 
 
Hydration number (q). The hydration number, q, of Dy-DOTAm-F12 was 
determined by 17O NMR according to the procedure of Peters.96 Standard solutions of 
[Dy-DTPA]2- (5% ligand excess) and Dy-DOTAm-F12 (5% ligand excess) were 
prepared at 60.4 mM and 50.0 mM, respectively, each with 10% D2O in H2O with 
0.05% 17O-labeled H2O. 17O resonances were recorded on a Bruker Avance-HD 500 at 
67.7 MHz. The resultant chemical shifts of the 17O resonances were plotted as a linear 
function of concentration; seven concentrations were used for each species. The 
hydration number of Dy-DOTAm-F12 relative to that of [Dy-DTPA]2- (q =1) was 
calculated by the ratio of the slopes (Figure 2-3).  
 
Gas-phase DFT calculations.  
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Geometry optimizations were carried out using Gaussian09101 with B3LYP 
functional by employing the 6-31G(d) basis set for the light elements (H, C, N, O and 
F) and the quasirelativistic effective core potential (RECP) of Dolg et al. and the 
related [5s4p3d]-GTO valence basis set for the TmIII.102,103 This RECP accommodates 
46+4fn electrons in the core for the lanthanide and the outermost 11 electrons are 
treated explicitly. Such RECP has been earlier used in DFT studies to understand the 
structure and energetics of the lanthanide complexes.104 The absence of imaginary 
frequency in the frequency calculation confirmed the optimized geometry as energy 
minima. 
X-ray crystallography 
Data collection. A crystal (approximate dimensions 0.1 × 0.1 × 0.1 mm3) was 
placed onto the tip of a 0.1 mm diameter glass capillary and mounted on a Bruker D8 
Photon 100 CMOS diffractometer for a data collection at 123(2) K.118  A preliminary 
set of cell constants was calculated from reflections harvested from three sets of 20 
frames.  These initial sets of frames were oriented such that orthogonal wedges of 
reciprocal space were surveyed.  This produced initial orientation matrices determined 
from 620 reflections.  The data collection was carried out using CuKα radiation 
(normal parabolic mirrors) with a frame time of 7.5/15 seconds and a detector distance 
of 4.0 cm.  A randomly oriented region of reciprocal space was surveyed to the extent 
of one sphere and to a resolution of 0.83 Å.  Twelve sets of frames with a sweep width 
of 0.5 were collected as determined by the data collection strategy in APEX II.  The 
intensity data were corrected for absorption and decay (SADABS) using an empirical 
correction for absorption anisotropy.119 Final cell constants were calculated from the 
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xyz centroids of 2823 strong reflections from the actual data collection after 
integration (SAINT).120   
Structure solution and refinement. The structure was solved using SHELXS-
97 and refined using SHELXL-97.121  The space group Cmca was determined based 
on systematic absences and intensity statistics.  A direct-methods solution was 
calculated which provided most non-hydrogen atoms from the E-map.  Full-matrix 
least squares / difference Fourier cycles were performed which located the remaining 
non-hydrogen atoms.  All non-hydrogen atoms were refined with anisotropic 
displacement parameters.  The protons on the nitrogen atoms were found from the 
difference map and refined with individual isotropic displacement parameters.  All 
remaining hydrogen atoms were placed ideally and refined with relative isotropic 
displacement parameters.  The final full matrix least squares refinement converged to 
R1 = 0.0635 and wR2 = 0.1928  (F2, all data). Platon Squeeze122,123 was used to 
remove the electron density that resulted from the disordered solvent.  The Squeeze 
results were consistent in removing 40 water molecules in the unit cell.   
MRI. Magnetic resonance images of samples in water and in blood were 
acquired at 33 °C in 3 mm NMR tubes using a 9.4-T, 31-cm horizontal bore magnet 
(Magnex Scientific, Oxford, UK) interfaced with a Varian Direct Drive console 
(Varian, Palo Alto, CA, USA).  The magnet was equipped with a gradient insert 
capable of reaching 450  mT/m in 200 µs (Resonance Research, Inc., Billerica, MA).  
A linear radiofrequency (RF) surface coil (12 mm diameter) tunable to both 1H (400.2 
MHz) and 19F (376.6 MHz) frequencies was used to transmit RF and receive the 
signal.  1H 3D gradient echo images were acquired using following parameters: 
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repetition time (TR) = 10 ms, echo time (TE) = 1.78 ms, field-of-view (FOV) = 20 mm 
x 40 mm x 20 mm, matrix = 128 x 256 x 128, number of averages (na) = 1.  19F 
gradient echo images were acquired at resonance frequencies of compounds using 
following parameters: TE = 1.34 ms, FOV = 32 mm x 32 mm, matrix = 64 x 64, slice 
thickness = 10 mm, flip angle = 90°.  TR was varied from 5 to 100 ms and na from 64 
to 512.  3D gradient-echo images were acquired at -78 ppm using following 
parameters: TR = 15 ms, TE = 0.99 ms, FOV = 32 mm x 32 mm x 32 mm, matrix = 64 
x 64 x 32, flip angle = 90°, na = 64.  SNR was calculated by taking the ratio of the 
mean intensity in the circular region of interest (ROI) containing whole sample over 
the mean intensity in an identically sized noise region of the image. 
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3 Optimization of 19F Paramagnetic Relaxation Enhancement: 
Lanthanide-Induced Shift, Effective Magnetic Moment, and BRW Theory 
Minimizations 
 
3.1 Introduction 
 The design principles required to produce a viable 19F MRI contrast agent require 
that the paramagnetic metal induce both a change in chemical shift, and a change in 
relaxation rates. Both of these effects can be obtained by using paramagnetic metal 
ions, which affect the 19F lanthanide-induced shift (19FLIS) and the 19F paramagnetic 
relaxation enhancement (19FPRE) of the complex. Not all fluorine probes, however, 
produce both of these effects to an appreciable degree.40 
Fluorine-based MRI contrast agents are also limited by sensitivity, which can be 
increased by optimizing the relaxation times of the 19F nuclei. In Chapter 2, the 
importance of incorporating a paramagnetic metal center within a 19F MRI contrast 
agent was examined using the same ligand, DOTAm-F12 (2-1), which decreased T1 and 
T2 values by over two orders of magnitude in some cases. 
Classic BRW theory indicates that a number of variables dictate R1 and R2 
values for a given probe, with the most pronounced effects dictated by (and typically 
measured in) the 19F-Ln(III) distance d (Å), the effective magnetic moment of the 
lanthanide µeff (Bohr magnetons), the electronic relaxation time T1e (ps), and the 
rotational correlation time τR (ps).7,31,124,125 The first term in each equation is known as 
the dipolar term, and the second term is the Curie term. Both contribute to R1 and R2 but 
at higher fields the Curie term is dominant. Equation 2-3 & 2-4 are provide below. 
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McConnel-Robertson theory (equation 2-2) dictates the magnitude of 19FLIS as 
dependent as well on d, as well as the angle θ between the 19F nuclei and the principal 
dipolar axis of the Ln(III). 
  
FLIS	@A = 	CD 	 E-FG$HI&- JK LMN- O4	@PQR STG     (2-2) 
 Different ligand designs affect relaxation and chemical shift properties imparted 
by paramagnetic Ln(III) ions. Trends in the data can be identified and exactly how the 
values of θ, d, µeff, T1e, and τR affect the observed trends can be determined, as well as 
how each ligand affects these properties of the coordination complex. Data obtained 
from these studies can provide valuable information about 19F probe systems that can 
be used to further enhance 19F sensitivity and functionality in future probe designs. 
3.2 To Determine Ideal 19F Probes for MRI 
 
 When considering the impact of fluorine’s R1 and R2 value in a contrast agent, 
classic BRW theory indicates that these two relaxation rates are dependent on the 
gyromagnetic ratio of 19F (γF) which is constant, the Zeeman frequency of fluorine (ωF) 
and the electron frequency, ωe, which are both functions of the magnetic field strength, 
B0. Work by Chalmers et al. has demonstrated that the 19F R1 and R2 values are 
enhanced with increasing field strength, up to 20 T as shown in their report.82 Higher 
sensitivity is predicted at higher field strengths (B0).82,126 However, higher field 
strengths also enhance R2 rates which can lead to line broadening and decreased SNR in 
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MRI. Additionally, at field strengths of ca. 10 T and above, the values of τR and d are 
more significant and must be taken into consideration.  
Values for d, µ eff, T1e, and τR, incorporated in two equations (2-3 and 2-4) yields 
two single values for the 19F relaxation rates of a metal-based probe. By altering a 
probe’s structure, R1 and R2 can be predicted by changing d (ligand structure), T1e 
(metal choice, ligand structure, or field strength), τR (ligand structure or solution state), 
and/or µeff of that probe (ligand structure, metal choice). This study is in effort to 
understand the parameters that yield an ideal 19F MRI contrast agent. 
Relaxation rates and subsequent 19F sensitivity are dominated by the electronics 
of the paramagnetic metal center. Since that metal center when chelated imparts its 
electronic effects on the 19F nuclei, different coordination functionalities ultimately 
determine how the paramagnetic behavior of the metal will influence the relaxation 
rates and ultimately the sensitivity of the probe. The electronic properties of lanthanides 
vary depending on their coordination complexes, and the electronic interactions 
between a lanthanide and a ligand produce a unique set of parameters that all factor in 
to classic BRW theory. The electronic behavior imparted by a ligand on a Ln(III) ion, 
and the Ln(III) ion’s interaction with the ligand are impacted by the ligand field 
environment.127-131 Thus, each Ln(III) ion and coordination complex has a unique MR 
profile.  
3.3 Three Ligands, Six Lanthanides 
 
For this project, three series of 19F probes were synthesized, with structures 
shown in Figure 3-1. In addition to DOTAm-F12 and its respective metal complexes 
with Tb(III), Dy(III), Ho(III), Er(III), Tm(III) and Yb(III), two new ligands were 
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synthesized: DOTA-F6 (3-1) and F-DOTPME (3-14), and their complexes with the 
same six lanthanides. These six lanthanides were chosen because they have the highest 
µeff values of the lanthanides(Gd (III) not considered due to the line broadening). All 
three ligands were constructed with a macrocyclic cyclen backbone, but have different 
oxygen donor functionalities used in creating their respective 8-coordinate complexes 
with lanthanide(III) ions, changing the relative hardness/softness of the overall chelate. 
In DOTAm-F12 (2-1), the oxygen donor groups are from amides; in DOTA-F6 (3-1) 
they are from carboxylic acids, and in F-DOTPME (3-14) they are from phosphonate 
esters.  
 
 
 
Figure 3-1: Metal complexes used in this study: [M-DOTAm-F12]3+ (2-2 to 2-10), [M-DOTA-F6]- (3-5 
to 3-13), and [M-F-DOTPME]- (3-16 to 3-24).  
 
3.3.1 Synthesis of Metal Complexes 
 
The detailed synthetic pathway for DOTAm-F12 (2-1) and its metal complexes is 
provided in Chapter 2. The synthetic pathways for the ligands DOTA-F6 (3-1) and F-
DOTPME (3-14) and their metal complexes are provided in. DOTA-F6 (3-1) was 
synthesized by reacting the protected carboxylic acid pendant arm with cyclen under 
basic conditions to yield exclusively the 1,7-disubstituted product. 
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Scheme 3-1: Reagents and conditions: (a) K2CO3, CH3CN, reflux, 18 h, 60.0 %; (b) tBu bromoacetate, 
K2CO3, 45 ˚C, 16 h, 96.0 %; (c) NaOH (aq.), 1 h; (d) HCl (aq.), 1 h, 93.9 % over two steps; (e) LnX3, 
H2O, reflux, 3 days, quant.; (f) paraformaldehyde, acetic acid, benzene, rt, 3 d; (g) NaOH, H2O, 100 ˚C, 
30 min; 22 ˚C, 2 d, 29% over 2 steps; (h) LnX3, H2O, reflux, 3 days, quant. 
 
Substitution at all four 2˚ nitrogens on cyclen was desired, but only the 
disubstituted product was formed, most likely due to the steric bulk imparted by the 
protected pendant arm. The remaining two nitrogens on the macrocycle were 
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substituted with tBu bromoacetate. Saponification of both ester groups yielded the free 
ligand as the tetrahydrochloride salt in quantitative yield. The ligand F-DOTPME (3-
14) was synthesized by Cutler Lewandowsky over two steps according to scheme 3-1. 
In the first step, cyclen was reacted with bis(2,2,2-trifluoroethyl)phosphite and 
paraformaldehyde in benzene to form the perester 3-15. Subsequent hydrolysis in basic 
water formed the ligand 3-14 as the tetrasodium salt. While this route was relatively 
low yielding for F-DOTPME (3-14), the syntheses of both DOTA-F6 (3-1) and F-
DOTPME (3-14) are easily scalable. Their metal complexes with La(III), Eu(III), 
Gd(III), Tb(III), Dy(III), Ho(III), Er(III), Tm(III), and Yb(III) were each synthesized 
quantitatively from their respective lanthanide trihalide salts in aqueous conditions at 
neutral pH to form the metal complexes 3-5 to 3-13 and 3-16 to 3-24, respectively. 
3.4 Lanthanide-Induced Shift 
 
 As mentioned in Chapter 2 (section 2.4.4), the shift in a fluorine resonance caused 
by a paramagnetic metal is defined as the 19F lanthanide-induced shift (19FLIS). The 
19FLIS can be approximated using the McConnell-Robertson equation (equation 2-2), 
and is dependent on the sign and magnitude of the Bleaney coefficient (CD), the 19F-
Ln(III) distance (d), and the angle between the principal magnetic dipolar axis of the 
Ln(III) ion (θ).  
The 19FLIS values for each series of complexes is reported in table 3-1. These 
values are averages of each 19FLIS measured at five different field strengths (4.7, 9.4, 
11.7, 14.1, and 16.5 T). 19FLIS is independent of field strength, so the values obtained 
at five fields were averaged over 5 data points. 
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Table 3-1: Chemical shifts (δ, ppm) of DOTAm-F12, DOTA-F6, and F-DOTPME metal complexes, and 
change in chemical shift (∆δ, 19FLIS) relative to the free ligand. aAverage chemical shifts from data 
acquired at 4.7, 9.4, 11.7, 14.1, and 16.5 T, 298 K. 
Compound 
 
Average δ (ppm)a ∆δ (ppm) (19FLIS) 
DOTAm-F12 (2-1) -79.2 n/a 
[La-DOTAm-F12]3+ -72.9 0 
[Eu-DOTAm-F12]3+ -73.1 -0.2 
[Tb-DOTAm-F12]3+ -53.8 +19.1 
[Dy-DOTAm-F12]3+ -51.8 +21.1 
[Ho-DOTAm-F12]3+ -61.7 +11.2 
[Er-DOTAm-F12]3+ -76.9 -4.0 
[Tm-DOTAm-F12]3+ -86.8 -13.9 
[Yb-DOTAm-F12]3+ -77.0 -4.1 
   
DOTA-F6 (3-5) -75.7 n/a 
[La-DOTA-F6]- -75.8 -0.1 
[Eu-DOTA-F6]- -70.7 +5.0 
[Tb-DOTA-F6]- -69.0 +6.7 
[Dy-DOTA-F6]- -68.2 +7.5 
[Ho-DOTA-F6]- -69.4 +6.3 
[Er-DOTA-F6]- -70.4 +5.3 
[Tm-DOTA-F6]- -70.1 +5.6 
[Yb-DOTA-F6]- -70.7 +5.0 
   
F-DOTPME (3-14) -75.8 n/a 
[La-F-DOTPME]- -75.6 +0.2 
[Eu-F-DOTPME]- -75.7 +0.1 
[Tb-F-DOTPME]- -32.4 +43.4 
[Dy-F-DOTPME]- -33.6 +42.2 
[Ho-F-DOTPME]- -56.8 +19.0 
[Er-F-DOTPME]- -94.8 -19.0 
[Tm-F-DOTPME]- -117.3 -41.5 
[Yb-F-DOTPME]- -82.7 -6.9 
 
3.4.1 19FLIS of DOTAm-F12 Complexes 
 
 The 19FLIS of the DOTAm-F12 series of metal complexes was explored at 7 T in 
chapter 2. The values reported in table 3-1 show only slight deviations within 
acceptable experimental error. The sign of the Bleaney coefficient still matches these 
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data, none of the data points indicate a change in geometry, suggesting the entire 
DOTAm-F12 series of complexes adopts a similar geometry with a similar d. 
3.4.2 19FLIS of DOTA-F6 Complexes 
 
 The 19FLIS of the DOTA-F6 series of complexes displays very different behavior 
from DOTAm-F12. The 19F chemical shift of the diamagnetic [La-DOTA-F6]- is in 
close agreement with the free ligand, and the remaining chemical shifts of the other 
metal complexes are all in very close agreement with each other, but not in agreement 
with the ligand. 
 This suggests that the resultant angle θ between the principal magnetic dipolar 
axis of the Ln(III) ions and the fluorines in DOTA-F6 complexes is ca. 45˚- 60˚. At this 
position, the 19FLIS based on equation 2-2 approaches 0. However, the angle θ is not 
incorporated in the BRW equations, and significantly enhanced relaxation rates are still 
observed. 
 Why [La-DOTA-F6] shows negligible shift with respect to the ligand, while all 
other complexes were shifted downfield by 5-8 ppm, is possibly due to lanthanide 
contraction. A square-anti-prismatic (SAP) geometry for as the La(III) complex, 
combined with a more rigid twisted-square-anti-prismatic (TSAP) geometry for the 
other metals might account for this observation. X-ray crystallographic data and/or 
DFT calculations, however, would be required to determine if this speculation is true.  
3.4.3 19FLIS of F-DOTPME Complexes 
 
 Like the DOTAm-F12 complexes, the 19FLIS of the F-DOTPME series of 
complexes follow the signs of the Bleaney coefficients, but are much larger than those 
observed for DOTAm-F12. Shifts exceeding 40 ppm are observed for Tb(III), Dy(III), 
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and Tm(III) complexes, over twice the highest values obtained for DOTAm-F12. The 
Ho(III) and Er(III) F-DOTPME complexes have the same shift magnitude but of 
opposite sign, whereas in DOTAm-F12 these two metals produced inequivalent 
magnitude. This observation is not in agreement with the McConnell-Robertson 
theorem (equation 2-2), in that the Bleaney coefficients are not accurate when applied 
to various ligands. Indeed, this was a stipulation clearly indicated in the original 1972 
report from Bleaney that is often overlooked.132 
3.5 Electronic Relaxation Rates (T1e) 
 
 The electronic relaxation rates of Ln(III) ions have been measured by NMR in 
only a few cases. Looking at aqua Ln(III) cations and some Ln(III) complexes, Alsaadi 
et al. calculated T1e values using estimated µeff and d values.57,133 While these reports 
were preliminary, they did predict correctly that Tb(III) and Dy(III) most often have the 
highest electronic relaxation rates, and Ho(III) and Er(III) have lower values. These 
studies were done at low field strengths. 
 Aime et al. found the same trend by looking at R1 at a single field and R2 at 
multiple fields,134 and Bertini et al. also investigated T1e values by NMR but looked at 
higher field values (up to 14 T).135 They assembled a nuclear magnetic relaxation 
dispersion (NMRD) profile for aqua-Ln(III) cations, and with the higher-field 
measurements were able to observe dominance of R1 on the Curie term of BRW theory 
(the second term in equations 2-3 and 2-4). 
3.5.1 Experimental Relaxation Data  
 
The BRW theorems (equations 2-3 and 2-4) can be used to interpret observed 
relaxation rates as a function of field strength (B0). This calculation, however, can only 
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be provided if the values of µeff, d, τR, and T1e are also known (or at least can be 
approximated). Since the parameters µeff, d, and τR are independent of B0, the relaxation 
rates measured at multiple field strengths can ultimately be applied to the BRW theory 
iteratively to determine T1e as a function of field strength, and then subsequently to 
determine µeff for each complex.31,82,136 
 In collaboration with Prof. David Parker at Durham University, Durham, England, 
the relaxation rates R1 for the 19F nuclei in each series of metal complexes were 
measured at five different field strengths using a standard inversion-recovery pulse 
sequence. Measurements were taken of a 5 mM sample of each complex in D2O on 4.7, 
9.4, 11.7, 14.1, and 16.5 T instruments (188, 376, 470, 564, and 658 MHz respectively 
for the 19F nucleus). Relaxation data for the diamagnetic La(III) complexes were used 
only as the control and are omitted, as well as for Gd(III) complexes which could not be 
determined due to extensive line broadening, even at lower field strengths. 
 
Table 3-2: T1 values reported are averages of three measurements obtained within 5% difference or less 
for each value. 
DOTAm-
F12: 
Metal 
T1 (ms),  
4.7 T 
T1 (ms),  
9.4 T 
T1 (ms),  
11.7 T 
T1 (ms),  
14.1 T 
T1 (ms),  
16.5 T 
Eu(III) 554 272 218 177 146 
Tb (III) 8.94 5.27 4.21 3.75 3.32 
Dy(III) 9.04 4.62 3.65 3.07 2.59 
Ho(III) 12.4 5.54 4.62 3.58 3.42 
Er(III) 12.9 10.4 7.62 5.71 4.82 
Tm(III) 41.6 20.5 15.9 12.8 12.1 
Yb(III) 173 112 86.1 72.0 59.1 
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Table 3-3: T1 values reported are averages of three measurements obtained within 5% difference or less 
for each value 
DOTA-F6: 
Metal 
T1 (ms),  
4.7 T 
T1 (ms),  
9.4 T 
T1 (ms),  
11.7 T 
T1 (ms),  
14.1 T 
T1 (ms),  
16.5 T 
Eu(III) 855 743 533 340 279 
Tb (III) 17.1 11.9 9.18 8.35 7.18 
Dy(III) 24.5 16.2 10.5 8.57 7.95 
Ho(III) 17.3 9.95 7.71 6.37 6.17 
Er(III) 15.9 8.89 7.52 6.76 6.19 
Tm(III) 55.1 46.6 39.3 24.9 21.6 
Yb(III) 172 111 99.1 83.8 77.9 
 
 
Table 3-4: T1 values reported are averages of three measurements obtained within 5% difference or less 
for each value. 
F-
DOTPME: 
Metal 
T1 (ms),  
4.7 T 
T1 (ms),  
9.4 T 
T1 (ms),  
11.7 T 
T1 (ms),  
14.1 T 
T1 (ms),  
16.5 T 
Eu(III) 899 429 348 268 245 
Tb (III) 19.0 11.1 8.29 7.62 7.32 
Dy(III) 13.5 7.86 6.55 5.81 4.99 
Ho(III) 17.8 9.53 8.19 6.51 5.95 
Er(III) 25.0 15.2 13.3 12.4 11.5 
Tm(III) 49.9 39.9 34.9 22.7 21.3 
Yb(III) 277 182 163 146 136 
 
 The T1 values of the remaining complexes for DOTAm-F12, DOTA-F6, and F-
DOTPME are provided in Table 3-2, Table 3-3, Table 3-4, respectively. T1 values 
reported are averages of three measurements obtained within 5% difference or less for 
each value. 
Upon initial analysis these data illustrate that the DOTAm-F12 family of 
complexes (Table 3-2) possess the greatest decreases in T1, with [Dy-DOTAm-F12]3+ 
showing the lowest T1 value measured of 2.59 ms at 16.5 T. The DOTAm-F12 series 
also produce only one resonance in the 19F NMR spectrum as previously mentioned. 
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The DOTA-F6 series (Table 3-3) show the longest T1 values, and the T1 values for the F-
DOTPME series (Table 3-4) reside in between the other two systems. 
 These data obtained contradicts the well documented trend that a reduced Ln(III)-
F distance enhances relaxation rates, as the 19F nuclei of DOTA-F6 are in much closer 
proximity to the Ln(III) metal than they are in the case of F-DOTPME.  
3.5.2 Application of BRW Theory to Determine T1e and µeff  - Data 
Minimization 
 
 The variation of experimental relaxation rate data as a function of field strength 
can be used to estimate values of T1e and µeff. The values for µeff commonplace in the 
literature are 9.8, 10.3, 10.4, 9.4, 7.6, and 4.5 for Tb(III), Dy(III), Ho(III), Er(III), 
Tm(III), and Yb(III), respectively.82,137-139 The data obtained are the T1 times of each 
complex as a function of field strength, B0. T1 values are inversely proportional to R1 
values, and assuming classic behavior adherent to BRW theory, the R1 values obtained 
can be used to iteratively determine the approximate values of T1e and µeff. Data coding 
was performed in MatLab using a series of minimization scripts written by Prof. Ilya 
Kuprov, and modified by Alexander M. Funk of the Parker group. Singular fittings for 
each metal ion are first performed, followed by global fitting of the entire ligand system 
data.  Fitting the relaxation rate data for the DOTAm-F12 complexes yields 
minimization values shown in Table 3-5. 
 The fitting algorithm subsequently generates a minimized value for d and τR that 
adhere to the initial singular fittings of µ eff and T1e. The adherence of relaxation rates to 
the BRW theory, using the values in Table 3-6, is provided in Figure 3-2. The trend 
lines plotted are the actual predictions of R1 from the minimalized values of µeff, T1e, d, 
and τR applied to the BRW equation (equation 2-3). 
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Table 3-5: Global minimizations of µeff, T1e as a function of relaxation rates for DOTAm-F12 
complexes. Subsequent iterations yielded the reported values for τR and d. 
DOTAm-
F12: 
Metal 
µeff  
(B. M.) T1e (ps) 
Tb(III) 9.77 0.52 
Dy(III) 10.4 0.36 
Ho(III) 9.88 0.28 
Er(III) 8.98 0.13 
Tm(III) 7.31 0.12 
Yb(III) 4.56 0.11 
 
 τR 231 ps 
 d 5.92 Å 
  
  
 
 
Figure 3-2: Global minimization of µeff, T1e, d, and τR based on R1 data at six field strengths for 
DOTAm-F12 complexes. 
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As shown in Figure 3-2, the BRW theory approximates the values of R1 based on 
the defined set of parameters shown in Table 3-5. The same fitting procedure was used to 
reach the minimization values of µeff and T1e, with subsequent generation of values for 
d and τR, and the results are provided for the DOTA-F6 series (Table 3-6and Figure 3-
3), and the F-DOTPME series (Table 3-7and Figure 3-4), provided below. 
 
Table 3-6: Global minimizations of µeff, T1e as a function of relaxation rates for DOTA-F6 complexes. 
Subsequent iterations yielded the reported values for τR and d. 
DOTA-F6: 
Metal µeff  (B. M.) T1e (ps) 
Tb(III) 8.74 0.50 
Dy(III) 8.96 0.27 
Ho(III) 9.49 0.33 
Er(III) 9.25 0.33 
Tm(III) 6.85 0.031 
Yb(III) 4.63 0.13 
 
 τR 205 ps 
 d 6.37 Å 
 89
 
 
 
Figure 3-3: Global minimization of µeff, T1e, d, and τR based on R1 data at five field strengths for DOTA-
F6 complexes. 
 
Table 3-7: Global minimizations of µeff, T1e as a function of relaxation rates for F-DOTPME complexes. 
Subsequent iterations yielded the reported values for τR and d. 
F-
DOTPME: 
Metal 
µeff  
(B. M.) T1e (ps) 
Tb(III) 9.87 0.43 
Dy(III) 10.6 0.59 
Ho(III) 10.3 0.37 
Er(III) 8.61 0.57 
Tm(III) 7.37 0.16 
Yb(III) 4.38 0.19 
 
 
τR 266 ps 
 
d 6.70 Å 
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Figure 3-4: Global minimization of µeff, T1e, d, and τR based on R1 data at five field strengths for F-
DOTPME complexes. 
3.5.3 Analysis of Data Fitted to Classic BRW Theory 
 
The first system analyzed was the DOTAm-F12 series of complexes. In addition 
to the five field strengths used for the tetraamide, these six complexes were also 
analyzed at low field in an additional collaborative effort between Prof. David Parker in 
Durham, England and Prof. Mauro Botta in Alessandra, Italy, as well as my adviser and 
myself. The data provided by Botta represents the low-field measurements plotted in 
figure 3-2 at 1.4 T (56.4 MHz for 19F). The data fittings conducted with these additional 
low-field measurements further validated the BRW minimization for the DOTAm-F12 
series, as trend lines plotted in Figure 3-2 indicate. The above minimizations for each 
system also were used to approximate values of τR and d, however these approximates 
are less accurate than the approximations of µeff and T1e.  
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3.5.4 Approximation of τR and d from BRW Theory and Drawbacks of Global 
Minimization 
  
The minimization techniques used to obtain the data above assume that 
isostructural series of metal complexes share the same value of d and τR across the 
entire series of lanthanides. This assumption disregards any component of lanthanide 
contraction across the series. This may only slightly change τR values, but d is not 
constant for these complexes due to lanthanide contraction.140-142 These observations 
suggest that the global minimization method has significant limitations. 
In all three of the preceding data fitting processes, the minimized data resulted 
in τR values that are much higher than expected. The tetraacid DOTA-F6 is very similar 
in structure to the unmodified DOTA ligand, for which the τR values have been found 
to be closer to 100 ps.7,143,144 The slight structural modifications to the DOTA ligand, as 
in the case of DOTA-F6, as well as DOTAm-F12 and F-DOTPME (with approximated 
τR values from the global fitting of 205, 231, and 266 ps, respectively) suggest that 
these values obtained are far too high.  
 Likewise, the values obtained for the Ln(III)-19F distance, d, are also in 
disagreement with the data obtained from X-ray crystallographic data and DFT 
calculations for DOTAm-F12, both described in Chapter 2. The Ln(III)-F distance 
found in both studies is ca. 6.2 Å, whereas the results of the minimization procedure 
indicate a distance of 5.9 Å. Classic BRW theory predicts R1 having a d3 dependency in 
the dipolar term, and in the Curie term—which is dominant at higher field strengths—a 
d6 dependency. What may appear to be a small difference in d has a much more 
pronounced significance in the BRW theory governing 19F relaxation rates, especially 
at higher field. 
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3.6 Other Methods Used to Determine τR and d 
 
 Determination of d was performed by X-ray crystallography of [Tm-DOTAm-
F12]3+ and gas- and solution-state DFT calculations performed by Dr. Kriti Srivastava 
and reported in Chapter 2. The results from both X-ray and DFT calculations result in d 
for [Tm-DOTAm-F12]3+ of 6.26 Å. 
3.6.1 Determination of τR Using NMRD and [Gd-DOTAm-F12]3+  
 
 In collaboration with Prof. Mauro Botta, the nuclear magnetic relaxation 
dispersion (NMRD) profile of [Gd-DOTAM-F12]3+ was obtained. NMRD is an indirect 
method of determining τR by measuring the relaxivity data of a Gd(III)-based metal 
complex as a function of field strength, often coupled with 17O spectroscopy. The NMR 
instrumentation required has the ability to vary the Larmor frequency measured to 
provide data from extremely low field strengths iteratively to high field strengths. 
NMRD profiles for Gd(III) metal complexes often share the same behavior as 
demonstrated in Figure 3-5. 
By examining the changes in relaxivities combined with 17O spectroscopy, the τR 
value can be further refined. The NMRD data provided by Botta, shown in Figure 3-5, 
has yielded a number of constants for the DOTAm-F12 ligand, as shown in Table 3-8. 
The value for τR is not ultimately constant across the series of DOTAm-F12 metal 
complexes, but using the value of 89 ps obtained for the Gd(III) complex should be 
quite similar to the other metal complexes, as only the relative size of the other metal 
complexes is due to the decreasing size of the metal ion (lanthanide contraction). 
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Figure 3-5: 1H NMRD profiles (pH = 6.9) at different temperatures (298, 310 and 318 K). The curves are 
calculated with the parameters of table 3-8. 
 
Table 3-8: Parameters obtained from the analysis of 17O NMR and NMRD dataa of [Gd-DOTAm-F12]3+ 
Parameter [GdL]3+ 
20
r1
298
 
(mM-1s-1) 2.6 
∆2 / 1019 s-2 1.6 
τV
298
 / ps 6.1 
τΜ
298
 
/  μs 19 
τR
298
 
/ ps 89 
q 1b 
r / Å 3.0b 
EV / kJ mol
-1
 1.0b 
∆H#M / kJ mol
-1
 45 
A/ħ / 106 rad s-1 -3.8 
aFor the parameters a, 298D, ΕR and ΕD the values of 4.3 Å, 2.24×10-5 cm2 s-1, 16 and -26 kJ mol-1, 
respectively, were used; b fixed in the fitting procedure. 
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3.7 Minimization of Data Using Known Values of τR and d  
 
 The minimization procedure and iteration process was used to calculate the values 
of µeff and T1e for the DOTAm-F12 complexes, having now definite values for d and τR 
from X-ray crystallographic data and NMRD profiling. Holding these values as 
constants for the model complex [Tm-DOTAm-F12]3+ (from which the X-ray value of 
d was obtained) has resulted in fitting of the BRW theory to the observed relaxation rate 
data obtained across five field strengths, and is shown in Figure 3-6.  
 
Figure 3-6: Minimization of [Tm-DOTAm-F12]3+ using fixed d = 6.26 Å and τR = 89 ps. Minimization 
results in µeff = 8.31 and T1e = 0.19 ps. 
 
3.7.1 Results 
 
The minimization for [Tm-DOTAm-F12]3+ has been fitted to the relaxation rate 
data points (Figure 3-6) with poorer agreement than that observed in Figure 3-2. 
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Specifically, the reconciliation of data points at 4.7 T and 9.3 T represent the poorest 
area of data fitting. This trend is also observed for the Tb(III), Dy(III), Ho(III), Er(III), 
and Yb(III) fittings (though these data assumed the same value of d as the Tm(III) 
complex, which is unlikely, as shown in Figure 3-7 and Table 3-9). The only resultant 
fit that matches the accuracy of the global fit with all variable terms is Yb(III), which, 
coincidentally, has the lowest µeff value of any of the preceding mentions, both 
provided as a literature standard of 4.5 when complexed with the non-fluorinated 
DOTAm ligand126 and fitted for the DOTAm-F12 system of 4.56 (global, all vary) and 
5.24 (global fit, fixed τR and d), meaning that the higher values of µeff found (>10 B. M. 
for Tb(III), Dy(III), Ho(III), and Er(III)) demonstrate most clearly the limitations of the 
global minimization approach. 
Table 3-9: Global minimizations of µeff and T1e as a function of relaxation rates for DOTAm-F12 
complexes, using an all-vary global fit, and then using fixed values of τR = 89 ps and d = 6.26 Å in a 
global fit. 
Ln(III) 
µeff  
(B. M.) 
(global, 
all vary) 
T1e (ps) 
(global, 
all vary) 
 µeff  
(B. M.) 
(global, 
fixed τR 
and d) 
T1e (ps) 
(global, 
fixed τR 
and d) 
Tb(III) 9.77 0.52  11.2 0.62 
Dy(III) 10.4 0.36  12.0 0.48 
Ho(III) 9.88 0.28  11.3 0.41 
Er(III) 8.98 0.13  10.3 0.20 
Tm(III) 7.31 0.12  8.31 0.19 
Yb(III) 4.56 0.11  5.24 0.12 
 
   
 τR 231 ps  τR 89 ps 
 
d 5.92 Å  d 6.26 Å 
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Figure 3-7: Minimization of Tb(III), Dy(III), Ho(III), Er(III), Tb(III), and Yb(III) using fixed d = 6.26 Å 
and τR = 89 ps. 
3.7.2 Analysis of Each Approach 
 
 Fitting the relaxation rate data to BRW theory as outlined and performed in this 
chapter has reached its limits of valid approximations to some extent. Not only has this 
global fitting procedure not matched BRW theory, it also resulted in an incorrect value 
of d (which again, at lower field carries a d3 and d6 dependency, and at higher field is 
dicated by the Curie term of the BRW theory which carries solely a d6 dependency), 
and it has also overestimated the τR value of each metal complex in the DOTAm-F12 
series by over two-fold. If the same fitting operations are performed holding the values 
of d and τR constant to what has been determined with utmost certainty by X-ray 
crystallography and by NMRD profiling, respectively, the discrepancies between the 
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dipolar term and the Curie term of BRW theory clearly are not approximated 
effectively.  
3.7.3 Additional Experiments to Determine µeff and d  
 
 The values of µeff and d can be determined using complementary procedures. 
These procedures have the potential to further weigh in on the values of µ eff and d. The 
effective magnetic moment of each complex can be measured by Superconducting 
Quantum Interference Device (SQUID), as long as the concomitant measurement of 
metal concentration by ICP-MS has been performed. SQUID measurements or Evans’ 
method NMR procedure, combined with ICP-MS to determine the magnetic component 
provided by the complex subtracting any residual salts formed in the complexation 
procedure, should yield the value of µeff with high accuracy. 
 Next, the values of d across the DOTAm-F12 series as well as the DOTA-F6 and 
F-DOTPME series can all be crystallized and analyzed by X-ray crystallography 
(though admittedly, this would be quite an undertaking). Further molecular modeling 
using DFT calculations in solution can be used to refine the X-ray crystallographic data 
or could be used in place of it. 
 While these options are open for further exploration, they have not been explored 
definitively at the time this document was written. 
3.8 Conclusions and Future Work 
 The work presented in this chapter demonstrates how the relaxation rates of three 
different series of macrocyclic 19F metal complexes behave at low and high field 
strength. The results reported can be taken into consideration when designing new 19F 
probes for MRI. 
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 The results obtained suggest that the relaxation rates of 19F nuclei in probes of this 
kind can benefit from higher field strength devices, the strength of which is limited by 
R2 values. With the demonstrated high T2/T1 ratio observed with Fe(II) complexes, the 
same ligands should be examined in this manner to possibly enhance further the 
resolution and sensitivity of 19F MR data.  
 The minimization of data incorporated in the BRW theory developed by Kuprov 
may have limitations with regard to τR and d approximations, but otherwise appears to 
be accurate for the determination of the electron relaxation rate (T1e) and the magnetic 
susceptibility (µeff). Since lanthanide contraction occurs across the series, the global 
fitting parameters could apply the contraction relative to one or more X-ray crystal 
structures or DFT calculations as a reference point. 
 With these design considerations in hand, new and responsive probes can be 
developed using functional groups of varying hardness and can be compared to those 
presented herein. While three types of ligands have been explored, many other designs 
are possible, including the use of alcohol donors similar to the commercial HP-DO3A 
Gd(III) contrast agent. These data can help predict the MR behavior of systems similar 
to those presented here.   
3.9 Experimental Materials and Methods 
 
General considerations. Starting materials were obtained from commercial suppliers 
and used without further purification.  Water was distilled and further purified by a 
Millipore cartridge system (resistivity 1.8 × 107 Ω).  All organic extracts were dried 
over anhydrous MgSO4 and solvents were removed under reduced pressure with a 
rotary evaporator. All synthetic compounds were characterized at the LeClaire-Dow 
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Chemical Instrumentation Facility at the Department of Chemistry at the University of 
Minnesota, Twin-Cities. 1H NMR spectra were recorded on a Varian 500 at 500 MHz, 
13C NMR spectra on a Bruker AV-500 at 125 MHz, and 19F NMR spectra were 
recorded on a Varian VXR-300 at 282 MHz. The residual solvent peak was used as an 
internal reference for 1H and 13C NMR; CFCl3 was used as an internal reference for 19F 
NMR of organic intermediates; and KF was used as an external standard for metal 
complexes. Data for 1H NMR are reported as follows: chemical shift (δ, ppm), 
multiplicity (s, singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet), 
integration, coupling constant (Hz). Data for 13C NMR and 19F NMR are reported in 
terms of chemical shift (δ, ppm). Longitudinal (T1) and transverse (T2) relaxation times 
of 19F nuclei of metal complexes in D2O were measured using the inversion recovery 
sequence and the Carr-Purcell-Meiboom-Gill sequence, respectively.  A delay time of 
30 ms and acquisition time of 64 ms were used for the collection of 1H and 19F NMR 
spectra of the paramagnetic M-DOTAm-F12 complexes. Mass spectra (HR, high 
resolution; ESI, electrospray ionization) were recorded on a Bruker BioTOF II at the 
Waters Center of Innovation for Mass Spectrometry at the Department of Chemistry at 
the University of Minnesota, Twin-Cities. 
 
Diethyl 2,2'-(1,4,7,10-tetraazacyclododecane-1,7-diyl)bis(4,4,4-trifluorobutanoate) 
(3-3): Cyclen (1.38 g, 8.03 mmol) was dissolved in dry CH3CN and magnetically 
stirred. K2CO3 (11.1 g, 80.3 mmol) was added, followed by 2-bromo-4,4,4-
trifluorobutyric acid ethyl ester (3.31 mL, 20.1 mmol) and the reaction mixture was 
heated to 105 ˚C for 18 h. The reaction mixture was then filtered, and the filtrate 
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concentrated under reduced pressure to yield a yellow oil that was then deposited on to 
silica and purified via flash chromatography (eluent: 1-8% MeOH in CH2Cl2) to yield 
the pure product as a light yellow semi-oil that was further dried under high vacuum 
overnight (3-3, 2.45 g, 60.0 %). 1H NMR (500 MHz, CDCl3) δ 4.16-4.08 (m, 4 H), 3.77 
(quintet, J = 8.0 Hz, 2 H), 2.79-2.57 (m, 22 H), 1.22 (t, J = 7.5 Hz, 6 H). 13C NMR (125 
MHz, CDCl3) δ 170.3, 126.6 (q, J = 286 Hz), 61.1, 57.2 (q, J = 59.1 Hz), 48.7, 45.4, 
32.1, 31.6, 13.9. 19F NMR (470 MHz, CDCl3) δ -63.6 (t, J = 10.8 Hz). HRMS-ESI 
(m/z) [M + H]+ calc for C20H30F6N4O4: 509.2557; found: 509.2560. 
 
Diethyl 2,2'-(4,10-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-
1,7-diyl)bis(4,4,4-trifluorobutanoate) (3-4): Compound 3-3 (1.29 g, 2.54 mmol) was 
dissolved in dry CH3CN and magnetically stirred. K2CO3 (2.31 g, 16.8 mmol) was 
added, followed by tert-butyl bromoacetate (826 µL, 5.59 mmol) and the reaction 
mixture was heated to 45 ˚C for 16 h. The reaction mixture was then filtered, and the 
filtrate concentrated under reduced pressure to yield a yellow that was further dried 
under high vacuum overnight yielding a yellow oil that did not need further purification 
(3-4, 1.80 g, 96.0 %). 1H NMR (500 MHz, CDCl3) δ 4.15 (q, J = 7.0 Hz, 4 H), 3.76-
3.73 (m, 2 H), 3.24 (s, 4 H), 2.84-2.64 (m, 20 H), 1.47 (s, 18 H), 1.26 (t, J = 7.0 Hz, 6 
H). 13C NMR (125 MHz, CDCl3) δ 170.8, 170.4, 126.9 (q, J = 286 Hz), 80.7, 60.9, 59.5 
(q, J = 58.3 Hz), 55.8, 52.9, 49.3, 32.6, 14.1. 19F NMR (470 MHz, CDCl3) δ -64.1 (t, J 
= 10.8 Hz). HRMS-ESI (m/z) [M + H]+ calc for C32H54F6N4O8: 737.3919; found: 
737.3910. 
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Disodium 2,2'-(4,10-bis(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane 
-1,7-diyl)bis(4,4,4-trifluorobutanoate) (3-5): Compound 3-4 (1.21 g, 1.64 mmol) was 
dissolved in MeOH (10 mL) and magnetically stirred in an ice bath. Aqueous NaOH (6 
M, 20 mL) was then added dropwise over 5 min., and the reaction mixture was allowed 
to warm to ambient temperature and stirred for 1 h. The aqueous phase was extracted 
with CHCl3 (30 × 50 mL), and the combined organic phases were washed with brine, 
dried over MgSO4, and concentrated under reduced pressure to yield a white crystalline 
solid that was further dried under high vacuum overnight (3-5, 1.15 g, 97.0 %). The 
solid was used immediately in the next step. 
 
2,2'-(4,10-Bis(carboxymethyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)bis(4,4,4-
trifluorobutanoic acid) tetrahydrochloride salt (DOTA-F6, 3-1): The disodium salt 
3-5 was dissolved in water (100 mL) and magnetically stirred in an ice bath. 
Concentrated HCl (36 % w/v, 6.0 mL) was added dropwise over 5 min., and the 
reaction mixture was allowed to warm to ambient temperature and stirred for 1 h. The 
reaction mixture was then concentrated under reduced pressure to yield a sticky, white 
gum, that was immediately dissolved in H2O (50 mL) and lyophilized to yield the 
tetraacid, tetrahydrochloride salt as a white solid (1.10 g, 93.9 % over two steps). 1H 
NMR (500 MHz, D2O) δ 4.37-4.08 (m, 4 H), 3.78-3.49 (m, 6 H), 3.32-2.77 (m, 16 H). 
13C NMR (125 MHz, D2O) δ 174.1, 168.2, 122.2 (q, J = 285 Hz), 69.8, 55.8, 55.0, 54.0, 
51.1, 44.4, 29.6, 27.1. 19F NMR (470 MHz, D2O) δ -75.7 (t, J = 10.8 Hz). HRMS-ESI 
(m/z) [M + H]+ calc for C20H30F6N4O8: 569.2041; found: 569.2031. 
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[La-DOTA-F6]- (3-5), representative procedure: Compound DOTA-F6 (3-1) (100. 
mg, 0.140 mmol) was dissolved in mQ H2O (25 mL) and magnetically stirred. An 
aqueous solution of LaCl3 (0.100 M, 1.40 mL) was then added, and dilute aq. NaOH 
solution was added to the reaction mixture until pH = 7.5. The reaction mixture was 
then heated to 90 ˚C for 3.5 days and lyophilized to yield the complex 3-5 as a white 
crystalline solid (139 mg, >99.0 %). HRMS-ESI (m/z) [M]- calc for C20H30F6LaN4O8: 
707.1026; found: 707.1033. 
[Eu-DOTA-F6]- (3-6): White solid, using EuCl3 (140 mg, >97.0 %). HRMS-ESI (m/z) 
[M]- calc for C20H30EuF6N4O8: 721.1175; found: 721.1170. The observed isotopic 
distribution matched the calculated one. 
 
[Gd-DOTA-F6]- (3-7): White solid, using GdCl3 (142 mg, >98.0 %). HRMS-ESI (m/z) 
[M]- calc for C20H30F6GdN4O8: 726.1203; found: 726.1201. The observed isotopic 
distribution matched the calculated one. 
 
[Tb-DOTA-F6]- (3-8): White solid, using TbCl3 (143 mg, >98.5 %). HRMS-ESI (m/z) 
[M]- calc for C20H30F6N4O8Tb: 727.1216; found: 727.1226. 
 
[Dy-DOTA-F6]- (3-9): Brown solid, using DyI3. (143 mg, >98.0 %). HRMS-ESI (m/z) 
[M]- calc for C20H30DyF6N4O8: 732.1254; found: 732.1254. The observed isotopic 
distribution matched the calculated one. 
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[Ho-DOTA-F6]- (3-10): Pink solid, using HoBr3 (144 mg, >97.0 %). HRMS-ESI (m/z) 
[M]- calc for C20H30F6HoN4O8: 733.1266; found: 733.1279. 
 
[Er-DOTA-F6]- (3-11): Brown solid, using ErI3 (146 mg, >98.0 %). HRMS-ESI (m/z) 
[M]- calc for C20H30ErF6N4O8: 734.1265; found: 734.1251. The observed isotopic 
distribution matched the calculated one. 
 
[Tm-DOTA-F6]- (3-12): White solid, using TmCl3 (147 mg, >98.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H30F6N4O8Tm: 737.1304; found: 737.1295. 
 
[Yb-DOTA-F6]- (3-13): White solid, using YbCl3 (146 mg, >98.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H30F6N4O8Yb: 742.1351; found: 742.1350. The observed 
isotopic distribution matched the calculated one. 
 
 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrakis(methanephosphonic acid 
di(2’,2’,2’-trifluoroethyl) ester) [F-DOTPME] (3-14). Cyclen (2.66 g, 15.4 mmol) 
was suspended in benzene (15 mL) and magnetically stirred. Glacial acetic acid (5 mL) 
was added, followed by paraformaldehyde (3.20 g, 110 mmol). Bis(2,2,2-
trifluoroethyl)phosphite (13.0 g, 52.8 mmol) diluted in benzene (15 mL), was then 
added, and the reaction was stirred at 25 ºC for 72 h. Volatiles were removed under 
reduced pressure to yield an off-white gum which was washed with benzene (2 × 30 
mL) and dried under high vacuum overnight yielding a hygroscopic white solid. This 
solid was dissolved in diethyl ether (50 mL) with stirring and water (30 mL) was added, 
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and the acidic mixture was neutralized with solid sodium bicarbonate. The organic 
layer was separated and the aqueous layer further extracted with diethyl ether (6 × 30 
mL). The organic phases were combined and dried over MgSO4, filtered, and 
concentrated under reduced pressure to yield the perester 3-15 as a white solid. 
Aqueous NaOH (5 M, 50 mL) was added to the solid, and the resultant suspension was 
heated at reflux for 30 min and further stirred at ambient temperature for 2 days. 
Additional aqueous NaOH (12 M, 50 mL) was added to the solution, refluxed for 1 h, 
and cooled to ambient temperature precipitating a white solid that was filtered off and 
collected. This step was repeated three more times, yielding F-DOTPME (3-14) as the 
tetrasodium salt (2.7 g, 2.8 mmol, 18%). 1H NMR (300 MHz, D2O) δ = 2.59 (s, 8 H), 
2.77 (d, J = 9.6 Hz, 16 H), 4.13 (quintet, J = 8.1 Hz, 8 H). 19F NMR (282 MHz, D2O) δ 
= -75.8. 31P NMR (121 MHz, D2O) δ = 23.3. HRMS-ESI (m/z) [M + 2Na]2- calc. for 
C20H32F12N4O12P4 459.0, found: 459.0. 
  
[La-F-DOTPME]- (3-16), representative procedure. Ligand 3-14 (220 mg, 0.233 
mmol) was dissolved in mQ water (15 mL). The solution was adjusted to pH = 7.5 with 
aq. HCl, and aq. thulium(III) chloride (0.291 M, 726 µL) was added. The pH was again 
adjusted to 7.5 with aq. NaOH. The reaction was stirred at 75 ºC for 72 h, then was 
lyophilized, yielding a white crystalline solid (278 mg, quant.). HRMS-ESI (m/z) calc. 
for C20H32F12LaN4O12P4 [M]-: 1010.9839, found: 1010.9861. 
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[Eu-F-DOTPME]- (3-17): White solid, using EuCl3 (129 mg, >99.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H32EuF12N4O12P4: 1024.9988; found: 1025.0001. The observed 
isotopic distribution matched the calculated one. 
 
[Gd-F-DOTPME]- (3-18): White solid, using GdCl3 (128 mg, >98.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H32F12GdN4O12P4: 1030.0017; found: 1030.0004. The observed 
isotopic distribution matched the calculated one. 
 
[Tb-F-DOTPME]- (3-19): White solid, using TbCl3 (129 mg, >99.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H32F12N4O12P4Tb: 1031.0029; found: 1031.0025. 
 
[Dy-F-DOTPME]- (3-20): Yellow solid, using DyI3. (128 mg, >98.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H32DyF12N4O12P4: 1036.0067; found: 732.1254. The observed 
isotopic distribution matched the calculated one. 
 
[Ho-F-DOTPME]- (3-21): Pink solid, using HoBr3 (130 mg, >99.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H32F12HoN4O12P4: 1037.0079; found: 1037.0031. 
 
[Er-F-DOTPME]- (3-22): Brown solid, using ErI3 (130 mg, >98.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H32ErF12N4O12P4: 1038.0078; found: 1038.0041. The observed 
isotopic distribution matched the calculated one. 
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[Tm-F-DOTPME]-  (3-23): White solid, using TmCl3 (131 mg, >99.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H32F12N4O12P4Tm: 1041.0118; found: 1041.0110. 
 
[Yb-F-DOTPME]- (3-24): White solid, using YbCl3 (128 mg, >96.0 %). HRMS-ESI 
(m/z) [M]- calc for C20H32F12N4O12P4Tm: 1046.0164; found: 1046.0155. The observed 
isotopic distribution matched the calculated one. 
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4 A Responsive 19F MRI Contrast Agent for Detection of Cu(I) 
4.1 Introduction 
 In the last decade, responsive MRI contrast agents have increasingly become the 
subjects of studies, with targets as varied as cations, sugars, proteins, enzymes, nucleic 
acids and viruses. However, to date, neither gadolinium nor particulate responsive 
contrast agents are frequently used for in vivo studies. The fundamental problem with 
these probes is that the response observed, that is the change in the relaxation time (T1 
for gadolinium and T2 for particulate contrast agents), depends on two parameters: the 
concentration of the targeted marker and that of the contrast agent. A single image, 
however, cannot differentiate these two parameters. Thus, in vivo images acquired 
using these responsive contrast agents are often inconclusive in the determination of 
the distribution of their targeted analytes.  
 The design considerations of a 19F MRI contrast agent that is both responsive and 
ratiometric require a response mechanism that is selective for a single analyte, and the 
presence of at least two unique fluorine signals, one of which changes with response to 
the analyte, and another that does not.  
 This problem can in theory be solved with the use of ratiometric responsive 
contrast agents. Of those, PARACEST agents145-151 and 1H and 19F chemical shift 
probes, have shown much promise, particularly by magnetic resonance spectroscopy 
(MRS). In the latter case, groundbreaking work by Mason,34,152-166 Ahrens66,167-177 and 
others demonstrated that the change in chemical shift induced by reaction with or upon 
reversible binding to an analyte can induce a shift significant enough to be observed 
by MRS in cells or tissues; although they are rarely large enough to enable three 
dimensional imaging by MRI.  In terms of shift reagents, 19F is preferred over 1H due 
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to the large chemical shift range of this nucleus which facilitates monitoring of 
multiple fluorines, thereby raising the enticing possibility of multichromic MRI and 
the development of ratiometric probes.178,179  
 Developed for this project is a proof-of-principle demonstration of a ratiometric, 
responsive MRI contrast agent that responds catalytically to Cu(I). In particular, the 
designed probe does not respond to Cu(II) nor to other metal ions. This biomarker was 
chosen for this study due to its relevance to in vivo pathology: Cu(I) is improperly 
sequestered in amyloid-beta (Aβ) plaques in the brain of patients with Alzheimer’s 
Disease (AD).180-186  
4.2 Challenges of Copper Detection 
 
 Several innate properties of this Cu (I) ion have made it particularly difficult to 
image. Copper’s redox ability can allow rapid interconversion between Cu(I) and 
Cu(II), presenting a challenge for imaging agents in that they must selectively respond 
to either Cu(I) or Cu(II). The intracellular reducing environment renders the copper as 
Cu(I), but in amyloid-beta plaques the reduction/oxidation potential is not known. 
Endogenous proteins, such as glutathione (GSH) and metallothionein, actively 
sequester, exchange, and transport copper throughout the body, limiting free copper to 
less than 1.6 µM in serum.187 On the other hand, bound copper concentrations can be 
as high as 100 µM188 in the brain and 400 µM in Aβ plaques. 189,190 
4.3 Tm-DOTA-Click 
 
 In order to address the demands of low fluorine sensitivity in 19F MRI probes, as 
well as having a ratiometric response generated by two unique fluorines to be imaged, 
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a new probe, Tm-DOTA-Click, was synthesized containing a Tm(III) metal center, 
two different fluorines, a response mechanism to detect Cu(I), while retaining high 
water solubility. Tm-DOTA-click contains a DOTA tetraamide ligand for the Tm(III) 
center, and contains two different types of 19F nuclei: four aromatic fluorines 
positioned away from the metal center in the unreacted state, and six aliphatic ones 
which are substantially closer to the paramagnetic ion. The reactive functionality pair 
of a terminal acetylene and an organic azide allows for the copper(I)-catalyzed 
Huisgen cycloaddition that clicks the terminal azide and acetylene groups together, 
thereby locking the probe in a substantially different conformation. This 
conformational change alters both the chemical shifts and the relaxation times of both 
fluorine signals.  
 Intermolecular reactions and the formation of oligomers, however is possible, 
especially at higher concentrations of the probe. Advantageously, whether the reaction 
occurs in an intra- or inter-molecular fashion has little bearing on the observed results, 
since the resultant configuration of the probe’s fluorines either in the monomeric or 
oligomeric forms of the probe add similar steric bulk to the aliphatic fluorines, causing 
a 19FLIS of those resonances. Either form as well would position the aryl fluorines 
much closer to the Tm(III) center, producing the same 19FLIS and 19FPRE response 
from either the monomeric or oligomeric forms of Tm-DOTA-click. The similarity in 
response between either the monomeric or polymeric forms of the reacted probe cause 
the same changes in the Tm(III)-19F distances for the aryl fluorines, and the same 
changes in the position the aliphatic fluorines relative to the principal magnetic axis of 
the paramagnetic Tm(III) center. As a result, either the reacted monomer or reacted 
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oligomer would render identical MRI/MRS data both with respect to the aryl fluorines 
as well as the aliphatic fluorines.  
 Reported in Chapters 2 and 3, it was demonstrated that M-DOTAm-F12 
complexes, which are readily soluble in water at concentrations as high as 100 mM, 
give excellent signal-to-noise ratios (SNR’s) in blood (up to 23 for 1 mM mixture) 
given acquisition parameters suitable for in vivo imaging (2 min scan times for 0.5 mm 
resolution). Note that the contrast of responsive probes is defined as the difference in 
signal intensity of the probe in the presence of the analyte divided by that in the 
absence of the latter. Thus, a DOTA tetraamide ligand was central to the probe design. 
The two different fluorines were installed on the probe, and the probe’s two 
configurations both before and after reaction with Cu(I) are indicated in Scheme 4-1 
 
Scheme 4-1: Chemical structure and proposed mode of action of the ratiometric fluorine responsive 
contrast agent for Cu(I), Tm-DOTA-click (4-1). Copper(I)-catalyzed cycloaddition clicks the terminal 
azide and acetylene groups together, inducing a conformational change that affects the chemical shift 
and longitudinal relaxation times of both the aliphatic (blue) and the aromatic (green) fluorines. The 
reactive functionality pair are indicated in purple 
 
In order to evaluate the different parameters that can be exploited to render 
paramagnetic fluorine complexes responsive, the lanthanide metal chosen for the 
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complex was thulium, creating a complex was designed and synthesized, Tm-DOTA-
click, depicted in Figure 4-1, which catalytically reports on the presence of Cu(I).  
4.4 Synthesis of Tm-DOTA-Click 
 
 
 
 
 
Scheme 4-2: Synthesis of Tm-DOTA-click (4-1); Reagents & conditions are as indicated. 
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 Tm-DOTA-click (1) was synthesized over eleven steps, illustrated in Scheme 4-2. 
Mild alkylation conditions allowed for regioselective substitution at the 1- and 7-
secondary nitrogens of cyclen with the aliphatic, CF3 fluorine label.  The third position 
was then alkylated with the propargylic group, and then the fourth with the BOC-
protected PEG spacer. Deprotection with TFA afforded the free amine distant from the 
chelate which was coupled to the complementary aryl fluorine label with the azide, 
previously synthesized from the bis-chloromethyl starting material. The final complex 
was obtained by refluxing the ligand with one equivalent of TmCl3 at neutral pH. 
4.5 Analysis of MR Properties for Tm-DOTA-Click 
4.5.1 19F Lanthanide-Induced Shift (19FLIS) 
 For lanthanide-based responsive fluorine MR probe, the lanthanide-induced shift 
of a fluorine signal, defined as 19FLIS, is the difference between the chemical shift of a 
19F in the presence and absence of the probe’s analyte (19FLIS = ∆δ = δprobe + analyte – 
δprobe).82 This shift is the sum of the contributions from the contact shift, δc, and the 
pseudocontact shift, δpc. 191,192 Since for steric reasons the fluorines cannot come closer 
than 5 Å to the lanthanide, the contribution from the contact shift is negligible, and the 
observed 19FLIS is primarily the result of the pseudocontact shift. Given this 
simplification, 19FLIS follows the McConnell–Robertson equation; it is inversely 
proportional to the cube of the distance separating the lanthanide from the 19F nuclei 
and follows a cosine relationship with the angle θ separating the lanthanide-fluorine 
vector and the principle magnetic dipolar axis of the complex. 191,193  
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Table 4-1: Chemical shift, δ, and longitudinal, T1, and transverse, T2, relaxation times of the signals of 
the aliphatic and aryl fluorine nuclei of Tm-DOTA-click (1) before and after reaction with Cu(I). 
Numbers in parentheses represent standard deviations, n = 3 
 
 - Cu(I) + Cu(I) 
aliphatic 19F   
δ (ppm) -80 – -90 -71 – -80 
T1 (ms) 23 (1) 23 (1) 
T2 (ms) 11 (1) 9 (1) 
aryl 19F   
δ (ppm) -142 – -146 -135 – -138 
T1 (ms) 241 (5) 18 (1) 
T2 (ms) 40 (3) 17 (1) 
 
  
Figure 4-1: NMR spectra of a) the free ligand DOTA-click (3-11), b) Tm-DOTA-click (3-1) in the 
absence of Cu(I), and c) Tm-DOTA-click (1) after addition of 0.10 eq. Cu(I)Asc. Note that it is 
necessary to maintain a long delay time in order to fully observe the aromatic 19F nuclei of the probe 
in the absence of Cu(I). Experimental conditions: [Tm-DOTA-click] = 1 mM, water pH 7, B0 = 11.7 
T, pulse-acquire, TR = 20 m. 
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 The copper-catalyzed cycloaddition thus affects the chemical shift of both the 
aliphatic and the aryl fluorines, albeit in a different manner. The aryl 19F are brought 
within close proximity of the thulium, which, as expected, results in a strong 
downfield shift in their signal by 12 ppm (Table 4-1, Figure 4-1) 
 
 
 
 The steric hindrance caused by the capping aryl fluorines also changes the 
conformation of the thulium macrocycle in such a way that its aliphatic fluorines are 
pushed further away from the principal magnetic dipolar axis. As a result, the angle θ 
is altered causing the aliphatic 19F signals to also shift by ~15 ppm. Although more 
difficult to predict than a change in Ln-19F distance, an analyte-induced 
conformational change of a lanthanide complex that the angle θ can yield an equal or 
greater signal shift than one varying d. Note that the greater the chemical shift 
Figure 4-1: NMR spectra of a) the free ligand DOTA-click (3-11), b) Tm-DOTA-click (3-1) in the 
absence of Cu(I), and c) Tm-DOTA-click (1) after addition of 0.10 eq. Cu(I)Asc. Note that it is 
necessary to maintain a long delay time in order to fully observe the aromatic 19F nuclei of the probe 
in the absence of Cu(I). Experimental conditions: [Tm-DOTA-click] = 1 mM, water pH 7, B0 = 11.7 
T, pulse-acquire, TR = 20 m. 
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difference between fluorine groups, the easier it is to image each fluorine group 
independently in three dimensions. 
 
 
 
 The 19FLIS response of both the aliphatic and aryl fluorines can be imaged in 
three dimensions by MRI, thereby giving two unique signals for ratiometric imaging. 
As illustrated in Figure 4-2 since the four fluorine signals - aliphatic and aryl before and 
after reaction with Cu(I) - are more than 10 ppm apart from each other, each can be 
imaged in three dimensions independently. Images of the aliphatic 19F nuclei of 
unreacted Tm-DOTA-click were acquired by centering the excitation pulse at -95 ppm 
and can be seen in Figure 4-3b. Any signal observed in this image indicates where the 
probe is present but copper(I) is absent. On the other hand, applying a pulse at -60 
ppm allows the observation of only the aliphatic 19F nuclei of the reacted probe, that is, 
regions where both the probe and copper were present, which can be seen in Figure 4-
3c.  
Figure 4-2: MR spectra of Tm-DOTA-click in water a) in the absence of Cu(I) and b) after 
addition of 0.10 eq. Cu(I)Asc obtained with the 19FLIRE sequence. The aromatic 19Fs of the 
probe in the absence of Cu(I) disappear due to the addition of an inversion time equal to ln(2)×T1 
(aromatic F) in the pulse sequence.  Without this inversion time, the NMR spectrum in a would be 
identical to that of Figure 3b. The signal of the aromatic fluorines only reappear after reaction 
with Cu(I) due to a change in the conformation of the probe that shortens their T1. Experimental 
conditions: [Tm-DOTA-click] = 1 mM, B0 = 11.7 T 
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Moreover, an absence of probe can readily be detected by an absence of any signal at 
both -60 ppm and -95 ppm, as in Figure 4-2, tube I. Note that similar results are 
obtained if one focuses instead on the aryl fluorines’ signal in the absence (-145 ppm, 
Figure 4-3d) and presence (-127 ppm) of copper (Figure 4-3e). This technique of 
multichromic MRI with a ratiometric response has a notable advantage:  the two 
parameters that affect contrast – the concentration of the probe and the presence of an 
analyte – can be distinguished by collecting two independent images 
4.5.2 19F Paramagnetic Relaxation Enhancement (19FPRE) Response 
 
The effect of the paramagnetic lanthanide ion on the longitudinal (T1) and 
transverse (T2) relaxation rates of the fluorines follows the Bloch-Redfield-Wangsness 
theory and a much steeper d6 dependence on the Ln-19F distance than 19FLIS, but is 
independent of the angle θ between the fluorine-lanthanide vector and the principal 
Figure 4-3: Ratiometric response of Tm-
DOTA-click to Cu(I). I) water, II) Tm-
DOTA-click (1) in water, III) Tm-DOTA-
click (1) + 0.10 eq. Cu(I)Asc in water. a) 
T1-weighted 1H gradient echo image; 
19F gradient echo images at b) -95 ppm 
and d) -145 ppm indicate indicate 
location of unreacted probe in the absence 
of Cu(I); 19F gradient echo images at c) -
60 ppm and e) -127 ppm indicate location 
of reacted probe in the presence of Cu(I).
Experimental conditions: [Tm-DOTA-
click] = 1 mM, B0 = 16.4 T, na = (c) 512, 
(b, d, e) = 2048. 
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magnetic dipolar axis of the lanthanide ion.194-196 As such, since the mean distance of 
the aliphatic 19F nuclei to the Tm(III) center of the probe does not vary upon reaction 
with Cu(I), neither does their T1 and T2.  
 In a 19FLIRE experiment, these aliphatic fluorines act as an internal standard, 
indicating the location and concentration of the probe. The distance separating the aryl 
fluorines from the lanthanide ion, however, changes substantially. As the probe reacts 
and the aryl 19F’s are brought closer to Tm, their T1 and T2 values decrease by 13-fold 
and 2-fold, respectively.  
 
Figure 4-4:  Pulse sequence used for 19FLIRE-based signal silencing. Recycle delay (d1) = 1.2 s, 180˚ 
pulse (p180) = 32 ns, T1(long) delay time (d2) = 340 ms, 90˚ pulse (pw) = 10 ns, acquisition time (at) = 
64 ms. 
 This substantial change in T1 can be readily utilized by MR spectroscopy to 
differentiate the unreacted form of the probe with the reacted form. Resonance 
suppression from 19FLIRE silenced the aromatic 19F nuclei of the unreacted form of 
Tm-DOTA-Click according to the pulse sequence in Figure 4-4.  
 The pulse sequence used and as depicted in Figure 4-4 Includes a recycle 
delay (d1) time of 5 × T1(long) (1.21 s) to allow all spins to relax between scans, a p180 
pulse (p1), and d2 which are set to ln (2) × T1(long) (340 ms, the time required for the 
slow relaxing nuclei to show no magnetization in the Z-direction and completely in the 
XY plane), after which the pw90 is applied and the acquisition is taken. With no Z-
component at the time of the pw90, the aromatic nuclei with T1(long) are then not 
observed. Using the same pulse sequence but with reacted Tm-DOTA-Click with 
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Cu(I), both signals were observed, allowing for the exploitation of the 19FLIRE, 
shortening T1(long) to 19 ms, providing an T1(short) value that is not observable using 
the aforementioned pulse sequence. Tm-DOTA-Cick was then explored by MRI 
phantom imaging in concentrations reasonable for MR field strength strengths. 
 With such a sequence, the signal corresponding to the fluorine with the 
longest T1 – the aryl fluorine in the absence of copper – is completely removed, as 
seen in Figure 4-6a. Without this inversion, the probe’s spectrum is identical to that of 
Figure 3b. The aryl fluorines are thus only observed when copper is present, whereas 
the signal of alkyl fluorines is always observed, regardless of the presence of the 
probe’s analyte. A ratiometric response is therefore maintained. Note that in three-
dimensional MR imaging, similar results, albeit ones that are not fully on/off, can be 
obtained with a standard T1-weighted gradient echo pulse sequence with a short 
repetition time.  
4.5.3 Sensitivity 
 
 As with any 19F MRI contrast agent, an important consideration is its 
sensitivity. The aliphatic fluorines of Tm-DOTA-Click are the same type of fluorines 
used in the DOTAm-F12 ligand and its complexes, except in Tm-DOTA-Click there 
are only two fluorine pendant arms rather than four, found in DOTAm-F12. While this 
difference does result in a loss of signal intensity, and the larger molecular weight of 
the compound renders the percentage of fluorine labeling much lower than DOTAm-
F12, the aliphatic fluorines of Tm-DOTA-Click were found to be easily imaged in 
water by MRI and in a reasonable amount of time and with high SNR values, as seen 
in Figure 4-3 b,c. 
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 Finally, the enhanced SNR of the aliphatic fluorines (Figure 4-3b-c) over the 
aromatic fluorines (Figure 4-3, d-e) result in a probe wherein the aliptatic signals are 
shifted between the reacted and unreacted forms of Tm-DOTA-Click. This change is 
provided in this probe by the aromatic ring changing the sterics of the aliphatic 
fluorines by increased steric bulk. In theory then, other reactive groups which 
increases the steric bulk (in the case of Tm-DOTA-Click, the aromatic ring) could be 
used to generate second-generation probes that operate in the same was as Tm-DOTA-
Click. 
4.5.4 Demonstration of Effective and Sensitive Response to Cu(I) 
 
 
19F NMR analysis was used in order to determine that the probe Tm-DOTA-
Click reacts efficiently and catalytically with Cu(I). Various concentrations of Tm-
DOTA-Click and Cu(I)-ascorbate (at catalytic levels) were incubated for 2 h at 37 ˚C. 
The resonances at -144 ppm and -136 ppm were used exclusively to monitor the 
percent conversion from the unreacted to the reacted state.  
 The results are summarized in Table 4-2. Tm-DOTA-Click is effectively and 
completely reacted at Cu(I) concentrations of 0.1% [Cu(I)] and higher. Given the short 
reaction time of 2 hours and the high concentrations of Tm-DOTA-Click in solution 
rather than biological media, show that Tm-DOTA-Click is quite sensitive to Cu(I), 
with an estimated limit of detection (LOD) at less than 10 µM. Additionally, to detect 
the presence of improperly sequestered Cu(I) in brain tissue of those with AD, the 
biological concentrations used with full catalytic conversion are observed.183,184,186 
However, this cannot be concluded with certainty that Tm-DOTA-click would 
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properly be catalyzed by Cu(I) in the brain, since neither its biodistribution nor its 
blood-brain-barrier (BBB) transmission in vivo has been determined.  
   
Table 4-2: Percentage of Tm-DOTA-Click catalyzed by Cu(I) when incubated in D2O for 2 h. The 
concentration of Cu(I) relative to the concentration of Tm-DOTA-Click is presented, as well as its net 
concentration. Mixtures of 0.1% Cu(I) or higher effectively catalyze all of the probe in the sample after 
2 h incubation period. 
[Tm-DOTA-
Click] 
[Cu(I)] relative to 
[Tm-DOTA-
Click] 
Actual 
[Cu(I)] 
% Catalyzed  
(2 h) 
50 µM 0.05 % 25 nM 65% 
50 µM 0.10 % 50 nM 92% 
250 µM 0.10 % 250 nM 100% 
250 µM 0.25 % 625 nM 100% 
250 µM 0.50 % 1.25 µM 100% 
1 mM 0.10 % 1.0 µM 100% 
1 mM 0.25 % 2.5 µM 100% 
1 mM 0.50 % 5.0 µM 100% 
1 mM 1.0 % 10 µM 100% 
 
 The probe Tm-DOTA-Click is a promising representation of a ratiometric and 
responsive 19F MRI contrast agent with demonstrated ability to be imaged in three 
dimensions by 19F MRI. Likewise, it provides evidence that other ratiometric probes 
can be developed and imaged using many of the principles that make Tm-DOTA-
Click effective. However, the probe does have several limitations in its design for two 
primary reasons. First, the reaction mechanism (1,3-Huisgen cycloaddition) is catalytic 
in nature. 
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4.5.5 Drawbacks of a Catalytic Response Mechanism  
 
 Since the response mechanism of Tm-DOTA-click is catalytic, a single Cu(I) 
center would react with many molecules of the probe in vivo. This potential drawback 
could be eliminated in the designs of future 19F MRI contrast agents wherein the 
response mechanism is not based on a catalytic reaction, but rather one that forms a 
complex with the analyte, sequestering its ability to participate in additional reactions 
with a other molecules of the probe. We chose the Cu(I)-catalyzed 1,3-Huisgen 
cycloaddition as mentioned before due to its relevance to AD, as well as our group’s 
complimentary effort in developing luminescent sensors for Cu(I). 
 With these considerations, the ideal 19F contrast agent would demonstrate a 
ratiometric response concomitant with a binding mechanism for its target analyte. 
4.6 Conclusions 
  
 The design, synthesis and in vitro evaluation of a ratiometric responsive MR 
contrast agent for Cu(I) that consists of a fluorinated thulium complex has been 
presented. The paramagnetic thulium ion increases the sensitivity of the fluorines by 
decreasing their longitudinal relaxation rates by two orders of magnitude, thereby 
enabling more scans to be acquired per unit time. Notably, Tm(III) also provides two 
mechanisms for obtaining a response: variations in the conformation of the complex 
shift the 19F signals by more than 10 ppm, whereas a change in the 19F-Tm distance 
alters both the chemical shift and the longitudinal relaxation times of the fluorines. 
The large range of chemical shifts of 19F, combined with the substantial response 
enables multichromic and ratiometric imaging of Cu(I) in three dimensions by MRI. 
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4.7 Experimental Materials and Methods 
4.7.1 General Considerations  
 
Unless otherwise noted, starting materials were obtained from commercial suppliers 
and used without further purification.  Water was distilled and further purified by a 
Millipore cartridge system (resistivity 1.8 × 107 Ω).  All organic extracts were dried 
over anhydrous MgSO4 and solvents were removed under reduced pressure with a 
rotary evaporator.  Flash chromatography was performed on Salicycle Silica Gel (230-
400 mesh) or Brockmann activated aluminum oxide (neutral, 60 mesh). 1H NMR 
spectra were recorded on a Varian 500 at 500 MHz, 13C NMR spectra on a Bruker 
AV-500 at 125 MHz or a Varian 300 at 75 MHz, and 19F spectra were recorded on a 
Bruker AV-500 at 471 MHz or a Varian Unity VXR-300 at 282 MHz at the LeClaire-
Dow Characterization Facility of the Department of Chemistry at the University of 
Minnesota. The residual solvent peak was used as an internal reference for 1H and 13C 
NMR, and CFCl3 or KF for 19F NMR. Data for 1H NMR are reported as follows: 
chemical shift (δ, ppm), multiplicity (s, singlet; br s, broad singlet; d, doublet: t, triplet; 
q, quartet; m, multiplet), integration, coupling constant (Hz). Data for 13C and 19F 
NMR are reported in terms of chemical shift (δ, ppm). Mass spectra (LR = low 
resolution; HR = high resolution; MS-ESI = electrospray mass spectrometry) were 
recorded on a Bruker BioTOF II at the Waters Center of Innovation for Mass 
Spectrometry at the Department of Chemistry at the University of Minnesota, Twin 
Cities. 
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4.7.2 Chemical Synthesis of Tm-DOTA-Click 
 
2-Bromo-N-(2,2,2-trifluoroethyl)acetamide (4-2): 2,2,2-Trifluoroethylamine (4.00 
mL, 27.5 mmol) was dissolved in CH2Cl2 (50 mL) and the solution was stirred in an 
ice bath.  A solution of K2CO3 (16.5 g, 120 mmol) in H2O (50 mL) and a solution of 
bromoacetyl bromide (2.40 mL, 27.7 mmol) in CH2Cl2 (50 mL) were simultaneously 
added dropwise over 30 min to the trifluoroethylamine, after which the reaction 
mixture was allowed to warm to room temperature and stirred for 1 h.  The organic 
phase was separated and washed with H2O (5 × 25 mL) and brine (1 × 20 mL), dried 
over MgSO4, and concentrated under reduced pressure to yield the product (4-2, 4.88 
g, 80.7 %) as white crystals. 1H NMR (500 MHz, CDCl3) δ 3.88-3.97 (m, 4H), 7.19 
(br s, 1H); 13C NMR (75 MHz, CDCl3) δ 28.9, 41.9 (q, J = 34.8 Hz), 124.4, (q, J = 277 
Hz), 167.4; 19F NMR (282 MHz, CDCl3) δ -72.9 (t, J = 8.7 Hz); MS (ESI) for 
[C4H5BrF3NO]+ ([M + H]+): m/z 219.9579, found: 219.9579.  The observed isotopic 
distribution matched the calculated one. 
 
2-Bromo-N-(prop-2-yn-1-yl)acetamide (4-3): Propargylamine (2.00 mL, 31.2 mmol) 
was dissolved in CH2Cl2 (25 mL) and the solution was stirred in an ice bath. A 
solution of K2CO3 (17.5 g, 127 mmol) in H2O (50 mL) and a solution of bromoacetyl 
bromide (2.80 mL, 32.3 mmol) in CH2Cl2 (50 mL) were simultaneously added 
dropwise to the propargylamine over 30 min, after which the reaction mixture was 
allowed to warm to room temperature and stirred for 45 min.  The organic phase was 
separated and washed with H2O (4 × 25 mL) and brine (1 × 20 mL), dried over 
MgSO4, and concentrated under reduced pressure to yield the product (4-3, 3.99 g, 
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72.8 %) as dull orange crystals. 1H NMR (500 MHz, CDCl3) δ 2.28 (t, J = 2.5 Hz, 1H), 
3.89 (s, 2H), 4.07 (dd, J1 = 2.5 Hz, J2 = 3.0 Hz, 2H), 6.82 (br s, 1H); 13C NMR (75 
MHz, CDCl3) δ 29.4, 30.6, 79.3, 166.0; HRMS (ESI) calc for [C5H6BrNO]- ([M - H]-): 
m/z 173.9555, found: 173.9545.  The observed isotopic distribution matched the 
calculated one. 
 
Tert-butyl (3-(2-(2-(3-aminopropoxy) ethoxy)ethoxy)propyl) carbamate (4-4): A 
solution of di-tert-butyl dicarbonate (10.0 g, 45.9 mmol) in CH2Cl2 (50 mL) was 
added dropwise to a stirred solution of 1,13-diamino-4,7,10-trioxotridecane (20.2 g, 
91.7 mmol) in CH2Cl2 (150 mL) over 1 h.  The reaction mixture was stirred overnight 
then extracted with 0.1 M HCl (aq) (2 × 25 mL).  The aqueous layer was slowly 
basified to pH = 4 with NaOH (aq) and back-extracted with CH2Cl2 (6 × 25 mL).  The 
combined organic phases were washed with brine (1 × 40 mL), dried over MgSO4, and 
concentrated under reduced pressure to yield the product (4-4, 26.5 g, 90.1 %) as an 
opaque colorless oil. 1H NMR (500 MHz, CDCl3) δ 5.16 (br s, 1H), 3.61-3.50 (m, 
12H), 3.19 (d, J = 5 Hz, 2H), 2.81 (t, J = 6 Hz, 2H), 2.81, 2.47 (s, 4H), 1.73 (m, 4H), 
1.41 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 156.3, 79.1, 70.7, 70.3, 70.3, 70.0, 69.7, 
69.6, 39.7, 38.5, 32.6, 29.8, 28.6; HRMS (ESI) calc for [C15H31N2O5]+ ([M + Na]+): 
m/z 343.2203, found: 343.2189. 
 
Tert-butyl (1-bromo-2-oxo-7,10,13-trioxa-3-azahexadecan-16-yl)carbamate (4-5): 
A solution of the carbamate 4-4 (843 mg, 2.63 mmol) in CH2Cl2 (50 mL) was stirred 
in an ice bath.  A solution of K2CO3 (422 mg, 3.05 mmol) in 20 mL H2O and a 
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solution of bromoacetyl bromide (754 mg, 3.73 mmol) in CH2Cl2 were added 
simultaneously over 30 min to the carbamate, after which the reaction mixture was 
allowed to warm to room temperature and stirred for 1.5 h.  The organic phase was 
separated and washed with H2O (2 × 25 mL) and brine (1 × 10 mL), dried over 
MgSO4, and concentrated under reduced pressure to yield the product (4-5, 691 mg, 
59.5 %) as a colorless oil that was used without further purification. 1H NMR (500 
MHz, CDCl3) δ 7.22 (br s, 1H), 5.28 (s, 2H), 4.94 (br s, 1H), 3.83 (s, 2H), 3.65-3.56 
(m, 10H), 3.51 (t, J = 6 Hz, 2H), 3.39 (q, J = 6 Hz, 2H), 3.19 (m, 2H), 1.79 (q, J = 6 
Hz, 2H), 1.73 (q, J = 6 Hz, 2H), 1.41, (s, 9H); 13C NMR (75 MHz, CDCl3) δ 165.7, 
156.2, 79.2, 70.7, 70.5, 70.5, 70.3, 69.7, 53.6, 39.2, 38.8, 29.8, 29.5, 28.6; HRMS 
(ESI) calc for [C17H33BrN2O6]+ ([M + H]+): m/z 441.1595, found: 441.1606.  The 
observed isotopic distribution matched the calculated one. 
 
(1-(Azidomethyl)-4-(chloromethyl)-2,3,5,6-tetrafluorobenzene) (4-6): 1,4-
Bis(chloromethyl)-2,3,5,6-tetrafluorobenzene (270. mg, 1.09 mmol) and sodium azide 
(113 mg, 1.74 mmol) were dissolved in anhydrous acetone (15 mL) and the reaction 
mixture was stirred at room temperature for 6 days.  The reaction mixture was then 
filtered and concentrated under reduced pressure, deposited onto silica and purified via 
flash chromatography eluting with hexanes to afford the azide 4-6 as a thin colorless 
oil (150. mg, 54.1%). 1H NMR (500 MHz, CDCl3) δ 4.68 (s, 2H), 4.48 (s, 2H); 13C 
NMR (75 MHz, CDCl3) δ 146.3 (tt, J1 = 16.5 Hz, J2 = 5.8 Hz), 142.9 (tt, J1 = 16.5 Hz, 
J2 = 5.8 Hz), 117.0 (t, J = 16.5 Hz), 114.0 (J = 16.5 Hz), 41.7, 31.3; 19F NMR (282 
MHz, CDCl3) δ -145.5, (ddd J1 = 102 Hz, J2 = 16.1 Hz, J3 = 7.9 Hz). 
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2,2'-(1,4,7,10-Tetraazacyclododecane-1,7-diyl)bis(N-(2,2,2-
trifluoroethyl)acetamide) (4-7): Cs2CO3 (11.6 g, 35.7 mmol) followed by the 
fluorinated acetamide 4-2 (3.43 g, 15.6 mmol) were added to a solution of 1,4,7,10-
Tetraazacyclododecane (1.54 g, 8.93 mmol) in anhydrous CH3CN (50 mL).  The 
reaction mixture was stirred at 60 ˚C for 44 h, then cooled to room temperature, 
filtered and concentrated under reduced pressure to yield a yellow oil that was 
deposited onto alumina and purified via column chromatography eluting with 1% 
MeOH in CH2Cl2 to yield the cyclen derivative (4-7, 2.48 g, 61.7%) as a colorless oil 
that was further dried under high vacuum overnight. 1H NMR (500 MHz, CD3OD) δ 
2.46-2.60 (m, 12H), 3.01-3.10 (m, 4H), 3.68-3.74 (m, 4H); 13C NMR (75 MHz, 
CD3OD) δ 55.1, 56.0 (d, J = 17 Hz), 61.6 (d, J = 10 Hz), 62.4, 62.6 (d, J = 6 Hz), 66.9, 
68.8 (d, J = 27 Hz), 126.9, 134.3 (q, J = 277 Hz), 181.8; 19F NMR (282 MHz, CD3OD) 
δ -73.1 (t, J = 8.7 Hz); HRMS (ESI) calc for [C16H28F6N6O2]+ ([M + H]+): m/z 
451.2251, found: 451.2256. 
 
2,2'-(4-(2-Oxo-2-(prop-2-yn-1-ylamino)ethyl)-1,4,7,10-tetraazacyclododecane-1,7- 
diyl)bis(N-(2,2,2-trifluoroethyl)acetamide) (4-8): K2CO3 (473 mg, 7.00 mmol) 
followed by the acetylene 4-3 (267 mg, 1.51 mmol) were added to a solution of the 
disubstituted cyclen 4-7 (1.05 g, 2.33 mmol) in anhydrous CH3CN (150 mL).  The 
reaction mixture was then stirred at 60 ˚C for 19 h, then cooled to room temperature, 
filtered, and concentrated under reduced pressure to yield a colorless oil which was 
further purified via column chromatography on alumina eluting with 0-5% MeOH in 
 127
CH2Cl2. The tri-substituted cyclen derivative 4-8 was obtained as a colorless glass 
(712 mg, 56.0%). 1H NMR (500 MHz, (CH3)2CO) δ 8.71 (br s, 1H), 8.62 (br s, 1H), 
8.27 (br s, 1H), 4.02-3.97 (m, 4H), 3.43 (s, 4H), 3.36 (s, 2H), 3.29 (s, 2H), 3.07-2.63 
(m, 16H), 2.07 (t, J = 2.2 Hz, 1H); 19F NMR (282 MHz, (CH3)2CO) δ -72.8 (t, J = 8.0 
Hz); HRMS (ESI) calc for [C21H33F6N7O3]+ ([M + H]+): m/z 546.2622, found: 
546.2606. 
 
Tert-butyl (1-(4,10-bis(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-7-(2-oxo-2-
(prop-2-yn-1-ylamino)ethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-2-oxo-7,10,13-
trioxa-3-azahexadecan-16-yl)carbamate) (4-9): K2CO3 (106 mg, 0.765 mmol) was 
added, followed by the carbamate 4-5 (135 mg, 0.306 mmol) were added to a solution 
of the tri-substituted cyclen derivative 4-8 (139 mg, 0.255 mmol) in anhydrous 
CH3CN. The reaction mixture was stirred at 70 ˚C for 19 h, cooled to room 
temperature, filtered, then deposited on to alumina and purified via column 
chromatography yielding the fully substituted cyclen 4-9 which was used immediately 
in the next step (223 mg, 96.7 %). 1H NMR (500 MHz, CD3OD) δ 4.04-3.95 (m, 4H), 
3.63-3.58 (m, 12H), 3.29-3.82 (m, 16H), 2.78-2.10 (dd, J1 = 13.5 Hz, J2 = 6.5 Hz, 
12H) 1.78 (q, J = 6.0 Hz, 4H), 1.72 (q, J = 6.5 Hz, 4H), 1.44 (s, 9H); 13C NMR (75 
MHz, CD3OD) δ 171.2, 169.2, 154.2, 154.1, 124.2, (q, J = 279 Hz), 79.8, 79.3, 73.2, 
72.2, 71.5, 70.5, 70.3, 69.2, 59.4, 58.2, 56.6, 56.2, 55.3, 52.7, 39.2, 38.3, 27,4, 21.1; 
19F NMR (282 MHz, (CH3)2CO) δ -72.8 (t, J = 8.0 Hz); HRMS (ESI) calc for 
[C21H33F6N7O3]+ ([M + H]+): m/z 546.2622, found: 546.2606. 
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2,2'-(4-(16-amino-2-oxo-7,10,13-trioxa-3-azahexadecyl)-10-(2-oxo-2-(prop-2-yn-1-
ylamino)ethyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)bis(N-(2,2,2-
trifluoroethyl)acetamide) (4-10): Trifluoroacetic acid (10 mL) was added dropwise 
over 5 min to a solution of the protected cyclen 4-9 (223 mg, 0.247 mmol) in CH2Cl2 
(50 mL) in an ice bath.  Once addition was complete, the reaction mixture was warmed 
to room temperature and stirred overnight. Volatiles were removed under reduced 
pressure, after which subsequent portions of cold MeOH (3 × 5 mL) were added and 
then concentrated. The final amine 4-10, obtained as a yellow oil, was further dried 
under high vacuum overnight (197 mg, 99.0%). 1H NMR (500 MHz, CD3CN) δ 7.57 
(br s, 1H), 7.41 (br s, 1H), 7.23 (br s, 2H), 3.97-3.89 (m, 8H), 3.67 (d, J = 3.3 Hz, 4H), 
3.59-3.48 (m, 16H), 3.35-2.73 (m, 20H), 1.72 (quintet, J = 7.2 Hz, 4H); 19F NMR (282 
MHz, CD3CN) δ -76.4; HRMS (ESI) calc for [C38H65F6N9O9]+ ([M + H]+): m/z 
905.4809, found: 905.4783. 
 
2,2'-(4-(1-(4-(Azidomethyl)-2,3,5,6-tetrafluorophenyl)-17-oxo-6,9,12-trioxa-2,16-
diazaoctadecan-18-yl)-10-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)bis(N-(2,2,2-trifluoroethyl)acetamide) (4-11): 
K2CO3 (377 mg, 2.73 mmol), followed by a stock solution of the azide 4-6 in 
anhydrous CH3CN (86.8 mg, 0.342 mmol), were added to a solution of the cyclen 
derivative 4-10 (550. mg, 0.683 mmol) dissolved in anhydrous CH3CN (40 mL). The 
reaction mixture was stirred at 50 ˚C for 34 h, then filtered, and purified via column 
chromatography over alumina eluting with 0-5% MeOH in CH2Cl2. The free ligand 
DOTA-click (4-11) was obtained as a clear colorless oil that was further dried under 
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high vacuum overnight (285 mg, 81.5 %). 1H NMR (500 MHz, CDCl3) δ 1.75-1.85 
(m, 4 H), 1.99-2.83 (m, 20 H), 2.84-3.31 (m, 12 H), 3.44-3.59 (m, 12 H), 3.75-3.99 (m, 
6 H), 4.45 (s, 2 H), 8.25 (br s, 2 H), 8.80 (br s, 2 H); 13C NMR (75 MHz, CDCl3) δ 
172.4, 171.9, 171.8, 171.3, 171.0, 170.9, 146.1, 143.0, 124.0 (q, J = 278 Hz), 79.8, 
77.0, 71.0, 70.1, 70.0, 69.8, 69.7, 69.6, 69.5, 69.3, 56.8, 56.8, 52.9, 50.1, 46.2, 41.6, 
40.6,  37.5, 29.3, 28.6; 19F NMR (282 MHz, CDCl3) δ -72.3 (t, J = 25.7 Hz), -143.9 
(dt, J1 = 87.1 Hz, J2 = 13.5 Hz); HRMS (ESI) calc for [C41H60F10N12O7]+ ([M + Na]+): 
m/z 1045.4440, found: 1045.4461. 
 
Tm-DOTA-click (4-1): H2O (10 mL) followed by a stock solution of TmCl3 in H2O 
(27.8 mg, 0.101 mmol) were slowly added to a solution of the free ligand 4-11 (103 
mg, 0.101 mmol) in CH3CN (10 mL). The acidic reaction mixture was stirred at room 
temperature, slowly basified with NaOH (aq) to pH 8, and then stirred at 70 ˚C for 19 
h.  The reaction mixture was then allowed to cool and diluted with H2O (30 mL), 
passed through 0.2 µm syringe filter and lyophilized to yield an off-white crystalline 
solid (4-1, 119 mg, 99.0%). 1H NMR (500 MHz, D2O) δ -27.7-(-16.1) (m), -12.7-9.8 
(m), 18.9-40.2 (m), 43.1-49.0 (br m); 19F NMR (282 MHz, D2O) δ -81.9-87.6 (m), -
145.3 (d, J = 127 Hz); HRMS (ESI) calc for [C41H62F10N12O7]2+ ([M - H]2+): m/z 
596.1984, found: 596.1997. 
 
19F NMR. 19F spectra were recorded on a Varian Unity VXR-300 at 282 MHz at 20 °C 
at the LeClaire-Dow Characterization Facility of the Department of Chemistry at the 
University of Minnesota. A KF solution in D2O was used as an external standard and 
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to lock and shim all samples containing the paramagnetic Tm-DOTA-click. Samples 
of Tm-DOTA-click were dissolved in deionized water further purified by a Millipore 
cartridge system (resistivity 1.8 × 107 Ω) and analyzed. Cu(I)ascorbate was then added 
to the contrast agent sample to bring the final concentration of Cu(I) to 0.10 eq of Tm-
DOTA-click. In each experiment, [ascorbate] = 5 × [Cu(I)]. The excess ascorbate is 
used in order to maintain all copper in its +1 oxidation state. Samples were allowed to 
react for 2 hours before measurements were performed. Longitudinal (T1) and 
transverse (T2) relaxation times of each fluorines in mQ water were measured using 
the inversion recovery sequence and the Carr-Purcell-Meiboom-Gill sequence, 
respectively. 19F lanthanide induced relaxation enhancement (FLIRE) spectra were 
acquired with the following parameters. A recycle delay equal to 5 × the longest 19F T1 
was followed by a 180° pulse and an inversion time equal to ln(2) × T1 (longest). At this 
point, fluorine nuclei with short T1 have recovered some magnetization in the Z-
direction whereas those with the longer T1 have not. A 90° pulse was then applied and 
the FID was recorded. This pulse sequence enabled elimination of the signal of the 
fluorine nuclei with the longer T1+, which in this case were the aromatic fluorines prior 
to reaction of the probe with Cu(I). 
 
MRI. MR images of samples in 3 mm NMR tubes were acquired on a 16.4 T, 26-cm 
horizontal bore magnet (Magnex Scientific, Oxford, UK) interfaced with a Varian 
Direct Drive console (Varian, Palo Alto, CA, USA).  The magnet was equipped with a 
gradient insert capable of reaching 1000 mT/m in 150 µs (Resonance Research, Inc., 
 131
Billerica, MA).  A linear surface coil (12 mm diameter) tunable to both 1H (698.1 
MHz) and 19F (656.8 MHz) frequency was used to transmit and receive the signal.  
1H gradient echo images were acquired using following parameters: repetition time 
(TR) = 40 ms, echo time (TE) = 1.28 ms, field of view (FOV) = 3 cm x 3 cm, matrix = 
128 x 128, slice thickness = 10 mm, flip angle = 20°.  19F gradient echo images were 
acquired using following parameters: TR = 20 ms, TE = 2.73 ms, FOV = 2 cm x 2 cm, 
matrix = 64 x 64, slice thickness = 10 mm, excitation pulse = 4 ms sinc, flip angle = 
90°, number of averages (na) = 512 or 2048. 
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5 In Vivo Analysis of 19F MRI Contrast Agents 
5.1 Introduction 
 
 In the final chapter of this dissertation, the work done to finally test 19F-based 
MRI contrast agents in vivo will be described. The complexes described in the 
preceding chapters have only been tested in vitro, and while they had always been 
designed with biocompatibility in mind, they had not been tested in vivo to this point. 
Some of the design considerations and goals of the aforementioned compounds were 
made with greater focus for sensitivity and responsive probes rather than with 
maintaining the characteristics of what makes for a biocompatible probe. This chapter 
addresses perhaps the most important property of any new potential therapeutic 
compound: biocompatibility. As such, a number of 19F MRI contrast agents were 
tested in rat models in vivo, and observations of their half-life and biodistribution were 
recorded, as well as monitoring the health of the rats following the administration of 
these probes. 
5.1.1 19F MRI Contrast Agents Used for in vivo Studies—Structure 
 
 Six paramagnetic contrast agents were used for 19F MRI in an attempt to 
overcome solubility and in particular, toxicity issues, the former of which were 
discussed in detail in Chapters 2 and 3. These six contrast agents were produced by 
combining one of three macrocyclic scaffolds, with one based on a cyclen-
tetraphosphontate (DOTP) ligand and two others with DOTA-tetraamide ligands, each 
with with the paramagnetic metal ion of either Tm(III) or Fe(II), as shown in Figure 5-
1. 
 133
 
 
Figure 5-1:19F MRI contrast agents for in vivo studies. Chemical structures of Three ligands used, six 
complexes 3-23 and 5-1, 2-9 and 2-11, and 5-2 to 5-3 explored as potential fluorine-based MRI contrast 
agents in this project. Each of three ligands was complexed with either Fe(II) or Tm(III). While the 
structures are similar, the six contrast agents each possess a different net charge (ranging from -2 to +3) 
and a slightly varied chemical structure, giving each compound unique pharmacological and magnetic 
properties.  
These structural motifs – of which their lanthanide complexes do have a significant 
history in the literature surrounding contrast agent development – were employed 
because they provide some of the highest levels of stability and kinetic inertness in 
complexes with gadolinium.197 These contrast agents were synthesized with either nine 
or twelve fluorine atoms per molecule, which enabled facile detection by 19F MRI, and 
Tm(III) and Fe(II)—rather than gadolinium—were used as the paramagnetic metal 
ions. These ions were chosen based on the study of T1 and T2 values of the DOTAm-
F12 ligand containing various paramagnetic metal ions in both aqueous solution and in 
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rat blood, described in Chapter 2. Tm(III) and Fe(II) showed the greatest reduction of 
T1 while maintaining a high ratio of T2/T1 in both systems. The combination of the 
high number of fluorine atoms per molecule and the Tm(III) or Fe(II) metal ions 
provided much greater sensitivity over currently available fluorinated contrast agents.  
 The number of fluorines per probe was maximized while employing different 
structural properties aimed at modulating the overall charge of the probes. The contrast 
agents in this study were all soluble in both water and saline buffer to concentrations 
over 50 mM. This high solubility in aqueous solutions made these compounds feasible 
for use as MRI contrast agents in biological systems. 
 The final aspect in this chapter is the evaluation of parameters that limit their 
toxicity. Many currently existing fluorinated contrast agents have either displayed very 
high toxicity in animal models or long retention times in biological systems, or they 
have not been studied in relevant systems to assess their toxicity. Structural similarities 
to clinically available gadolinium-based agents—which feature tight chelation of the 
metal ion—possess the potential to be non-toxic to live animals. Additionally, using 
three different ligands and two different metals provided greater diversity of molecular 
structure, charge, and size, maximizing the possibility that a nontoxic contrast agent 
with the highest sensitivity in in vivo imaging could be found for the complexes 
examined. Finally, the use of iron eliminated any gadolinium- or lanthanide-based 
toxicity, which is a major drawback of currently available MRI contrast agents. While 
thulium has similar toxicity issues as gadolinium, the iron counterparts do not, and the 
iron complexes were predicted to produce much less toxicity issues if they were to 
dissociate from the complex in vivo. 
 135
 Even though the basic architecture of these contrast agents was derived from 
work already published in the literature, the two DOTA-tetraamide ligands shown in 
Figure 5-1 were designed and synthesized for the first time in this project. The other 
ligand, F-DOTPME, was originally reported by Kim et al., but was only characterized 
in aqueous solutions and not in a biological environment.84 Additionally, Fe(II) and 
Tm(III) have not previously been used in vivo as paramagnetic metals in MRI contrast 
agents. Finally, this work is the first systematic study of acute toxicity, retention times 
and biodistribution of any metal-based 19F MRI contrast agent in vivo.  
 In this study, each of the six potential contrast agents was synthesized and 
characterized to ensure purity and to determine magnetic relaxation times T1 and T2. 
Additionally, a systematic pharmacological and toxicological study was undertaken by 
injecting rats with each of the contrast agents to first determine acute toxicity of the 
compounds. Blood and tissue samples taken from each animal were then analyzed for 
contrast agent concentration to assess organ biodistribution and blood retention times 
for each agent. These experiments aimed to identify the most favorable of the six 
compounds for in vivo use.  
 The ligand DOTAm-F12 was synthesized as reported in Chapter 2. The ligand 
F-DOTPME was synthesized as reported in Chapter 3. The ligand DOTAm-F9-PO3 
(5-8) was obtained over six steps, shown in Scheme 5-1. First, the amine (5-4) was 
obtained through cleavage of the commercially available Garbriel adduct with 
hydrazine. 
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5.1.2 Synthesis of Contrast Agents 
 
Scheme 5-1: Synthesis of f-DOTPME and DOTAm-F9-PO3. Experimental conditions: (a) hydrazine, 
EtOH, 22 ºC, 18 h -> reflux, 3 h, 45%; (b) bromoacetyl bromide, NaOH, CH2Cl2/H2O, 0 ºC -> 22 ºC, 1 h, 
60%; (c) cyclen, triethylamine, CHCl3, 60 ºC, 18 h, 57%; (d) 2-bromo-N-(2,2,2-trifluoroethyl)acetamide, 
K2CO3, CH3CN, 60 ºC, 18 h, 54%; (e) TMS-Br, DMF, 0 ºC -> rt, 18 h, 55%. 
 Subsequent alkylation with bromoacetyl bromide yielded the protected 
phosphate arm (5-5) and singly alkylated to cyclen to yield 5-6. The cyclen ring was 
then exhaustively alkylated with the -CF3 pendant arm to yield the protected ligand 5-7 
before hydrolysis of the phosphate esters with TMS-Br, and the final product was 
purified by reverse-phase HPLC and lyophilized to yield the free ligand DOTAm-F9-
PO3 (5-8) as a white powder. 
Metallation of 5-8 with Tm(III) and Fe(II) was accomplished in similar fashion as for 
DOTAm-F12, described in Chapter 2, using instead a 10% excess of the ligand 
relative to the metal to yield [Tm-F-DOTPME]- (3-23), [Fe-F-DOTPME]2- (5-1), [Tm-
DOTAm-F9-PO3]+ (5-2) and Fe-DOTAm-F9-PO3 (5-3). All six resultant metal 
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complexes were readily soluble in water at neutral pH at concentrations greater than 
100 mM. 
5.1.3  19F Relaxation Times 
 
 Before in vivo testing was undertaken, the six contrast agents were tested in 
aqueous environments at neutral pH to determine the T1 and T2 relaxation times of the 
fluorine nuclei on each compound. As described earlier, contrast agents having high 
T2/T1 ratios as close to 1 as possible have produced the strongest signals and highest 
SNR ratios when imaged by MR. The T1 and T2 values for the two new free ligands and 
their respective Tm(III) and Fe(II) metal complexes were measured by 19F NMR at 282 
MHz and compared to the values obtained for the DOTAm-F12 ligand and its Tm(III) 
and Fe(II) complexes reported in Chapter 2. The results are reported in table 5-1. 
As expected, the fluorine nuclei located on the three organic ligands lacking a 
paramagnetic metal ion exhibited very long relaxation times, ranging from 650 to 1000 
milliseconds . Introduction of a paramagnetic ion induced significant reductions in the 
relaxation times to a range of 5 to 40 milliseconds, with the DOTA-tetraamides 
DOTAm-F12 and DOTAm-F9-PO3 (5-13) displaying very similar values. As shown in 
Table 5-1  all of the contrast agents utilized in this study possessed T1 values of 50 ms 
or less, and the highest T2/T1 ratios were observed for [Fe-DOTAm-F12]2+ (0.98) and 
Fe-DOTAm-F9-PO3 (5-3) (0.83 and 0.63). 
 The T1 and T2 values of 5.7 and 5.6 milliseconds for contrast agent 2-9 and 5.8 
and 4.8 milliseconds for contrast agent 5-3 in this study were among the lowest 
fluorine relaxation times of any compound found in the literature.82,198,199 
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Table 5-1: T1 and T2 relaxation values for 19F nuclei. T1 and T2 values of the 19F nuclei in the three 
precursor ligands and in their Tm(III) and Fe(II) complexes, measured in aqueous solution at neutral pH 
at 282 MHz. aValue found by Kim et al.84 bSpectrum for 5-1 displayed multiple resonances 
corresponding to stereoisomers. axial and equatorial  over a wide frequency range, each with distinct T1 
and T2 values. cFor compounds with spectra displaying two signals over a narrow frequency range (i.e. 
both could be imaged in a single MRI scan), individual relaxation time values are given for each signal. 
 
Contrast Agent T1 Relaxation 
Time (ms) 
T2 Relaxation 
Time (ms) 
F-DOTPME (5-8) 928 312a 
3-23 11 (ax.), 41 (eq.)b 5 (ax.), 19 (eq.) 
5-1 29.5c 
35.0 
4.9 
10.1 
DOTAm-F12 880 680 
2-9 26.0 16.0 
2-11 5.7 5.6 
DOTAm-F9-PO3 (5-13) 719 154 
5-2 25.8 17.1 
5-3 6.4c 
5.8 
4.0 
4.8 
 
Fe(II) was particularly effective at reducing relaxation times and producing high T2/T1 
ratios for the compounds used in this study, further indicating its potential for use and 
development in 19F contrast agents. In fact, this study is the first report of an Fe(II)-
based 19F MRI contrast agent that has been tested in vivo. Using Fe(II) as the 
paramagnetic metal ion rather than lanthanides has yielded some of the most sensitive 
probes discussed herein, and may likely reduce potential safety concerns. 
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5.1.4  19F Signal Intensity 
 
 As reported by Kim et al., metal complexes of the F-DOTPME ligand (5-8) 
result in the formation of multiple stereoisomers in solution, resulting in multiple 
fluorine signals over a wide chemical shift range.84 These resonances are produced 
from various combinations of isomers, wherein the -CF3 groups can adopt either an 
axial or equatorial orientation relative to the metal center.  Four unique combinations 
of R and S are possible for the four chiral centers. The peaks cluster at two main 
frequencies near -60 ppm and -120 ppm for fluorine atoms either in the axial or 
equatorial positions, respectively, relative to the principle magnetic axis of the 
paramagnetic metal (θ). The shifts in frequencies observed are rationalized by the 
McConnel-Robertson equation’s (2-2) dependence on the angle θ between the 
paramagnetic metal center and the detected nuclei. 
 The presence of multiple peaks across the wide frequency range reduces MR 
sensitivity. In this case, the sensitivity would be reduced, as only six of the total twelve 
fluorine nuclei of the probe could be imaged with one pulse sequence. For the Tm(III) 
complex 3-23, these would be the clustered signals from equatorial fluorines centered 
at δ = -39 ppm. The signals from axial fluorines are too distant from one another to be 
imaged together. In addition, while MRI could detect the equatorial fluorines in one 
pulse sequence, the images produced would further suffer a loss in resolution when 
imaged together, as was illustrated in the case of PFOB described in Chapter 1. Kim et 
al. briefly noted in that F-DOTPME epimerizes to a single isomer in the presence of 
aqueous detergents in their 1997 report but didn’t explore this effect further at the 
time. However, in 2009 the same group reported that a metal complex—very similar to 
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3-23—epimerized to a single isomer with a single resonance when in blood, after 
originally displaying the expected twelve resonances by 31P NMR in neutral aqueous 
media alone.200 While contrast agent 3-23 was not tested in blood or serum albumin, it 
is possible that the same effect would occur. Thus, the problem of having signals 
spread over too wide a range for MRI may be eliminated.  
 Although the spectrum of contrast agent 3-23 displayed multiple signals over a 
wide frequency range, the other five compounds tested did not. Overall, the relaxation 
data obtained combined with high water solubility suggests that all six of these 
compounds should be sensitive enough for MR imaging at physiologically safe 
concentrations. These compounds would be especially advantageous over many of the 
perfluorocarbon agents described above that displayed very long T1 relaxation times 
and low T2/T1 ratios. 
5.2  Preliminary In Vivo Experiments 
 
 In order to examine the biocompatibility of the proposed contrast agents and to 
determine their retention times and distributions within a biological system, the six 
metal complexes were injected into rats fixed with a catheter. To minimize the 
potential toxicity produced by these injections, the compounds were determined to be 
pure by nuclear magnetic resonance spectroscopy and final determination of purity 
was analyzed by HPLC. Prior to injection, the contrast agents were also tested in the 
presence of the metal indicator xylenol orange to ensure that the injection contained no 
free metal ions. Each contrast agent was dissolved in phosphate-buffered saline (PBS) 
to form 1 mL of a 50 mM solution. The solutions of each agent were injected into a 
pair of three-month old rats fitted with jugular vein catheters for each compound. The 
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rats were monitored over a period of four hours, with blood samples removed 
throughout that period. Animals were euthanized after four hours so that tissue 
samples could also be removed. The four-hour period was chosen in order to 
accurately assess the physiological distribution of the contrast agent while limiting 
chronic toxicity effects. Because those chronic effects could result from the 
dissociation of metal ions from the ligand, they would require a much longer period of 
time to produce negative impacts on the animals.  
5.2.1  Acute Toxicity of DOTAm-F12 Complexes 
 
 The first in vivo studies conducted were with the DOTAm-F12 contrast agents 
2-9 and 2-11 (Figure 5-1). These two complexes resulted in death of all rats within 
five minutes post-injection. This demonstration of acute toxicity was hypothesized to 
be a result of ionic shock. These two contrast agents carry an overall charge of +3 and 
+2 for the Tm(III) and Fe(II) complexes, respectively. Previous studies of similar 
cationic compounds have found that the highly cationic charge interferes with, and 
may even completely stop, heart function.201 Regardless of the actual cause of death, 
because the animals tested with these compounds died quickly, and contrast agents 2-9 
and 2-11 were no longer considered for further study. 
5.2.2  Four New Contrast Agents with Reduced Charge 
 
 Two new ligands were then designed and synthesized as discussed above to 
maintain high fluorine labeling but to reduce overall charge of the metal complexes. 
The DOTAm-F12 ligand is charge-neutral and produces Tm(III) and Fe(II) complexes 
of +3 and +2, whereas the F-DOTPME ligand and the DOTAm-F9-PO3 ligand carry a 
-4 and -2 overall charge respectively, forming -1/-2 and +1/0 metal complexes with 
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Tm(III)/Fe(II). The other four contrast agents produced no visible impacts on the six 
rats over the course of the observation period. Rats injected with these contrast agents 
tolerated the compounds and were alive and active until the end of the four-hour 
period. 
5.3 Biodistribution Properties 
 
5.3.1 Blood Retention 
 
 Following injection of each contrast agent into rats, 500 µL blood samples were 
removed via the jugular vein catheter after 5, 15, 30, 60, 120, and 240 minutes. Each 
blood sample was then digested with heat and nitric acid to produce a clear, yellow 
liquid. The concentration of fluorine within the sample following acid digestion was 
determined using 19F NMR using an external standard. The integration values for the 
peaks in the NMR spectrum corresponding to the digested sample were compared to 
integration values for the external standard solution of aqueous potassium fluoride of 
known concentration contained in a smaller, sealed capillary tube present along with 
the sample. As endogenous fluorine concentrations are extremely low (<0.1 ppm) in 
normal plasma, monitoring the concentration of fluorine over time served as a good 
proxy for following the concentration of the contrast agent as it was excreted.202 The 
results are shown in Table 5-2. 
 As shown in Table 5-2, the concentrations of contrast agents 3-23 and 5-2 
decreased rapidly within the first hour after injection, while the iron-containing agents 
5-1 and 5-3 were removed from the blood at a slower, but nonetheless at rate for 
clearance of 4-6 hours. These clearance times are slightly longer than those for Gd(III)-
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based contrast agents, but are still within an acceptable timeframe for established safety 
protocols.  
  
 Table 5-2:  Summary of in vivo contrast agent injections. The blood half-life is the amount of time after 
injection at which half of the injected contrast agent was present in the blood, and the primary organs 
are those in which the highest concentrations of contrast agent were found four hours post-injection 
(p.i.). 
 
Contrast 
Agent 
Net 
Charge 
 Animal 
Outcome 
Blood 
Half-
Life 
Primary 
Organs 
F-DOTPME 
 
    
5-1 
 
+1 Survived 49 
min. 
kidney 
5-2 
 
0 Survived 72 
min. 
kidney 
DOTAm-
F12 
 
  
 
 
 
 
5-3 
 
+3 Died – 5 
minutes p.i. 
n/a n/a 
5-4 
 
+2 Died – 2 
minutes p.i. 
n/a n/a 
DOTAm-
F9-PO3 
 
  
 
 
 
 
5-5 
 
-1 Survived 58 
min. 
kidney 
5-6 
 
-2 Survived 55 
min. 
kidney 
 
 Each contrast agent examined in vivo was done so in triplicate to identify 
outliers. There is a clear trend in all four agents that only a fraction of the original 
amount of contrast agent remains in the blood after four hours. 
 As indicated in Table 5-2, clearance to half the initial concentrations found for 
each agent in the blood was between 45 and 75 minutes. This is not be confused with 
each probe’s actual half-life but does suggest that the probes are rapidly cleared. For 
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comparison, all but one of the FDA-approved gadolinium-based contrast agents 
demonstrate elimination half-lives between 60 and 120 minutes.24 Thus, the contrast 
agents in this study displayed retention and clearance times comparable to the contrast 
agents used today. These half-lives would allow for a 30-60 minute period of high 
concentration for imaging, followed by rapid clearance from the body. This time course 
suggests that the requisite sensitivity for MR imaging can be provided while 
maintaining a strong safety profile. 
 In terms of chronic toxicity, the Fe(II)-based contrast agents 5-1 and 5-3 in this 
study negated one major hazard of currently available MRI contrast agents, which is 
the gadolinium-based nephrogenic systemic fibrosis (NSF) that occurs in patients with 
moderate to severe kidney impairment.203 The toxicity of Tm(III)-based contrast 
agents has not been studied in great detail, but, as a lanthanide metal that is not 
normally present in the body in large quantities, it is likely to have similar side effects 
to that of Gd(III). On the other hand, iron is far less toxic than gadolinium and is 
present at relatively high concentrations in most biological systems. For example, the 
average concentration of iron in human blood is 473 ± 88 ppm.204 Most of this iron in 
the blood is not in its free ionic form because the human body has several mechanisms 
that maintain iron homeostasis. Hepcidin is a hormone produced by the liver that 
regulates the metabolism of iron by other cell types, and iron is also incorporated into 
other biological macromolecules, such as transferrin and ferritin.205 An injection of the 
iron-containing contrast agents in this study at the standard concentration of 0.1 
mmol/kg would increase the concentration by roughly 70 ppm. However, this increase 
would only be realized if all iron ions dissociated from their ligands. Work by Morrow 
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has demonstrated that Fe(II) complexes such as the contrast agents in this study are 
highly inert in the presence of other physiological anions, indicating that very little 
iron dissociates from the complexes in biological environments. 206 
 
Figure 5-2: Mean concentration of contrast agents in rat blood over 4 hours post-injection. Mean 
concentrations of 19F in blood samples from rats injected with contrast agent indicated. Concentrations 
are given in units of parts per million (ppm), error bars represent standard deviation (n = 3). 
 In addition, while iron and specifically Fe(II) are known to catalyze the 
formation of harmful reactive oxygen species (ROS) such as hydroxyl radical and 
nitric oxide, the same study also demonstrated that Fe(II) metal complexes similar to 
5-1 and 5-3 used for this study produce extremely low ROS levels, thus limiting the 
degree of iron toxicity that these contrast agents might produce in this manner. 
5.3.2  Organ Distribution 
 
 The four contrast agents that were non-lethal to rats in vivo were further 
studied by analyzing organ samples collected from the rat models euthanized 4 hours 
post-injection. Portions of brain, heart, kidney, liver, lung, and spleen were removed to 
determine the concentration of contrast agent within each vital organ. Like the blood 
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samples, the organ samples were also digested with heat and nitric acid, and the 
concentrations of fluorine were determined using NMR. The results are shown in 
Figure 5-3. 
 In this case, the data shown represents the percentage of total injected fluorine 
– out of 11.4 mg for 3-23 and 5-1 and 8.55 mg for 5-2 and 5-3 – that was present in 
each organ after four hours (Figure 5-2). Like gadolinium-based contrast agents, it was 
expected that these agents would primarily be excreted via the kidneys, given the basic 
structural similarities between the compounds. The data in Figure 5-3 indicates that the 
kidneys possessed the highest amount of each contrast agent, which is consistent with 
the renal system being the primary mode of elimination. The spleen, heart, brain, and 
lungs all displayed low levels of fluorine, which most likely stemmed from the 
vascularization of these organs and any excess blood that was removed when the 
organs were excised. The liver contained a slightly higher level of all three agents, but 
that was likely due to the fact that the liver is a much larger organ. There are two 
exceptions to the above trends in the data. One animal displayed a very high level of 
contrast agent 5-1 in the brain, and another showed a high level of contrast agent 2-9 
in the liver.  
 Since the fluorine was found to accumulate at a significantly higher level in the 
kidneys than in other organs, it can be assumed that the urinary system is likely the 
primary mode of excretion for these contrast agents. The compounds’ high water 
solubility also supports this conclusion. As in the case of gadolinium-based contrast 
agents, this mode of excretion provides the most rapid clearance from the body, 
limiting the potential for toxicity produced by transmetallation of metal ions. 
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Figure 5-3: Concentration of contrast agents within vital organs. This figure shows the mean percentage 
(n = 3) of total contrast agent injected that accumulated in each of the six vital organs examined in the 
experiment. The concentration of 19F in each organ was first determined in parts per million. Then, the 
mass of each organ and the total mass of fluorine contained in each 1 mL injection volume were used to 
determine the percentages shown. Error bars represent the standard error of the mean 
5.4 Imaging 19F Contrast Agents Directly In Vivo  
 
 The final step of this project would be to acquire in vivo images of rats injected 
with the contrast agents presented in this chapter. These images will help determine if 
the non-lethal concentration used in these studies provides sufficient sensitivity for in 
vivo MRI. The concentration used for these experiments was near 0.2 mmol/kg. For 
the currently available gadolinium-based agents, the standard dose is 0.1 mmol/kg and 
the maximum dose allowed by the FDA is near 0.6 mmol/kg.24 Thus, the concentration 
that would be used in this study to examine toxicity and sensitivity by collecting MR 
images is relevant to clinically available contrast agents. 
 While these final experiments are planned as future work in this study, they 
were unable to be completed by the time this document was written. 
 148
5.5 Conclusions and Future Work 
 
 Despite the promising nature of the results presented above, there are some 
important qualifications that merit identification and discussion. The most important is 
that although the compounds had no adverse effects on the rats in which they were 
tested, this study did not conduct a rigorous examination of those potential effects. It 
was noted whether or not the rats survived the injections for four hours, but no detailed 
examination was performed to determine any possible disruptions of internal 
physiological processes. Additionally, the compounds are modeled off existing 
structural motifs that produce high stability and inertness and prevent release of the 
metal ion from the organic ligand.197 However, these parameters were not explored for 
these compounds specifically. Stability experiments and binding assays with 
competing metal ions that are present in tissues would need to be conducted to 
determine the behavior of interaction between the metal ion and the organic ligand in 
biological environments.  
 While numerous additional studies are required to assess the safety, 
pharmacology, and practicality of the contrast agents studied, the data presented in this 
chapter clearly indicates the potential of 19F MRI contrast agents as diagnostic tools in 
medicine. These compounds, designed to possess high kinetic inertness and 
thermodynamic stability, displayed relaxation times consistent with high sensitivity for 
in vivo imaging. The Fe(II) contrast agents had relaxation parameters superior to any 
other 19F MRI contrast agent described in the literature to date. In vivo 
experimentation demonstrated that four of the proposed agents produced no visible 
adverse effects on rats over a period of four hours, displayed adequate blood retention 
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time for imaging, and showed no abnormal accumulation in vital organs. With the 
observations made in this chapter, these compounds could serve as candidates for 
future in-depth pharmacological and toxicological testing that would further establish 
their suitability for 19F MRI applications.  
 Combined with the results of the prior four chapters, this thesis is the first 
documented work that has examined and presented the design principles and behaviors 
of 19F MRI contrast agent systems in three areas: 1) theoretical predictions used to 
yield rational designs with high sensitivity and high water solubility, 2) demonstration 
that 19F contrast agents can be responsive as well as ratiometric with a single probe, 
and 3) validation of their biocompatibility using in vivo models. Also reported herein 
are the first examples of 19F contrast agents using Fe(II) as the paramagnetic metal ion 
that have been used in vivo. These results reported here represent significant advances 
in the field of 19F MRI contrast agents to guide further studies in the area, and the 
improvements and observations made with these contrast agents could behave as 
templates for the production and study of future generations of 19F MRI contrast 
agents for in vivo imaging. 
5.6 Experimental Materials and Methods 
 
General considerations. Starting materials were obtained from commercial suppliers 
and used without further purification. Water was distilled and further purified by a 
Millipore cartridge system (resistivity 1.8 × 107 Ω). All solvents were removed under 
reduced pressure with a rotary evaporator. All synthetic compounds were 
characterized at the LeClaire-Dow Chemical Instrumentation Facility at the 
Department of Chemistry at the University of Minnesota, Twin-Cities. 1H NMR 
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spectra were recorded on a Varian VXR-300 at 300 MHz, 13C NMR spectra at 75 
MHz, 19F NMR spectra at 282 MHz, and 31P NMR spectra at 121 MHz, unless 
otherwise noted. The residual solvent peak was used as an internal reference for 1H 
and 13C NMR; CFCl3 was used as an internal reference for 19F NMR of organic 
intermediates; and KF was used as an external reference for tissue sample analysis. 
Data for 1H NMR are reported as follows: chemical shift (δ, ppm), multiplicity (s, 
singlet; br s, broad singlet; d, doublet; t, triplet; q, quartet; quin, quintet; m, multiplet), 
integration, coupling constant (Hz). Data for 13C, 19F, and 31P NMR are reported in 
terms of chemical shift (δ, ppm). Longitudinal (T1) and transverse (T2) relaxation times 
of 19F nuclei of metal complexes in D2O were measured using the inversion recovery 
sequence and the Carr-Purcell-Meiboom-Gill sequence, respectively, at 300 MHz.  A 
delay time of 30 ms and acquisition time of 64 ms were used for the collection of 1H 
and 19F NMR spectra of the paramagnetic metal complexes. Mass spectra (HR, high 
resolution; ESI, electrospray ionization) were recorded on a Bruker BioTOF II at the 
Waters Center of Innovation for Mass Spectrometry at the Department of Chemistry at 
the University of Minnesota, Twin-Cities. 
5.6.1 Synthesis of F-DOTPME (3-14), DOTAm-F12-PO3 (5-13), and Metal 
Complexes 
 
Tm(F-DOTPME)- (3-23). Ligand 3-14 (220 mg, 0.233 mmol) was dissolved in mQ 
water (15 mL). The solution was adjusted to pH = 7.5 with aq. HCl, and aq. 
thulium(III) chloride (0.291 M, 726 µL) was added. The pH was again adjusted to 7.5 
with aq. NaOH. The reaction was stirred at 75 ºC for 72 h. Analysis using xylenol 
orange in phosphate buffer indicated the absence of free metal. The reaction was 
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lyophilized, yielding a white solid (3-23, 278 mg, quant.). 19F NMR (282 MHz, D2O) δ 
= -49.21, -54.25, -75.98, -76.37, -117.69, -118.15, -118.54, -118.79, -119.05, -119.48. 
ESI-MS [m/z] calc. for C20H32F12N4O12P4Tm [M]-: 1041.0, found: 1041.0. 
 
Fe(F-DOTPME)2- (5-1). Ligand 3-14 (105 mg, 0.109 mmol) was dissolved in mQ 
water (1 mL). Then, methanol (14 mL) was added, and the reaction flask was flushed 
with argon for 15 minutes. Iron(II) trifluoromethanesulfonate (35.3 mg, 0.100 mmol) 
was added carefully to prevent introduction of air into the reaction. The reaction was 
stirred at 75 ºC for 48 h under Ar, then the temperature was increased to 90 ºC for 24 h 
to dry the reaction under Ar. The product was passed through a Sep-Pak Vac 6 cc (1 g) 
C18 cartridge (Waters) to exchange the coordinated trifluoromethanesulfonate ions 
with chloride. Briefly, the column was conditioned by eluting 1 volume (5 mL) of 
acetonitrile, followed by 1 volume of mQ water. The product, dissolved in mQ water 
(5 mL), was then deposited onto the column. 2 volumes of 1 M sodium chloride 
solution were passed through the column to perform ionic exchange, followed by 1 
volume of mQ water to remove excess NaCl. Then, 2 volumes of acetonitrile were 
used to elute the product from the column as a pale yellow liquid. This liquid was 
lyophilized to yield the iron complex 5-1 as an orange powder. 19F NMR (D2O) δ = -
73.73, -74.68. ESI-MS [m/z] calc. for C20H32F12N4O12P4Fe [M]2+: 464.0, found: 463.9. 
 
Fe(DOTAm-F12)2+ (2-11). Ligand 2-1 (50. mg, 68.7 µmol) was dissolved in 
methanol and acetonitrile (1:1, 25 mL) and magnetically stirred. Iron(II) 
trifluoromethanesulfonate (24.3 mg, 68.7 µmol) was added and the reaction mixture 
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was heated to 70ºC for 30 h under Ar (g).  The resultant mixture was then concentrated 
under reduced pressure to yield the iron complex 2-11 as an orange solid in 
quantitative yield. Coordinated trifluoromethanesulfonate ions were exchanged for 
chloride by depositing the product on a Sep-Pak Vac 6 cc (1 g) C18 cartridge 
(Waters). The cartridge was washed with 2 volumes (5 mL each) of 1 M aqueous 
sodium chloride, followed by 1 volume of mQ water. The product was then eluted 
from the cartridge with 1 volume of acetonitrile. This eluent was collected and 
lyophilized to yield the desired product. 19F NMR (D2O) δ = -70.9 ppm. HRMS-ESI 
[m/z]: calc. for C24H36F12FeN8O4 [M]2+: 392.1009; found: 392.1000. 
 
Diethyl (aminomethyl)phosphonate monooxalate (5-4). Diethyl ((1,3-
dioxoisoindolin-2-yl)methyl)phosphonate (12.5 g, 42.1 mmol) was dissolved in 
absolute ethanol (250 mL). Hydrazine (1.68 mL, 52.6 mmol) was added, and the 
reaction was stirred for 18 hours at 22ºC as a white precipitate formed, followed by 
reflux at 100ºC for 3 hours. Next, mQ water (50 mL) was added to quench the 
remaining hydrazine, and the reaction was cooled to ambient temperature. The 
precipitate was removed by gravity filtration, and the remaining solution was 
concentrated under reduced pressure to 10 mL volume, then diluted with diethyl ether 
(250 mL) and filtered again. The solution was then added dropwise to a solution of 
oxalic acid (12.9 g, 143 mmol) in ethanol, forming the product as a white, flocculent 
precipitate. This precipitate was collected by vacuum filtration and dried under high 
vacuum (5-4, 4.85 g, 44.8%). 1H NMR (500 MHz, D2O) δ = 1.23 (t, J = 7.0 Hz, 6 H), 
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3.37 (d, J = 14 Hz, 2 H), 4.13 (tt, J1 = 7.0 Hz, J2 = 2.0 Hz, 4 H). 13C NMR (125 MHz, 
D2O) δ = 15.5, 33.0, 64.8, 165.0. 31P NMR (201 MHz, D2O) δ = 19.9. 
 
Diethyl((2-bromoacetamido)methyl)phosphonate (5-5). The amine-phosphonate 5-4 
(4.00 g, 16.5 mmol) was dissolved in a mixture of mQ water (25 mL) and methylene 
chloride (50 mL) and magnetically stirred in an ice bath. A solution of sodium 
hydroxide (2.50 g, 64.2 mmol) in water (50 mL) was added, followed by the dropwise 
addition of a solution of bromoacetyl bromide (2.03 mL, 23.3 mmol) in methylene 
chloride (10 mL) over 15 min. The reaction mixture was allowed to warm to ambient 
temperature and stirred for 70 min.  The organic phase was separated and washed with 
water (5 × 25 mL), dried over MgSO4 and concentrated under reduced pressure to 
yield the product as a colorless white crystal (5-5, 1.76 g, 60.3%). 1H NMR (500 MHz, 
CDCl3) δ = 1.34 (t, J = 7.0 Hz, 6 H), 3.72 (dd, J1 = 12.5 Hz, J2 = 6.0 Hz, 2 H), 3.90 (s, 
2 H), 4.15 (quintet, J = 7.5 Hz, 4 H), 7.12 (br s, 1 H). 13C NMR (125 MHz, CDCl3) δ = 
16.4, 35.6 (d, J = 156 Hz), 62.8, 165.7. 31P NMR (201 MHz, CDCl3) δ = 19.9 (s). 
 
Diethyl ((2-(1,4,7,10-tetraazacyclododecan-1-yl)acetamido)methyl)phosphonate 
(5-6). Cyclen (10.6 g, 61.8 mmol) was dissolved in dry chloroform (300 mL), and the 
solution was magnetically stirred at room temperature. Triethylamine (1.03 mL, 7.42 
mmol) was added, followed by the bromo-phosphonate arm 5-5 (1.76 g, 6.18 mmol). 
The reaction flask was then purged with Ar (g) and heated to 55 ºC under Ar (g) 
overnight. The reaction mixture was allowed to cool to ambient temperature and 
washed with 1 M aqueous sodium hydroxide (3 × 30 mL) and mQ water (3 × 50 mL), 
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dried over MgSO4, filtered and concentrated under reduced pressure to yield the 
product as a clear colorless oil (5-6, 1.32 g, 56.6 %). 1H NMR (500 MHz, CDCl3) δ = 
1.28 (t, J = 7.0 Hz, 6 H), 2.61-2.75 (m, 19 H), 3.18 (d, J = 5.5 Hz, 2 H), 3.69 (dd, J1 = 
11.5 Hz, J2 = 5.0 Hz, 2 H), 4.08 (quintet, J = 7.0 Hz, 4 H), 9.09 (br s, 1 H). 13C NMR 
(125 MHz, CDCl3) δ = 16.5, 34.5 (d, J = 155 Hz), 47.4 (d, J = 64.8 Hz), 53.9, 58.9, 
62.5, 172.2. 31P NMR (201 MHz, CDCl3) δ = 21.6 (s). HRMS-ESI [m/z] calc. for 
C15H34N5O4P [M + H]+: 380.2421, found 380.2416. 
 
Diethyl ((2-(4,7,10-tris(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1,4,7,10-tetra 
azacyclododecan-1-yl)acetamido)methyl)phosphonate (5-7). The mono-substituted 
cyclen 5-6 (0.72 g, 1.90 mmol) was dissolved in acetonitrile (40 mL), and the solution 
was magnetically stirred. Potassium carbonate (4.20 g, 30.4 mmol) was added, 
followed by 2-bromo-N-(2,2,2-trifluoroethyl)acetamide (1.40 g, 6.27 mmol), and the 
reaction mixture was purged with Ar(g) and heated to 70 ºC overnight under Ar. The 
reaction mixture, which became orange overnight, was filtered and concentrated unde 
reduced pressure to yield an orange, translucent oil. The oil was suspended in water 
and chloroform (1:1, 200 mL), then washed with additional chloroform (2 × 25 mL) 
and diethyl ether (1 × 25 mL) before it was concentrated under reduced pressure to 
yield the protected ligand as an orange glass that was further dried under high vacuum 
overnight (5-7, 1.02 g, 53.7 %). 1H NMR (500 MHz, CD3OD) δ = 1.17 (t, J = 7.5 Hz, 
6 H), 2.67-3.58 (m, 28 H), 3.93-4.09 (m, 8 H), 7.88 (br s, 3 H), 8.39 (br s, 1 H). 
HRMS-ESI [m/z] calc. for C27H46F9N8O7P [M + Na]+: 819.2976, found 819.2989. 
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((2-(4,7,10-Tris(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-1,4,7,10-
tetraazacyclododecan-1-yl)acetamido)methyl)phosphonic acid (5-8, DOTAm-F9-
PO3): The diethyl-protected phosphonate ligand 5-7 (285 mg, 0.358 mmol) was 
dissolved in dry dimethylformamide (2 mL), and the reaction mixture was 
magnetically stirred. Trimethylsilylbromide (378 µL, 2.86 mmol) was added in four 
portions, causing a white smoke to evolve. The reaction mixture was stirred at room 
temperature overnight, after which methanol (5 mL) was added, and the reaction 
mixture was stirred for an additional 4 h. Volatiles were removed under reduced 
pressure to yield a brown gum. This gum was dissolved in 2 mL of a 0.1% TFA/H2O 
mixture, and the resulting solution was purified by reverse-phase HPLC, eluting with 
0-60% acetonitrile in 0.1% TFA/H2O over 12 min., then 60% to 0% acetonitrile from 
12-17 min. Fractions containing the product were collected and lyophilized to yield the 
product as a tetra-trifluoroacetic acid salt. The trifluoroacetate counter anions were 
removed by reacting the product with a high excess of propylene oxide (0.5 mL) at 
room temperature in the dark in methanol overnight; then the methanol and the 
remaining propylene oxide were removed under reduced pressure. The residue was 
subsequently washed and concentrated with methanol (3 x 5 mL), and then a 
methanol:diethyl ether (1:9) mixture, precipitating a white solid. The mixture was then 
concentrated under reduced pressure, dissolved in water (5 mL), and lyophilized to 
yield the free acid of ligand 5-8 as an off-white powder. (144 mg, 54.3%). 1H NMR 
(500 MHz, D2O) δ = 2.61-4.12 (m, 32 H). 19F NMR (470 MHz) δ = -72.4 (t, J = 8.0 
Hz), -72.3 (t, J = 8.0 Hz). 13C NMR (125 MHz, D2O) δ = 39.9 (d, J = 155 Hz), 54.6 (d, 
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J = 64.8 Hz), 54.4, 54.6, 55.1, 162.7, 163.0. HRMS-ESI [m/z] calc. for C23H38F9N8O7P 
[M + H]+: 741.2530, found 741.2536. 
 
Tm(DOTAm-F9-PO3)+ (5-2): The phosphonate ligand 5-8 (40 mg, 0.0540 mmol) was 
dissolved in mQ water (15 mL). The solution was adjusted to pH = 7 with dilute 
sodium hydroxide. Then, aqueous thulium(III) chloride (169 µL of 0.291 M solution) 
was added (0.0492 mmol, 0.91 eq). The pH was again adjusted to 7.4 with dilute 
sodium hydroxide. The reaction was stirred at 75ºC for 72 hours, with pH maintained 
between 7 and 8 daily. Xylenol orange test indicated that reaction had run to 
completion. Reaction was lyophilized, yielding the thulium complex as a white solid 
(5-2, 53 mg, 100%). 19F NMR (D2O) δ = -78.74, -86.41, -88.52. ESI-MS [m/z] calc. 
for C23H37F9N8O7P4Tm [M2+]: 454.1, found: 454.0. 
 
Fe(DOTAm-F9-PO3) (5-3): The phosphonate ligand 5-8 (139 mg, 0.188 mmol) was 
dissolved in mQ water (5 mL). Methanol (15 mL) was added, and the solution was 
magnetically stirred and flushed with Ar (g) for 30 minutes. 
Iron(II)trifluoromethanesulfonate (57.9 mg, 0.163 mmol) was added, and the reaction 
mixture was heated to 70ºC for 30 h under Ar (g).  The resultant mixture was then 
concentrated under reduced pressure to yield the product 5-3 as an orange solid in 
quantitative yield. Coordinated trifluoromethanesulfonate ions were exchanged for 
chloride ions using a Sep-Pak Vac 6 cc (1 g) C18 cartridge (Waters). 19F NMR (D2O) 
δ = -70.50, -71.29. ESI-MS [m/z] calc. for C23H37F9FeN8O7 [M]+: 795.2; found: 795.2. 
5.6.2 Testing For Free Metal Ions 
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 Complex solutions were tested for unbound metal ions using xylenol orange as 
described by Averill et al.207 Acetic acid (1.4 mL) was added to mQ water (400 mL), 
and the pH was adjusted to 5.8 using 1.0 M ammonium hydroxide. Additional mQ 
water was then added to bring the volume to 500 mL. An aliquot of this buffer was 
removed, and xylenol orange was added to produce a 16 µM solution. For each sample 
tested, 0.3 mg of the compound was added to 0.3 mL buffer, followed by 3 mL of the 
xylenol orange solution. A change in color from yellow to dark pink or violet indicated 
the presence of uncomplexed metal ions. 
5.6.3 In Vivo Procedures 
 
 Female Sprague Dawley rats (230-250 g) fitted with jugular vein catheters were 
acquired from Harlan Labaratories (Madison, WI). Each contrast agent was prepared 
as a 50 mM solution in phosphate-buffered saline diluted with mQ water from a 10X 
commercial stock. 1 mL of this solution was injected into each animal through the 
catheter. Animals were then observed over a 4-hour period, with 500 µL blood 
samples collected through the catheter 5, 15, 30, 60, 120, and 240 minutes after 
administration of the complex. Following the final blood collection, the animals were 
euthanized with CO2, and the brain, lung, liver, spleen, kidney, and heart were 
removed. Blood and organ samples were stored at 4ºC and -20ºC, respectively, until 
digestion. All animal experiments were conducted by Dr. Henry Wong of the Institute 
for Therapeutics Discovery and Development at the University of Minnesota. 
Protocols for animal experiments were generated by Dr. Wong and approved by the 
Institutional Animal Care and Use Committee at the University of Minnesota (protocol 
#1308-30830A).  
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5.6.4 Determination of Fluorine Concentration 
 
 Fluorine concentrations in blood and organ samples were determined following 
digestion in concentrated HNO3. Each 500 µL blood sample was incubated with 500 
µL concentrated nitric acid and stirred at 90 ºC for 15 h. For each organ sample, 3 mL 
concentrated nitric acid was used. Digestion yielded a clear, yellow liquid. The 
digested organ samples were reduced to a volume of 700 µL by removing solvent 
under reduced pressure. 
 Fluorine concentrations were then determined by 19F NMR, referenced internally 
to aq. KF. Capillary tubes containing a 10 mM solution of KF in mQ water were 
prepared and flame sealed. A calibration curve was produced to determine the 
concentration of F- in the capillary tubes. The capillary tube was inserted into an NMR 
tube containing 700 µL of potassium fluoride solutions in concentrated nitric acid with 
concentrations ranging from 30 to 300 ppm F-. By comparing the 19F NMR integration 
values of the capillary tube solution peak at -120 ppm with the main NMR tube 
solution peaks at -20 ppm, -76 ppm, -128 ppm, -148 ppm, and -164 ppm, the capillary 
tubes were determined to be equivalent to 38 ppm when inserted into a 700 µL 
external solution. All NMR spectra were gathered on a Varian 300 using delay time = 
1.5 s, acquisition time = 600 ms, and number of transients = 1024. The standardized 
capillary tubes were then inserted into each 700 µL-volume digested blood or organ 
sample and scanned using the same parameters. The NMR integration values between 
the reference at δ = -120 ppm and the dominant resonance from the digested samples 
were compared to determine 19F concentrations of each sample. Not all peaks were 
found in spectra for all samples. 
 159
References 
 (1) Control, C. f. D. 2013. 
 (2) Damadian, R. Science 1971, 171, 1151. 
 (3) Damadian, R.; Zaner, K.; Hor, D.; DiMaio, T. Proc Natl Acad Sci U S A 1974, 71, 
1471. 
 (4) Hollis, D. P., Economou, J. S., Parks, Leon C., Eggleston, Joseph C., Saryan, 
Leon A., Czeisler, Jeffrey L. Cancer Research 1973, 2156. 
 (5) Hazlewood, C. F., Chang, D. C., Medina, D., Cleveland, G., Nichols, B. L. Proc 
Natl Acad Sci U S A 1972, 1478. 
 (6) Merbach, A. E., Toth, E. John Wiley and Sons 2001. 
 (7) Caravan, P.; Ellison, J. J.; McMurry, T. J.; Lauffer, R. B. Chem Rev 1999, 99, 
2293. 
 (8) Aime, S.; Barge, A.; Botta, M.; Howard, J. A. K.; Kataky, R.; Lowe, M. P.; 
Moloney, J. M.; Parker, D.; de Sousa, A. S. Chem Commun 1999, 1047. 
 (9) Yeh, T. C.; Zhang, W. G.; Ildstad, S. T.; Ho, C. Magnet Reson Med 1993, 30, 
617. 
 (10) Moore, A.; Weissleder, R.; Bogdanov, A. Jmri-J Magn Reson Im 1997, 7, 1140. 
 (11) Weissleder, R.; Cheng, H. C.; Bogdanova, A.; Bogdanov, A. Jmri-J Magn Reson 
Im 1997, 7, 258. 
 (12) Sipe, J. C.; Filippi, M.; Martino, G.; Furlan, R.; Rocca, M. A.; Rovaris, M.; 
Bergami, A.; Zyroff, J.; Scotti, G.; Comi, G. Magn Reson Imaging 1999, 17, 1521. 
 (13) Modo, M.; Hoehn, M.; Bulte, J. W. M. Mol Imaging 2005, 4, 143. 
 (14) Laurent, S.; Forge, D.; Port, M.; Roch, A.; Robic, C.; Elst, L. V.; Muller, R. N. 
Chem Rev 2008, 108, 2064. 
 (15) Skjold, A.; Amundsen, B. H.; Wiseth, R.; Stoylen, A.; Haraldseth, O.; Larsson, H. 
B. W.; Jynge, P. J Magn Reson Imaging 2007, 26, 720. 
 (16) Small, W. C.; Macchi, D. D.; Parker, J. R.; Bernardino, M. E. Acad Radiol 1998, 
5, S147. 
 (17) Wendland, M. F. Nmr Biomed 2004, 17, 581. 
 (18) Grobner, T. Nephrol Dial Transpl 2006, 21, 1104. 
 (19) High, W. A.; Ayers, R. A.; Chandler, J.; Zito, G.; Cowper, S. E. J Am Acad 
Dermatol 2007, 56, 21. 
 (20) Atanasijevic, T.; Zhang, X. A.; Lippard, S. J.; Jasanoff, A. Inorg Chem 2010, 49, 
2589. 
 (21) Gilad, A. A.; Walczak, P.; McMahon, M. T.; Na, H. B.; Lee, J. H.; An, K.; 
Hyeon, T.; van Zijl, P. C. M.; Bulte, J. W. M. Magnet Reson Med 2008, 60, 1. 
 (22) Kim, T.; Momin, E.; Choi, J.; Yuan, K.; Zaidi, H.; Kim, J.; Park, M.; Lee, N.; 
McMahon, M. T.; Quinones-Hinojosa, A.; Bulte, J. W. M.; Hyeon, T.; Gilad, A. A. J Am Chem 
Soc 2011, 133, 2955. 
 (23) Taylor, K. M. L.; Rieter, W. J.; Lin, W. B. J Am Chem Soc 2008, 130, 14358. 
 (24) Aime, S.; Caravan, P. J Magn Reson Imaging 2009, 30, 1259. 
 (25) Nasu, H.; Takehara, Y.; Isogai, S.; Kodaira, N.; Takeda, H.; Saga, T.; Nakajima, 
S.; Sakata, I.; Sakahara, H. J Magn Reson Imaging 2004, 20, 294. 
 (26) Winter, M. B.; Klemm, P. J.; Phillips-Piro, C. M.; Raymond, K. N.; Marletta, M. 
A. Inorg Chem 2013, 52, 2277. 
 160
 (27) Cheng, W. R.; Ganesh, T.; Martinez, F.; Lam, J.; Yoon, H.; Macgregor, R. B.; 
Scholl, T. J.; Cheng, H. L. M.; Zhang, X. A. J Biol Inorg Chem 2014, 19, 229. 
 (28) Qazi, S.; Uchida, M.; Usselman, R.; Shearer, R.; Edwards, E.; Douglas, T. J Biol 
Inorg Chem 2014, 19, 237. 
 (29) Harris, R. K.; Becker, E. D.; de Menezes, S. M. C.; Goodfellow, R.; Granger, P. 
Solid State Nucl Mag 2002, 22, 458. 
 (30) Code, R. F.; Harrison, J. E.; Mcneill, K. G.; Szyjkowski, M. Magnet Reson Med 
1990, 13, 358. 
 (31) Harvey, P.; Kuprov, I.; Parker, D. Eur. J. Inorg. Chem. 2012, 2015. 
 (32) Senanayake, P. K.; Kenwright, A. M.; Parker, D.; van der Hoorn, S. K. Chem 
Commun 2007, 2923. 
 (33) Higuchi, M.; Iwata, N.; Matsuba, Y.; Sato, K.; Sasamoto, K.; Saido, T. C. Nat 
Neurosci 2005, 8, 527. 
 (34) Yu, J. X.; Liu, L.; Kodibagkar, V. D.; Cui, W. N.; Mason, R. P. Biorg. Med. 
Chem. 2006, 14, 326. 
 (35) Holland, G. N.; Bottomley, P. A.; Hinshaw, W. S. Journal of Magnetic 
Resonance 1977, 28, 133. 
 (36) Lauterbur, P. C. Nature 1973, 242, 190. 
 (37) Wolf, W.; Albright, M. J.; Silver, M. S.; Weber, H.; Reichardt, U.; Sauer, R. 
Magn Reson Imaging 1987, 5, 165. 
 (38) Li, C. W.; Negendank, W. G.; PadavicShaller, K. A.; ODwyer, P. J.; 
MurphyBoesch, J.; Brown, T. R. Clin Cancer Res 1996, 2, 339. 
 (39) Kuribayashi, H.; Doi, Y.; Kanazawa, Y. Magnet Reson Med 2001, 46, 864. 
 (40) Yu, J. X.; Kodibagkar, V. D.; Cui, W. N.; Mason, R. P. Curr Med Chem 2005, 12, 
819. 
 (41) Partlow, K. C.; Chen, J. J.; Brant, J. A.; Neubauer, A. M.; Meyerrose, T. E.; 
Creer, M. H.; Nolta, J. A.; Caruthers, S. D.; Lanza, G. M.; Wickline, S. A. Faseb J 2007, 21, 
1647. 
 (42) Hall, L. W., Jackson, S. R. K., Massey, G. M. Oxford 1975. 
 (43) Park, B. K.; Kitteringham, N. R.; O'Neill, P. M. Annu Rev Pharmacol 2001, 41, 
443. 
 (44) Flaherty, D. P.; Walsh, S. M.; Kiyota, T.; Dong, Y.; Ikezu, T.; Vennerstrom, J. L. 
J Med Chem 2007, 50, 4986. 
 (45) Flogel, U.; Ding, Z.; Hardung, H.; Jander, S.; Reichmann, G.; Jacoby, C.; 
Schubert, R.; Schrader, J. Circulation 2008, 118, 140. 
 (46) Kuethe, D. O.; Behr, V. C.; Begay, S. Magnet Reson Med 2002, 48, 547. 
 (47) Kauczor, H. U.; Chen, X. J.; van Beek, E. J. R.; Schreiber, W. G. Eur Respir J 
2001, 17, 1008. 
 (48) Kenwright, A. M.; Kuprov, I.; De Luca, E.; Parker, D.; Pandya, S. U.; 
Senanayake, P. K.; Smith, D. G. Chem Commun 2008, 2514. 
 (49) Kodibagkar, V. D.; Yu, J. X.; Liu, L.; Hetherington, H. P.; Mason, R. P. Magn 
Reson Imaging 2006, 24, 959. 
 (50) Sled, J. G.; Pike, G. B. Journal of Magnetic Resonance 2000, 145, 24. 
 (51) Alfakih, K.; Plein, S.; Thiele, H.; Jones, T.; Ridgway, J. P.; Sivananthan, M. U. J 
Magn Reson Imaging 2003, 17, 323. 
 (52) Oshio, K.; Feinberg, D. A. Magnet Reson Med 1991, 20, 344. 
 161
 (53) Idiyatullin, D.; Corum, C.; Park, J. Y.; Garwood, M. Journal of Magnetic 
Resonance 2006, 181, 342. 
 (54) Idiyatullin, D.; Corum, C.; Moeller, S.; Garwood, M. Journal of Magnetic 
Resonance 2008, 193, 267. 
 (55) Gianolio, E.; Napolitano, R.; Fedeli, F.; Arena, F.; Aime, S. Chem Commun 2009, 
6044. 
 (56) Lauffer, R. B. Chem. Rev. 1987, 87, 901. 
 (57) Alsaadi, B. M.; Rossotti, F. J. C.; Williams, R. J. P. J Chem Soc Dalton 1980, 
2151. 
 (58) Alsaadi, B. M.; Rossotti, F. J. C.; Williams, R. J. P. J Chem Soc Dalton 1980, 
813. 
 (59) Smolensky, E. D.; Marjanska, M.; Pierre, V. C. Dalton T 2012, 41, 8039. 
 (60) Deutsch, C. J.; Taylor, J. S. Biophys J 1989, 55, 799. 
 (61) Vervoort, J.; Rietjens, I. M. C. M.; Moonen, C. T. W.; Vonkienlin, M.; Despres, 
D. Nmr Biomed 1991, 4, 255. 
 (62) Mizukami, S.; Takikawa, R.; Sugihara, F.; Hori, Y.; Tochio, H.; Walchli, M.; 
Shirakawa, M.; Kikuchi, K. J Am Chem Soc 2008, 130, 794. 
 (63) Takaoka, Y.; Kiminami, K.; Mizusawa, K.; Matsuo, K.; Narazaki, M.; Matsuda, 
T.; Hamachi, I. J Am Chem Soc 2011, 133, 11725. 
 (64) Wang, K.; Peng, H.; Thurecht, K. J.; Puttick, S.; Whittaker, A. K. Polymer 
Chemistry 2013, 4, 4480. 
 (65) Hendrick, R. E.; Kneeland, J. B.; Stark, D. D. Magnetic Resonance Imaging 1987, 
5, 117. 
 (66) Janjic, J. M.; Srinivas, M.; Kadayakkara, D. K. K.; Ahrens, E. T. J. Am. Chem. 
Soc. 2008, 130, 2832. 
 (67) Nurmi, L.; Peng, H.; Seppala, J.; Haddleton, D. M.; Blakey, I.; Whittaker, A. K. 
Polymer Chemistry 2010, 1, 1039. 
 (68) Jiang, Z.-X.; Feng, Y.; Yu, Y. B. Chem. Commun. 2011, 47, 7233. 
 (69) Rossi, S.; Benaglia, M.; Ortenzi, M.; Micotti, E.; Perego, C.; De Simoni, M. G. 
Tetrahedron Lett. 2011, 52, 6581. 
 (70) Criscione, J. M.; Le, B. L.; Stern, E.; Brennan, M.; Rahner, C.; Papademetris, X.; 
Fahmy, T. M. Biomaterials 2009, 30, 3946. 
 (71) Peng, H.; Blakey, I.; Dargaville, B.; Rasoul, F.; Rose, S.; Whittaker, A. K. 
Biomacromolecules 2009, 10, 374. 
 (72) Ogawa, M.; Nitahara, S.; Aoki, H.; Ito, S.; Narazaki, M.; Matsuda, T. Macromol. 
Chem. Phys. 2010, 211, 1602. 
 (73) Ogawa, M.; Nitahara, S.; Aoki, H.; Ito, S.; Narazaki, M.; Matsuda, T. Macromol. 
Chem. Phys. 2010, 211, 1369. 
 (74) Ogawa, M.; Kataoka, H.; Nitahara, S.; Fujimoto, H.; Aoki, H.; Ito, S.; Narazaki, 
M.; Matsuda, T. Bull. Chem. Soc. Jpn. 2012, 85, 79. 
 (75) Du, W.; Xu, Z.; Nyström, A. M.; Zhang, K.; Leonard, J. R.; Wooley, K. L. 
Bioconjugate Chem. 2008, 19, 2492. 
 (76) Du, W.; Nystrom, A. M.; Zhang, L.; Powell, K. T.; Li, Y.; Cheng, C.; Wickline, 
S. A.; Wooley, K. L. Biomacromolecules 2008, 9, 2826. 
 (77) Thurecht, K. J.; Blakey, I.; Peng, H.; Squires, O.; Hsu, S.; Alexander, C.; 
Whittaker, A. K. J. Am. Chem. Soc. 2010, 132, 5336. 
 162
 (78) Neubauer, A. M.; Myerson, J.; Caruthers, S. D.; Hockett, F. D.; Winter, P. M.; 
Chen, J.; Gaffney, P. J.; Robertson, J. D.; Lanza, G. M.; Wickline, S. A. Magnetic Resonance in 
Medicine 2008, 60, 1066. 
 (79) Caruthers, S. D.; Neubauer, A. M.; Hockett, F. D.; Lamerichs, R.; Winter, P. M.; 
Scott, M. J.; Gaffney, P. J.; Wickline, S. A.; Lanza, G. M. Invest Radiol 2006, 41, 305. 
 (80) Takaoka, Y.; Kiminami, K.; Mizusawa, K.; Matsuo, K.; Narazaki, M.; Matsuda, 
T.; Hamachi, I. J. Am. Chem. Soc. 2011, 133, 11725. 
 (81) Chalmers, K. H.; Botta, M.; Parker, D. Dalton Transactions 2011, 40, 904. 
 (82) Chalmers, K. H.; De Luca, E.; Hogg, N. H. M.; Kenwright, A. M.; Kuprov, I.; 
Parker, D.; Botta, M.; Wilson, J. I.; Blamire, A. M. Chem-Eur J 2010, 16, 134. 
 (83) Chalmers, K. H.; Kenwright, A. M.; Parker, D.; Blamire, A. M. Magnetic 
Resonance in Medicine 2011, 66, 931. 
 (84) Kim, W. D.; Kiefer, G. E.; Huskens, J.; Sherry, A. D. Inorg Chem 1997, 36, 4128. 
 (85) Harvey, P.; Chalmers, K. H.; De Luca, E.; Mishra, A.; Parker, D. Chemistry-a 
European Journal 2012, 18, 8748. 
 (86) Placidi, M. P.; Botta, M.; Kálmán, F. K.; Hagberg, G. E.; Baranyai, Z.; Krenzer, 
A.; Rogerson, A. K.; Tóth, I.; Logothetis, N. K.; Angelovski, G. Chemistry – A European 
Journal 2013, 19, 11644. 
 (87) Tsitovich, P. B.; Morrow, J. R. Inorg. Chim. Acta 2012, 393, 3. 
 (88) Dorazio, S. J.; Olatunde, A. O.; Tsitovich, P. B.; Morrow, J. R. J Biol Inorg Chem 
2014, 19, 191. 
 (89) Dorazio, S. J.; Tsitovich, P. B.; Siters, K. E.; Spernyak, J. A.; Morrow, J. R. J. 
Am. Chem. Soc. 2011, 133, 14154. 
 (90) Crull, G. B.; Kennington, J. W.; Garber, A. R.; Ellis, P. D.; Dawson, J. H. J. Biol. 
Chem. 1989, 264, 2649. 
 (91) Tierney, D. L.; Gassner, G. T.; Luchinat, C.; Bertini, I.; Ballou, D. P.; Penner-
Hahn, J. E. Biochemistry 1999, 38, 11051. 
 (92) Belle, C.; Béguin, C.; Hamman, S.; Pierre, J.-L. Coord. Chem. Rev. 2009, 253, 
963. 
 (93) Tanaka, K.; Kitamura, N.; Takahashi, Y.; Chujo, Y. Bioorg Med Chem 2009, 17, 
3818. 
 (94) Mandal, S. K.; Que, L. Inorg. Chem. 1997, 36, 5424. 
 (95) Bleaney, B. Journal of Magnetic Resonance (1969) 1972, 8, 91. 
 (96) Alpoim, M. C.; Urbano, A. M.; Geraldes, C. F. G. C.; Peters, J. A. Journal of the 
Chemical Society-Dalton Transactions 1992, 463. 
 (97) Aime, S.; Barge, A.; Bruce, J. I.; Botta, M.; Howard, J. A. K.; Moloney, J. M.; 
Parker, D.; de Sousa, A. S.; Woods, M. J Am Chem Soc 1999, 121, 5762. 
 (98) Beeby, A.; M. Clarkson, I.; S. Dickins, R.; Faulkner, S.; Parker, D.; Royle, L.; S. 
de Sousa, A.; A. Gareth Williams, J.; Woods, M. J. Chem. Soc., Perkin Trans. 2 1999, 493. 
 (99) Parker, D.; Dickins, R. S.; Puschmann, H.; Crossland, C.; Howard, J. A. K. Chem. 
Rev. 2002, 102, 1977. 
 (100) Di Bari, L.; Salvadori, P. Chemphyschem 2011, 12, 1490. 
 (101) Frisch, M. J. T., G. W.; Schlegel, H. B.; Scuseria, G. E.; Robb, M. A.; 
Cheeseman, J. R.; Scalmani, G.; Barone, V.; Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; 
Caricato, M.; Li, X.; Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.; Sonnenberg, J. L.; 
Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, 
 163
Y.; Kitao, O.; Nakai, H.; Vreven, T.; Montgomery, J. A., Jr.; Peralta, J. E.; Ogliaro, F.; Bearpark, 
M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov, V. N.; Kobayashi, R.; Normand, J.; 
Raghavachari, K.; Rendell, A.; Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; 
Millam, N. J.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.; Jaramillo, J.; 
Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. 
W.; Martin, R. L.; Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.; Dannenberg, J. 
J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.; Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. 
J. Gaussian 09, Revision D.01; Gaussian, Inc.: Wallingford CT, 2009. 
 (102) Dolg, M.; Stoll, H.; Preuss, H. Theoretica chimica acta 1993, 85, 441. 
 (103) Dolg, M.; Stoll, H.; Savin, A.; Preuss, H. Theoretica chimica acta 1989, 75, 173. 
 (104) Platas-Iglesias, C. Eur. J. Inorg. Chem. 2012, 2012, 2023. 
 (105) Amin, S.; Voss, D. A.; Horrocks, W. D.; Lake, C. H.; Churchill, M. R.; Morrow, 
J. R. Inorg. Chem. 1995, 34, 3294. 
 (106) Dickins, R. S.; Howard, J. A. K.; Maupin, C. L.; Moloney, J. M.; Parker, D.; 
Riehl, J. P.; Siligardi, G.; Williams, J. A. G. Chem-Eur J 1999, 5, 1095. 
 (107) Berger, R.; Resnati, G.; Metrangolo, P.; Weber, E.; Hulliger, J. Chem. Soc. Rev. 
2011, 40, 3496. 
 (108) Jacoby, C.; Temme, S.; Mayenfels, F.; Benoit, N.; Krafft, M. P.; Schubert, R.; 
Schrader, J.; Flogel, U. Nmr Biomed 2014, 27, 261. 
 (109) Harvey, P.; Kuprov, I.; Parker, D. Eur. J. Inorg. Chem. 2012, 2015. 
 (110) Bertini, I.; Turano, P.; Vila, A. J. Chem. Rev. 1993, 93, 2833. 
 (111) Bertini, I.; Capozzi, F.; Luchinat, C.; Nicastro, G.; Xia, Z. C. J. Phys. Chem. 
1993, 97, 6351. 
 (112) Peters, J. A.; Huskens, J.; Raber, D. J. Prog Nucl Mag Res Sp 1996, 28, 283. 
 (113) Christian, G. D.; Dasgupta, P.; Schug, K. Analytical Chemistry; 7th ed.; John 
Wiley & Sons: New YorkS, 2014. 
 (114) Godek, M. L.; Michel, R.; Chamberlain, L. M.; Castner, D. G.; Grainger, D. W. 
Journal of biomedical materials research. Part A 2009, 88, 503. 
 (115) Kiaei, D.; Hoffman, A. S.; Horbett, T. A. J Biomater Sci Polym Ed. 1992, 4, 35. 
 (116) De Luca, E.; Harvey, P.; Chalmers, K.; Mishra, A.; Senanayake, P. K.; Wilson, J. 
I.; Botta, M.; Fekete, M.; Blamire, A.; Parker, D. J. Biol. Inorg. Chem. 2013, 1. 
 (117) Idiyatullin, D.; Corum, C.; Park, J.-Y.; Garwood, M. Journal of Magnetic 
Resonance 2006, 181, 342. 
 (118) SMART V5.054, Bruker Analytical X-ray Systems Madison, WI 2001. 
 (119) Blessing, R. Acta Cryst. 1995, A51, 33. 
 (120) SAINT+ V6.45, Bruker Analytical X-Ray Systems Madison, WI, 2003. 
 (121) SHELXTL V6.14, Bruker Analytical X-Ray Systems Madison, WI, 2000. 
 (122) Spek, A. L. Acta Cryst. 1990, A46, C34. 
 (123) Spek, A. L. PLATON, A Multipurpose Crystallographic Tool Utrecht University, 
Utrecht, The Netherlands, 2000. 
 (124) Solomon, I. Physical Review 1955, 99, 559. 
 (125) Bloembergen, N. M., L. O. J. Chem. Phys. 1961, 34, 842. 
 (126) Chalmers, K. H.; Kenwright, A. M.; Parker, D.; Blamire, A. M. Magnet Reson 
Med 2011, 66, 931. 
 (127) Ren, J.; Whangbo, M. H.; Dai, D. D.; Li, L. M. J Chem Phys 1998, 108, 8479. 
 (128) Ishikawa, N. J Phys Chem A 2003, 107, 5831. 
 164
 (129) Ishikawa, N.; Iino, T.; Kaizu, Y. J Phys Chem A 2002, 106, 9543. 
 (130) Zbiri, M.; Daul, C. A.; Wesolowski, T. A. J Chem Theory Comput 2006, 2, 1106. 
 (131) Ishikawa, N.; Sugita, M.; Okubo, T.; Tanaka, N.; Lino, T.; Kaizu, Y. Inorg Chem 
2003, 42, 2440. 
 (132) Bleaney, B. J. Magn. Reson. 1972, 8, 91. 
 (133) Alsaadi, B. M.; Rossotti, F. J. C.; Williams, R. J. P. J Chem Soc Dalton 1980, 
2147. 
 (134) Aime, S.; Barbero, L.; Botta, M.; Ermondi, G. J Chem Soc Dalton 1992, 225. 
 (135) Bertini, I.; Capozzi, F.; Luchinat, C.; Nicastro, G.; Xia, Z. C. J Phys Chem-Us 
1993, 97, 6351. 
 (136) Funk, A. M.; Harvey, P.; Finney, K. L. N. A.; Fox, M. A.; Kenwright, A. M.; 
Rogers, N. J.; Senanayake, P. K.; Parker, D. Phys Chem Chem Phys 2015, 17, 16507. 
 (137) Bertini, I.; Turano, P.; Vila, A. J. Chem Rev 1993, 93, 2833. 
 (138) Chevalier, B. T., S.; Andre, G.; Matier, S. F.; Gaudin, E. J. Phys. Conf., Ser. 
2010, 200. 
 (139) Gignoux, D.; Schmitt, D.; Zerguine, M. J Magn Magn Mater 1987, 66, 373. 
 (140) Quadrelli, E. A. Inorg Chem 2002, 41, 167. 
 (141) Liu, Q. D.; Gao, S.; Li, J. R.; Ma, B. Q.; Zhou, Q. Z.; Yu, K. B. Polyhedron 2002, 
21, 1097. 
 (142) Seitz, M.; Oliver, A. G.; Raymond, K. N. J Am Chem Soc 2007, 129, 11153. 
 (143) Geraldes, C. F. G. C.; Sherry, A. D.; Lazar, I.; Miseta, A.; Bogner, P.; Berenyi, 
E.; Sumegi, B.; Kiefer, G. E.; Mcmillan, K.; Maton, F.; Muller, R. N. Magnet Reson Med 1993, 
30, 696. 
 (144) Luz, Z. M., S. J. Chem. Phys. 1964, 40, 2686. 
 (145) Raghunand, N.; Zhang, S. R.; Sherry, A. D.; Gillies, R. J. Acad. Radiol. 2002, 9, 
S481. 
 (146) De, L.-R. L. M.; Lubag, A. J. M.; Malloy, C. R.; Martinez, G. V.; Gillies, R. J.; 
Sherry, A. D. Acc. Chem. Res. 2009, 42, 948. 
 (147) De Leon-Rodriguez, L. M.; Lubag, A. J. M.; Malloy, C. R.; Martinez, G. V.; 
Gillies, R. J.; Sherry, A. D. Accounts Chem Res 2009, 42, 948. 
 (148) Borden, M. A.; Zhang, H.; Gillies, R. J.; Dayton, P. A.; Ferrara, K. W. 
Biomaterials 2007, 29, 597. 
 (149) Gillies, R. J.; Raghunand, N.; Garcia-Martin, M. L.; Gatenby, R. A. IEEE Eng. 
Med. Biol. Mag. 2004, 23, 57. 
 (150) Garcia-Martin, M. L.; Martinez, G. V.; Raghunand, N.; Sherry, A. D.; Zhang, S. 
R.; Gillies, R. J. Magn. Res. Med. 2006, 55, 309. 
 (151) Raghunand, N.; Howison, C.; Sherry, A. D.; Zhang, S. R.; Gillies, R. J. Magn. 
Res. Med. 2003, 49, 249. 
 (152) Yu, J. X.; Otten, P.; Ma, Z. Y.; Cui, W. N.; Liu, L.; Mason, R. P. Bioconjugate 
Chem. 2004, 15, 1334. 
 (153) He, S.; Mason, R. P.; Hunjan, S.; Mehta, V. D.; Arora, V.; Katipally, R.; 
Kulkarni, P. V.; Antich, P. P. Bioorgan Med Chem 1998, 6, 1631. 
 (154) Mason, R. P. Curr. Med. Chem. 1999, 6, 481. 
 (155) Yu, J. X.; Kodibagkar, V. D.; Cui, W. N.; Mason, R. P. Curr. Med. Chem. 2005, 
12, 819. 
 (156) Liu, L.; Kodibagkar, V. D.; Yu, J.-X.; Mason, R. P. FASEB J. 2007, 21, 2014. 
 165
 (157) Mehta, V. D.; Kulkarni, P. V.; Mason, R. P.; Constantinescu, A.; Aravind, S.; 
Goomer, N.; Antich, P. P. FEBS Lett. 1994, 349, 234. 
 (158) Zhao, D. W.; Jiang, L.; Mason, R. P. Imag. Biol. Res., Pt B 2004, 386, 378. 
 (159) Hunjan, S.; Zhao, D. W.; Constantinescu, A.; Hahn, E. W.; Antich, P. P.; Mason, 
R. P. Int. J. Rad. Onc. Biol. Phys. 2001, 49, 1097. 
 (160) Mason, R. P.; Ran, S.; Thorpe, P. E. J. Cell. Biochem. 2002, 45. 
 (161) Yu, J. X.; Mason, R. P. J. Med. Chem. 2006, 49, 1991. 
 (162) Kodibagkar, V. D.; Yu, J.; Liu, L.; Hetherington, H. P.; Mason, R. P. Magn. Res. 
Im. 2006, 24, 959. 
 (163) Cui, W. N.; Otten, P.; Li, Y. M.; Koeneman, K. S.; Yu, J. X.; Mason, R. P. Magn. 
Res. Med. 2004, 51, 616. 
 (164) Hunjan, S.; Mason, R. P.; Mehta, V. D.; Kulkarni, P. V.; Aravind, S.; Arora, V.; 
Antich, P. P. Magn. Res. Med. 1998, 39, 551. 
 (165) Yu, J.; Ma, Z.; Li, Y.; Koeneman, K. S.; Liu, L.; Mason, R. P. Med. Chem. 2005, 
1, 255. 
 (166) Yu, J.-X.; Kodibagkar, V. D.; Liu, L.; Mason, R. P. NMR Biomed. 2008, 21, 704. 
 (167) Srinivas, M.; Morel, P. A.; Ernst, L. A.; Laidlaw, D. H.; Ahrens, E. T. Magn. Res. 
Med. 2007, 58, 725. 
 (168) Janjic, J. M.; Ahrens, E. T. Nanomed. Nanobiotechnol. 2009, 1, 492. 
 (169) Srinivas, M.; Turner, M. S.; Janjic, J. M.; Morel, P. A.; Laidlaw, D. H.; Ahrens, 
E. T. Magn. Res. Med. 2009, 62, 747. 
 (170) Helfer, B. M.; Balducci, A.; Nelson, A. D.; Janjic, J. M.; Gil, R. R.; Kalinski, P.; 
de Vries, I. J. M.; Ahrens, E. T.; Mailliard, R. B. Cytotherapy 2010, 12, 238. 
 (171) Kadayakkara, D. K. K.; Janjic, J. M.; Pusateri, L. K.; Young, W.-B.; Ahrens, E. T. 
Magn. Res. Med. 2010, 64, 1252. 
 (172) Srinivas, M.; Heerschap, A.; Ahrens, E. T.; Figdor, C. G.; Vries, I. J. M. d. Trends 
Biotechnol. 2010, 28, 363. 
 (173) Bonetto, F.; Srinivas, M.; Heerschap, A.; Mailliard, R.; Ahrens, E. T.; Figdor, C. 
G.; de Vries, I. J. M. Int, J. Cancer 2011, 129, 365. 
 (174) Hitchens, T. K.; Ye, Q.; Eytan, D. F.; Janjic, J. M.; Ahrens, E. T.; Ho, C. Magn. 
Res. Med. 2011, 65, 1144. 
 (175) Balducci, A.; Helfer, B.; Ahrens, E.; O'Hanlon, C.; Wesa, A. J. Inflam. 2012, 9, 
24. 
 (176) Bible, E.; Dell’Acqua, F.; Solanky, B.; Balducci, A.; Crapo, P. M.; Badylak, S. F.; 
Ahrens, E. T.; Modo, M. Biomaterials 2012, 33, 2858. 
 (177) Kadayakkara, D. K.; Ranganathan, S.; Young, W.-B.; Ahrens, E. T. Lab. Invest. 
2012, 92, 636. 
 (178) Ruiz-Cabello, J.; Barnett, B. P.; Bottomley, P. A.; Bulte, J. W. M. NMR Biomed. 
2011, 24, 114. 
 (179) Yu, J.-X.; Hallac, R. R.; Chiguru, S.; Mason, R. P. Prog. Nucl. Magn. Reson. 
Spectrosc. 2013, 70, 25. 
 (180) Que, E. L.; Chang, C. J. J Am Chem Soc 2006, 128, 15942. 
 (181) Que, E. L.; Chang, C. J. Chem Soc Rev 2010, 39, 51. 
 (182) Que, E. L.; Domaille, D. W.; Chang, C. J. Chem Rev 2008, 108, 4328. 
 (183) Que, E. L.; Domaille, D. W.; Chang, C. J. Chem Rev 2008, 108, 1517. 
 166
 (184) Que, E. L.; Gianolio, E.; Baker, S. L.; Aime, S.; Chang, C. J. Dalton T 2010, 39, 
469. 
 (185) Que, E. L.; Gianolio, E.; Baker, S. L.; Wong, A. P.; Aime, S.; Chang, C. J. J Am 
Chem Soc 2009, 131, 8527. 
 (186) Que, E. L.; New, E. J.; Chang, C. J. Chem Sci 2012, 3, 1829. 
 (187) Squitti, R.; Quattrocchi, C. C.; Salustri, C.; Rossini, P. M. Prion 2008, 2, 23. 
 (188) Kardos, J.; Kovacs, I.; Hajos, F.; Kalman, M.; Simonyi, M. Neurosci Lett 1989, 
103, 139. 
 (189) Maynard, C. J.; Bush, A. I.; Masters, C. L.; Cappai, R.; Li, Q. X. Int J Exp Pathol 
2005, 86, 147. 
 (190) Hureau, C.; Faller, P. Biochimie 2009, 91, 1212. 
 (191) Allegrozzi, M.; Bertini, I.; Janik, M. B. L.; Lee, Y.-M.; Liu, G.; Luchinat, C. J. 
Am. Chem. Soc. 2000, 122, 4154. 
 (192) McConnell, H. M.; Robertson, R. E. J. Chem. Phys. 1958, 29, 1361. 
 (193) Peters, J. A.; Huskens, J.; Raber, D. J. Prog. Nucl. Magn. Reson. Spectrosc. 1996, 
28, 283. 
 (194) Wangsness, R. K.; Bloch, F. Phys. Rev. 1953, 89, 728. 
 (195) Redfield, A. G. IBM J. Res. Dev. 1957, 1, 19. 
 (196) Kubo, R. Hyperfine Interact. 1981, 8, 731. 
 (197) Frenzel, T.; Lengsfeld, P.; Schirmer, H.; Hutter, J.; Weinmann, H. J. Invest Radiol 
2008, 43, 817. 
 (198) Jiang, Z. X.; Liu, X.; Jeong, E. K.; Yu, Y. B. Angewandte Chemie-International 
Edition 2009, 48, 4755. 
 (199) Jiang, Z. X.; Feng, Y.; Yu, Y. B. Chem Commun 2011, 47, 7233. 
 (200) Pereira, G. A.; Ball, L.; Sherry, A. D.; Peters, J. A.; Geraldes, C. E. G. C. Helv 
Chim Acta 2009, 92, 2532. 
 (201) Woods, M.; Caravan, P.; Geraldes, C. F. G. C.; Greenfield, M. T.; Kiefer, G. E.; 
Lin, M.; McMillan, K.; Prata, M. I. M.; Santos, A. C.; Sun, X. K.; Wang, J. F.; Zhang, S. R.; 
Zhao, P. Y.; Sherry, A. D. Invest Radiol 2008, 43, 861. 
 (202) Agalakova, N. I.; Gusev, G. P. Biol Trace Elem Res 2013, 153, 340. 
 (203) Pierre, V. C.; Allen, M. J.; Caravan, P. J Biol Inorg Chem 2014, 19, 127. 
 (204) Chin-Thin, W.; Wei-Tun, C.; Tzu-Ming, P.; Ren-Tse, W. Clin Chem Lab Med 
2002, 40, 1118. 
 (205) Ganz, T. Physiol Rev 2013, 93, 1721. 
 (206) Dorazio, S. J.; Tsitovich, P. B.; Gardina, S. A.; Morrow, J. R. J Inorg Biochem 
2012, 117, 212. 
 (207) Averill, D. J.; Garcia, J.; Siriwardena-Mahanama, B. N.; Vithanarachchi, S. M.; 
Allen, M. J. Jove-J Vis Exp 2011. 
 
 
